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Abstract 
 
Effective delivery of primary health care is arguably the best way to improve health 
outcomes. A more integrated primary health care system should lead to higher 
quality service to clients. Community pharmacy is well placed to play a constructive 
and dynamic support role in the provision of effective primary health care. In addition 
to being one of the first port of call for health advice for the general population, 
referral to other health services is emerging as an important strength of community 
pharmacy.  
 
Bowel symptoms such as diarrhoea, constipation and rectal bleeding are common, 
and a number of bowel diseases share common clinical presentations. Certain 
symptoms significantly raise the probability of serious underlying conditions such as 
cancer, colitis, or large adenomatous polyps. Seeking medical advice and initiation of 
treatment in the early stage of a disease improves the prognosis and quality of life. 
To reduce delayed diagnosis of bowel pathologies, there must be increased efforts to 
identify people with high-risk symptoms and refer them to appropriate care. Self-
administered questionnaire can be an effective tool in supporting primary health care 
professionals to triage cases that warrant further investigation for indicators of 
possible colorectal conditions.  
 
This thesis explores the use of pharmacy setting to triage clients for investigation of 
symptoms that may indicate colorectal pathology. The purpose of this thesis was to 
develop and test a simple screening tool with high sensitivity for bowel disease (Jodi 
Lee Test; JLT) that could be used by pharmacy staff to identify and encourage 
individuals to seek medical help. Furthermore, this thesis examines the intention of 
the pharmacists and pharmacy assistants to change practice when consulting clients 
with bowel symptoms. The thesis also measures the willingness to pay for the 
deployment of a tool such as the JLT when used in the pharmacy during consultation 
with a client. 
 
xiv 
 
The design of this project was guided by the Medical Research Council framework, 
which outlines the appropriate steps in designing complex interventions. The 
behavioural study was based on the Theory of Planned Behaviour. Data were 
collected using various techniques: on-site in pharmacies, online using video 
vignettes and telephone follow-up. The tools used to collect data were self-
administered questionnaires: JLT, a questionnaire based on Theory of Planned 
Behaviour, a post-evaluation questionnaire, video vignettes based willingness to pay 
questionnaire and notes from pharmacists. 
 
The major outcomes from the thesis are: 
 
 Study 1: The JLT, a short, self-administered questionnaire was developed and 
validated against an existing validated screening tool, the Patient Consultation 
Questionnaire (PCQ), to assess the sensitivity and specificity of JLT. The JLT 
contains eight questions. It has a Flesh-Kincaid reading score of 79.5. Different 
score thresholds on the gold standard, the PCQ, were considered, and a 
receiver-operator characteristic (ROC) curve was calculated to assess 
effectiveness of the JLT. From a sample of 118 subjects, the area under the 
ROC curve was 0.94. At a threshold score of 30 on the PCQ, the sensitivity was 
100% for identifying the clients with high risk of bowel disease. The specificity 
was 65%. 
 
 Study 2: The JLT was trialled using a prospective pre-post design to examine 
the feasibility and effectiveness of use of the JLT as a screening tool in 
pharmacies for easy identification of bowel symptoms that would benefit 
from further medical investigations. Studies were conducted in 21 community 
pharmacies in Western Australia. Data were collected to describe usual 
practice of pharmacy staff when consulting clients with bowel symptoms. This 
was followed by data collection for consultation in the pharmacies using the 
JLT as the intervention tool. The value of the JLT was assessed between the 
two phases of the study by comparing the referrals to, and subsequent 
contact with, the clients’ general practitioner (GP) for those considered to 
xv 
 
have signs of potentially-serious disease. Eighty-four participants were 
recruited for usual-practice phase and 80 for the JLT (Intervention) phase. The 
quantitative impact measures comparing ‘usual practice’ and ‘the JLT 
intervention’ indicated a significantly-higher referral rate in the Intervention 
group (38%) compared to the usual-practice group (20%). The p-value (chi-
square) for comparison of the proportions of clients who were recommended 
to consult a GP was p=0.029. The participants’ acceptance rate of GP referral 
was also higher for the Intervention group (40% vs 6%), with the p-value 
(Fisher’s exact test) being p=0.017. Forty-seven pharmacy staff completed the 
feedback questionnaire. Thirty (64%) of the pharmacy staff agreed that the 
JLT could be incorporated in the pharmacy, and 33 (70%) indicated they would 
use the JLT in future when managing clients with bowel symptoms. 
 
 Study 3: A cross-sectional design was used to assess the intention of the 
pharmacy staff to change practice and to use a screening tool such as the JLT 
when consulting clients with bowel symptoms. A pre-JLT-intervention survey 
and post-JLT-intervention survey was conducted to compare the factors that 
influence the intention to change practice before and after the intervention 
(the JLT). A questionnaire was developed based on the Theory of Planned 
Behaviour (TPB), and assessment of internal consistency and scoring were 
completed based on recommendations by Francis et al.[1] For purposeful 
selection of variables, univariate analysis was performed and the chi-square 
statistic was then used to assess the association between each of the 
questions and the intention to provide the cognitive service inclusive of the 
JLT. Logistic regression analysis was performed to identify independent 
variables contributing significantly to the prediction of intention. One 
hundred and ninety-three pharmacy staff completed the TPB questionnaire 
at baseline (Pre-JLT-intervention) from 21 participating pharmacies. The 
perceived behavioural control (Confidence) questions (p=0.002), and 
subjective norm (p=0.002) were independently associated with the intention 
to provide cognitive services. Perceived behavioural control (Confidence) 
questions (p=0.046) and subjective norm (p=0.022) showed independent 
xvi 
 
association with intention to change practice. Social or subjective norm, and 
self-efficacy of the pharmacy staff to identify ‘red-flag’ symptoms and to give 
recommendations for such clients, were the most influencing factors of the 
intention of staff to change practice and deploy JLT as screening tool for 
pharmacy clients presenting with bowel symptoms. Forty-seven participants 
completed the post-JLT-intervention TPB questionnaire. The pattern of the 
response appeared to be similar to the baseline survey. 
 
 Study 4:  A willingness to pay (WTP) study was conducted as a survey-based 
method to determine monetary valuations of a standard pharmacy 
consultation versus cognitive service, a quality-enhanced service where the 
pharmacists offer advice and written referral to the GP, with reference to 
response to a self-administered questionnaire about the presenting 
symptoms completed by the client. A video-vignette based WTP survey was 
adopted. Participants viewed two videos online – one depicting standard 
client-consultation practice, and the other depicting a quality-enhanced 
consultation based on a screening tool with greater privacy – and then 
completed a brief WTP questionnaire online. Descriptive statistics were used 
to report the study sample and identify the proportion of the consumers who 
were willing to pay. Logistic regression was used to explore the influence of 
demographic data on their responses. A total of 175 participants completed 
the WTP survey. Almost one-third (49/175, 28%) indicated WTP for service 
offered in Video 2 (quality-enhanced practice), indicating a median payment 
of AUD15. 
 
Overall, this thesis found that guided communication by appropriately-trained 
pharmacy personnel around symptoms is effective in alerting health professionals 
and clients to the need for clinical consultation. This early intervention, at a point 
where clients may be seeking symptomatic relief through a pharmacy, has the 
potential to be extended to other symptom complexes for which clients might benefit 
from discussion with a general practitioner. 
1 
 
1. Introduction 
 
1.1. Background 
 
Bowel symptoms – such as diarrhoea, constipation and rectal bleeding – are 
common, with around one in four people experiencing these symptoms each year in 
developed countries.[2-4] In the majority of cases, these symptoms are benign, 
however some may cause considerable distress or may be due to a serious underlying 
disease. A number of bowel diseases such as cancer, inflammatory bowel disease, 
irritable bowel disease, large adenomatous polyps and diverticular disease, share 
common clinical presentation.[5-7]  
 
Early detection and treatment of these diseases may improve prognosis and quality 
of life. Failure to seek help in the early stages of disease, thus delaying diagnosis, may 
result in a poor prognosis.[8, 9] There is robust evidence to suggest many people with 
bowel disease present late with symptoms, even when they have been persistent.[3, 
10-12] Definitive diagnosis of persistent symptoms requires medical 
consultation.[13] Recognition of the significance of symptoms by the general public 
is a key factor in motivating people to seek medical help. However, in studies 
conducted with people with bowel symptoms in Australia, the United States (US) and 
the United Kingdom (UK), the rates of medical practitioner consultation varied from 
14% to 41%.[14-16]  
 
In Australia, it has been estimated that there are over 250 million occasions each year 
during which pharmacists could provide professional advice and service to their 
clients.[17-19] An Australia-wide survey by Mott[20] reported that one in three of 
the 2,005 respondents used a pharmacy as a prelude to making an appointment with 
a general practitioner (GP). Published data suggest that some people consult a 
pharmacist for advice on their lower bowel symptoms.[21-23] For example, in 16 
pharmacies recruited to a study in Western Australia (WA), it was estimated that at 
least three clients per pharmacy present every week seeking treatment for bowel 
symptoms.[21] Interactions between pharmacists and their symptomatic clients offer 
2 
 
an ideal opportunity to explore how pharmacy staff can identify clients with possible 
risk factors for bowel disease and encourage them to consult their GP. 
 
However, in another WA-based survey of pharmacists, it was demonstrated that 
high-risk bowel symptoms were not recognised in a significant proportion of 
cases.[13] When compared to an expert panel’s opinion, 30% of pharmacists of the 
167 registered pharmacists surveyed did not agree that rectal bleeding for four weeks 
duration warrants a GP referral. Over 60% of pharmacists did not consider persistent 
diarrhoea in a 65-year-old client as a likely symptom of significant bowel pathology, 
which was in contrast to cancer guidelines.[13, 24]  
 
Discussing embarrassing symptoms has been reported as a barrier to seeking help, a 
challenge encountered by pharmacists when trying to obtain an accurate history and 
symptom details from their clients.[25]  
 
Screening tools for identification and triage of people at higher risk of bowel disease 
affords effective continuity of care in the primary health care system.[26-28] 
Research supports the use of short, self-administered questionnaires to help 
pharmacists identify clients whose symptoms may warrant further investigation for 
bowel pathology in a more efficient and private manner.[29-31] Despite this, there is 
a lack of literature around the availability of valid and reliable tools to help 
pharmacists identify clients with symptoms that would require further investigations 
for possible irritable bowel syndrome, diverticulosis, haemorrhoids, polyps, 
inflammatory bowel disease and cancer. 
 
In light of the above, a self-administered decision-aid tool (i.e. the Jodi Lee Test; JLT) 
was developed which could be offered to pharmacy clients presenting with bowel 
symptoms. Clients’ responses on the JLT guided pharmacy staff in identifying those 
who might benefit from medical review. Furthermore, this study evaluated clients’ 
willingness to pay for such a service through pharmacies. The feasibility of 
implementing the JLT was also considered including factors that might influence 
change of pharmacy practice.  
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Through its component studies, this research provided an understanding of the 
process of development, validation and trial of a pharmacy-led decision-making tool 
(the JLT) that identifies clients who might benefit from medical intervention for bowel 
symptoms and encourages them to seek timely help.  
 
1.2. Research Questions 
 
As evident in the literature, many adults do not seek timely help for their bowel 
symptoms. [32-36] Furthermore, a significant proportion of people identified 
pharmacies as a good source of advice for their bowel symptoms.[21] This led to the 
opportunity to investigate if early identification of pharmacy clients presenting with 
significant bowel symptoms would encourage them to seek medical help.  
 
Nine research questions formed the framework of this thesis: 
 
1: Can community pharmacy help to identify clients who might be at high risk of 
bowel disease? 
2: Do pharmacy staff know which clients should be encouraged to consult their 
general practitioner (GP) based on symptoms? 
 
After confirming that pharmacies were suitable locations for early identification of 
bowel symptoms, it was essential to search the literature for any existing screening, 
triage procedures and/or decision-making tools available for early detection of bowel 
disease.  
 
3: What are the available screening and triage tools for bowel symptoms? 
 
The next step was to develop a simple tool for use by pharmacy staff to guide their 
consultation with symptomatic clients.  
 
4 
 
4: Can a simple, easy-to-use, self-administered questionnaire (i.e. the JLT) be 
developed to identify pharmacy clients who might be at risk of bowel disease? 
5: Is the JLT a valid tool for assisting pharmacy staff to identify clients at risk of 
bowel disease in a pharmacy and to encourage them to consult a GP?  
 
It was then essential to test the JLT in community pharmacies to examine the 
effectiveness of this decision aid to guide pharmacy staff in identification and referral 
of at-risk clients for further investigation.  
 
6: Is the JLT an effective assessment tool for pharmacy clients presenting with 
bowel symptoms, assisting pharmacy staff to identify at-risk clients and provide a 
referral to consult their GP?  
7:  Can use of the JLT and referral from pharmacies encourage clients to consult 
their GP? 
 
Implementation of new behaviour or any change in behaviour requires 
understanding of specific factors that influence the behaviour.[37] As a result, it 
became important to identify factors that might influence the pharmacy staff to 
change practice. 
 
8: Do attitudes, perceived barriers and social pressure affect the intention of 
pharmacy staff to perform an activity? 
 
Lack of reimbursement for clinical services is one of the most common reasons cited 
by pharmacists regarding their failure to provide extended services.[38-41] This led 
to the determination of clients’ willingness to pay (WTP) if a screening service, where 
a self-administered questionnaire (the JLT) guides the pharmacist-client consultation 
and results in a referral to the GP if the response to the questionnaire warrants one, 
were offered in the pharmacy. 
 
9: Will Australians pay for healthcare screening and triage service from a 
community pharmacy? 
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1.3. Theoretical Framework Guiding the Project  
 
Complex interventions are often used to investigate or address health issues in fields 
such as health services, public health practice and areas of social policy making.[5] An 
intervention is considered complex when it has a number of elements:[42] several 
interacting components, a study of behaviours of those delivering or receiving the 
intervention, a number of groups or organisational involved in the intervention, 
variability of the outcomes and a degree of flexibility permitted.[43]  
 
This study was considered a complex intervention because of the following: 
  
 there was no single primary outcome in this study - a range of outcomes were 
examined 
 the intention of the pharmacy staff (who delivered the intervention) to change 
behaviour was examined   
 several dyads were examined, including the client-pharmacist, client-researcher 
and client-GP 
 there were three groups of subjects in this study: 
 pharmacy clients with bowel symptoms, recruited when they visited the 
pharmacy for management of their symptoms  
 pharmacy staff, in terms of their intention to change practice and behaviour 
relating to the intervention  
 the general population, sampled in the WTP for screening services, such as 
the screening using the JLT, if offered in pharmacies.  
 
The design of this study was guided by the Medical Research Council (MRC) 
framework.[43] The MRC framework was introduced in 2000 (and extended in 2006) 
to assist researchers to identify and adopt appropriate steps when designing a 
complex intervention.[42, 43] More attention to the initial development of the 
intervention, and a less linear and more flexible approach, were included in the 
extended version.[43] The extended version of MRC framework recognised that an 
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intervention may require adaptation to local settings, and that there may be 
difficulties in fully evaluating experimental designs in practice.[43]  
  
The MRC framework states the phases of a complex intervention are:[42, 43] 
 
 Preclinical or theoretical phase: identifying the evidence available for the 
research questions  
 Modelling/development phase: defining the components of the intervention 
based on existing evidence 
 Assessing feasibility: testing the feasibility of the intervention 
 Evaluation phase: trialing the intervention to assess its effectiveness, 
measuring outcomes and understanding the change process 
 Implementation phase: examining the possibility of implementation of the 
intervention into practice. 
  
Table 1.1 shows how the MRC framework [43] guided this thesis.  
 
Table 1.1: Overview of Thesis Chapters Based on MRC Framework  
 
Thesis Chapters MRC Framework 
1. Introduction  
2. Literature Review Preclinical phase 
Assessing feasibility 
3. Development and Validation of a     
Bowel Symptom Consultation Guide 
Modelling/development phase 
4. Jodi Lee Test - Prospective 
Observational study 
Evaluation phase – assessing effectiveness 
and measuring outcomes 
5. Intention to Change Practice in 
Community Pharmacy 
Evaluation phase – understanding change 
6. Willingness to Pay for Quality-Enhanced 
Service in Community Pharmacy 
Evaluation phase – examining willingness to 
pay for tool such as the JLT 
7. Discussion  
8. Conclusion and Recommendations Implementation phase 
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1.4. Significance 
 
Evidence documents that the prevalence of bowel symptoms in the community is 
high. Over a one-year period, almost one in four people in most developed countries 
experience lower gastrointestinal symptoms, such as rectal bleeding and 
diarrhoea.[2, 3] Many people attempt to manage their symptoms through over-the-
counter pharmacy preparations rather than present to their GP, with rate of doctor 
consultation among these patients varying from 14% to 41%.[2-4, 20] A definitive 
diagnosis for persistent bowel symptoms requires a medical consultation.[13] There 
is evidence to suggest that many symptomatic people with bowel disease present 
late and only a minority of them seek timely medical advice.[3, 10-12] Delayed 
diagnosis of serious colorectal pathology occurs mainly due to delay in the 
presentation to a GP, delayed referral to a specialist, and delay in diagnosis.[44] 
 
Pharmacy staff are well placed to help identify symptomatic clients and encourage 
them to consult a GP. Pharmacies are readily accessible to the general community, 
and many of their clients with bowel symptoms visit a pharmacy for non-prescription 
medicine purchases. Early intervention at a point where clients may simply be seeking 
symptomatic relief from a pharmacy is possible. Pharmacies could potentially screen 
clients who might benefit from medical advice especially when symptoms described 
suggest significant risk of colorectal disease and encourage them to consult their GP 
by providing them a formal, written referral letter to the GP.  
 
There is evidence that a self-administered questionnaire can be an effective tool in 
supporting pharmacists triage cases that need further investigation for bowel 
pathology.[30] Challenges, however, relate to conducting a private consultation with 
clients in a pharmacy setting who may have embarrassing signs or symptoms, and 
require referral for further investigation. Another obstacle that often precludes 
delivery of pharmacy-led primary prevention initiatives is a heavy workload.[38-40]  
 
There is a need for a simple, brief decision-making aid that can be used by pharmacy 
staff to identify clients with bowel symptoms that require medical consultation, and 
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thus may potentially improve prognoses for these clients through more timely 
diagnosis of serious conditions such as bowel cancer. 
 
This research makes a contribution to identifying how community pharmacy staff can 
be proactively involved in the continuum of health care of their clients by: 
 
 examining the effectiveness of the JLT, a decision-making aid tool, as a guide 
to pharmacy staff to identify and refer clients with bowel symptoms 
 determining factors that influence the intention of the pharmacy staff to 
change practice, and 
 estimating the proportion of the general population who are willing to pay for 
pharmacists’ quality-enhanced services, such as screening for bowel disease 
and referring to a GP for further medical investigation.  
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2. Literature Review 
 
2.1. Primary Health Care 
 
 Philosophy of Primary Health Care 
 
The World Health Report 2008 noted robust primary healthcare systems are the most 
effective way to “produce better health outcomes, improve health equity and 
respond to social expectations.”[45-47] According to the Australian Primary Health 
Care Research Institute,[48] primary health care is defined as a “socially-appropriate, 
universally-accessible, scientifically-sound first-level care provided by a suitably-
trained workforce supported by integrated referral systems in a way that gives 
priority to those most in need, maximises community and individual self-reliance and 
participation, and involves collaboration with other sectors.”[28, 48] The Australian 
Medical Association also endorses this definition,[28] stating the need for  balance 
between curative services and promotion, prevention and rehabilitation.[28] 
 
The philosophy behind primary health care is based upon understanding health and 
wellbeing and recognising determinants of health, such as gender, housing, 
education, planning, social and other services. Involvement of communities and 
individuals in planning, accessibility, acceptance and affordability of services to 
people in need remains a focus of primary health care. As such, the importance of 
health promotion and disease prevention in eliminating causes of ill health is 
recognised.[45]  
 
The Alma-Ata Declaration,[49] convened by the World Health Organization and 
United Nations Children’s Fund, made primary health care a core policy.[46] The 
Declaration was signed in 1978 by 134 health ministries during the International 
Conference on Primary Health Care, urging all participating governments to 
formulate policies to effectively implement primary health care.[50] The Declaration 
defined primary health care as “incorporating curative treatment given by the first 
contact provider along with promotional, preventive and rehabilitative services 
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provided by multi-disciplinary teams of healthcare professionals working 
collaboratively.”[28] This definition is reflected in the Australian Primary Health Care 
Research Institute definition of primary health care. This development was significant 
in entrenching the idea of health care as a human right and recognising the 
importance of primary health care in achieving this.[51]  
 
Primary health care includes health promotion, illness prevention, care of the sick, 
advocacy and community development.[28, 48] Health promotion is one of the key 
principles of primary health care. Health promotion, according to the Ottawa Charter, 
is “the process of enabling people to increase control over, and to improve, their 
health.”[52] The Ottawa Charter was the first International Conference on Health 
Promotion, held in 1986, and built on the progress from the Declaration on Primary 
Health Care at Alma-Ata.[52] According to the Charter, health promotion demands 
coordinated action by all concerned: individuals, community groups, health 
professionals, health service institutions and governments. It is about reorienting 
health services, which would lead to change of attitudes and organisation of health 
services to refocus on the needs of the individual.[52]  
 
 Primary Health Care Delivery 
 
The philosophy of delivery of efficient health care is based on social, biomedical and 
health services research.[45] The National Primary Health Care Strategic Framework 
takes a broad and comprehensive view of primary health care,[53] recognising that 
the concept of primary health care extends beyond the traditional ‘general practice’ 
focus of care.[53]  
 
Primary health care is delivered in the community outside of hospitals. Community-
based providers are diverse (Table 2.1), and include GPs, practice nurses, 
psychologists, physiotherapists, community health workers and community 
pharmacists.[54] 
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Table 2.1: Health Care System - Primary Healthcare Services  
Services Promoting Health  Primary Healthcare Services Secondary Healthcare Services Tertiary Healthcare Services 
Sectors that have 
relationships between health 
and wellbeing 
Usually the first point of contact for 
patients; generally do not require referral 
to access the service 
 
Usually do not have first contact 
with the patient; require 
referral to access services or 
services provided in a hospital 
setting 
Specialist referral services 
 Housing and community 
services 
 Economy and employment 
 Security and justice 
 Education and early life 
 Infrastructure, planning 
and transport 
 Environmental  
sustainability 
 General practice 
 After-hours medical locum service 
 Residential and community aged care 
 Allied health 
 Ambulance services 
 Aboriginal Medical Services 
 Community Pharmacy 
 Community health services 
 Child and Family Health Centres 
 Non-Government Organisations and peak 
bodies which provide health services 
 Private community based services 
 Nurse-led clinics 
 School nurses 
 Self-help organisations 
 Consumer organisations 
 Dental services 
 Health-direct Australia 
 Government services outside Health 
Directorate and Community Services 
 Pathology 
 Radiology 
 Specialists 
 Hospital inpatient services 
 Emergency Departments 
 Hospital-based allied health 
services 
 Ambulatory care clinics 
 Specialist care such as 
intensive or coronary care, 
neurosurgery 
Adapted with permission from the ACT Health Government[45] 
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In accordance with the aforementioned definitions (Section 2.1.1), for a primary 
healthcare system to be effective, it should help patients better self-manage their 
health conditions and prevent disease. It is crucial that individuals receive the health 
care they need, when and where they need it.[54] An effective way to deliver primary 
care is through primary care teams comprising GPs and other skilled healthcare 
professionals, such as pharmacists, physiotherapists or dietitians.[28] This is 
discussed in later sections of this chapter, in the context of pharmacy-GP coordinated 
care. In general terms, the primary health care team affords patients continuity of 
care through access to a comprehensive range of professional expertise.[28] 
 
2.2. Primary Health Care and Community Pharmacy 
 
The vast majority of Australians consult a GP or another primary care health 
professional at least once per year.[48] Traditionally, the primary role of pharmacies 
is to provide medication; however, pharmacists are providing an increasingly wider 
range of healthcare services in the community.[55] Community pharmacy is well 
placed to play a constructive and dynamic support role in the provision of effective 
primary health care.[55] Pharmacies have become the most accessible points of 
contact for individuals within the healthcare system, regardless of location; indeed, 
consumers can expect to receive professional attention almost immediately and 
without an appointment.[55]  
 
The Pharmacy Guild of Australia[56] and Pharmaceutical Society of Australia[57] have 
released papers explaining the broader role of community pharmacy in primary 
health care.[54] In general terms, the role includes assisting consumers with chronic 
disease, in their adherence with medication and other management, and with the 
consumer’s lifestyle and preventative health issues. Community pharmacies also play 
an important role in assisting other health professionals’ clinical decisions based on 
individuals’ medication profiles, and serve as a focal point for health screening 
programs and a referral point for government health campaigns.[54] 
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In Australia, community pharmacists represent a large professional body of 
individuals who are tertiary trained.[55] Pharmacists are registered by the Pharmacy 
Board of Australia.[58] They practise according to Australian Government and state 
and territory government legislation and regulations, and interact extensively with 
other health professionals, especially the medical profession.[55, 59] As such, 
community pharmacists should be fully integrated members of the healthcare 
system, as they play a role in primary health care and health education, and are often 
the first point of contact within the healthcare system for the general public.[60] It is 
recognised that community pharmacists balance the delivery of wide range of 
healthcare services with the supply of medicinal products.[55]  
 
In the Consumer Experience, Needs and Expectation of Community Pharmacy project, 
undertaken as part of the Third Community Pharmacy Agreement in Australia, 30% 
of the respondents reported using a community pharmacy to decide whether to 
consult a doctor.[54] That study also identified that whilst people over 65 years make 
up approximately 14% of the Australian population they contribute to 80% of the 
prescription volume in pharmacies.[54] This supports the view that older people are 
extensive users of community pharmacies.[61] People over 65 years of age were 
reported to be more likely to patronise a particular pharmacy because the pharmacist 
appeared to take a keen interest in them and gave good advice.[61] Together, these 
reports suggest loyalty plays a significant role in developing trust and continuity of 
care for people with greater needs for primary care. 
 
Despite Australia having among the lowest population density in the world, the 
extensive network of community pharmacies provides Australians with convenient, 
reliable and high-quality access to health services.[19] There are approximately 5,500 
community pharmacies across Australia, where the population exceeds 23 
million.[19, 55, 60, 62] On average, Australians visit a community pharmacy 14 times 
each year.[63] Other data suggest there are over 250 million occasions each year 
during which pharmacists may provide professional advice and service.[18, 19, 64] 
Ninety-four percent of Australian adults use a pharmacy each year, and 3.9 million 
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Australians ask a pharmacist for health advice each year, with 79% reporting the 
advice met their needs completely.[65]   
 
 Staffing in Pharmacies    
 
Key features of the staffing functions and operational responsibility in Australian 
community pharmacies are:[66] 
 
 A pharmacy manager/owner is in a position of responsibility and leadership.  
 There will always be a qualified pharmacist on duty. 
 Dispensary assistants’ work concentrates on dispensing activities, but may 
include some front-of-shop activities. 
 Pharmacy assistants’ duties may include non-dispensing activities and limited 
elements of dispensing (e.g. collection of prescriptions). 
 Pharmacy assistants may also be involved in back-of-shop tasks (e.g. ordering). 
 There may be a range of other staff in a pharmacy, including nurses, dietitians 
and storeperson. 
A number of these features are described below in the context of provision of 
pharmacy services. 
 
2.2.1.1. Pharmacists in Australia 
 
In 2014, there were over 28,000 registered pharmacists in Australia (Figure 2.1).[67] 
The available data do not indicate the proportion of these in active community 
practice; however, 2006 Australian Bureau of Statistics data cited in a national 
workforce report[68] indicate two-thirds of registered pharmacists were active in 
pharmacy workforce, and approximately 85% of pharmacists were employed in the 
community sector. 
 
 
15 
 
 
 
Figure 2.1:  Pharmacists – Percentage Distribution across Australian States  
(N=28,883)  
Adapted with permission from Pharmacy Board of Australia[67]  
 
Of the 28,883 pharmacists registered in Australia,[67] approximately 11,000 are aged 
25-34 years, followed by about 5,800 in the age range of 35-44 years.[67] Analysis by 
gender shows more female (n≤17,400; ~60%) than male (n≤11,400; ~40%) 
pharmacists.[67] Over half of employed pharmacists are women.[69] The percentage 
of male and female pharmacists across Australia based on 2014 Pharmacy registrant 
data[67] are illustrated in Figure 2.2. These demographic data are not available 
specifically for pharmacists practising in community settings. 
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Figure 2.2: Pharmacists – Percentage by Gender across Australia in 2014 
Adapted with permission from Pharmacy Board of Australia[67] 
 
In Australia, pharmacists complete either a four-year Bachelor degree or a two-year 
Graduate Entry Master degree, followed by a one-year internship.[70] The subtypes 
for registration of pharmacists, according to data from the Australian Health 
Practitioner Regulation National Boards,[58] are ‘general’, ‘provisional’, ‘limited’ and 
‘non-practising’. Pharmacy interns are granted provisional registration, and must 
obtain general registration before they are eligible to work unsupervised. The 
transition from provisional registration to general registration entails completion of 
intern training, oral and written examinations and 1,824 hours of approved 
supervised practice.[58] 
 
Limited registration is generally awarded to overseas-qualified pharmacists who do 
not qualify for general registration until they undertake a period of supervised 
practice in Australia. The supervised practice required is less than the full internship 
period of 1,824 hours required for conversion of provisional to general 
registration.[71] 
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2.2.1.2. Pharmacy Assistants in Australia 
 
There are over 43,300 pharmacy assistants employed across Australia.[70] Pharmacy 
employees are predominantly females (nearly 88%), with a mix of full-time, part-time 
and a small number of casual employees.[70] Relatively few are employed full-
time.[60]  
 
A pharmacy technician is a person who assists pharmacists in the dispensary, and 
undertakes customer service and sales.[66, 72] The primary distinguishing feature 
between a pharmacy technician and pharmacy assistant is the more significant 
involvement of the technician in dispensing area.[68] The role of pharmacy assistants 
can vary according to the legislation applicable in the relevant state and/or workplace 
setting.[72] Due to indistinct role classifications, the term ‘pharmacy assistant’ has 
been used in this thesis to collectively refer to pharmacy assistants and pharmacy 
technicians. 
 
Pharmacy assistants must have successfully completed, or be in the process of 
completing, a course recognised by the registering authority of the state in which the 
pharmacy is located. They also receive ongoing training in line with State Government 
requirements and in the area of involvement in the pharmacy.[72] The training for 
pharmacy assistants is undertaken at the vocational education and training sector 
level,[66] by State/Territory-registered training organisations. There are around 80 
competency units in the training package included in Certificate levels I to IV.[66] The 
training for supervised provision of Pharmacy (Schedule 2) Medicines and 
management of requests for Pharmacist Only (Schedule 3) Medicines forms a critical 
component of Certificate II, III and IV.[60]  
 
An overview of the Certificates is as follows:[66] 
 
 Certificate I: designed for an employee who is new to the industry, covering tasks 
such as customer relationships, sales skills and stock handling. 
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 Certificate II: requires a greater understanding of medications and more product-
specific knowledge. The pharmacy assistant is expected to develop skills to enable 
recommendation of non-prescription medicines to customers, and to learn how 
to ‘filter’ information for referral to the pharmacist for Pharmacist Only (Schedule 
3) Medicines. 
 Certificate III: designed for more experienced employees who do not require 
supervision and who may begin specialising in a particular area of pharmacy 
practice, e.g. dispensary assistant roles or front-of-shop coordination. Emphasis 
is also placed on skills for ‘filtering’ information for referral to the pharmacist. 
 Certificate IV: more management focused, covering tasks such as staff 
management and training, pharmacy management, and stock control. Training 
also includes advice and information about medicines and medicinal products to 
clients under the supervision of the pharmacist. 
 
A nationwide survey[66] of pharmacies to examine workflow processes and gain 
insight into the use of pharmacists and pharmacy assistants produced responses from 
80 of 400 pharmacies, with 39 pharmacists and 248 pharmacy assistants providing 
data.[66] Most commonly, pharmacy support staff had not completed formal training 
(Table 2.2), and there were none who had successfully completed Certificate IV at the 
time of the survey.[66]  
 
Table 2.2: Levels of Pharmacy Staff Training in Australia  
 
Current level of training % (N=248) 
Secondary schooling less than Year 12 31.9% 
Secondary schooling to Year 12 42.3% 
On the job training 56.9% 
Formal pharmacy training 22.2% 
Certificate I 13.3% 
Certificate II 27.0% 
Certificate III 15.3% 
Pharmacy Guild of Australia Industry Grade 3 3.2% 
Pharmacy Guild of Australia dispensary training 12.1% 
Adapted with permission from The Pharmacy Guild of Australia[66] 
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Twenty-eight percent of the respondents were either front-of-pharmacy managers, 
salespersons or in an administrative support role. Fifty-three percent were pharmacy 
assistants and 19% were dispensary technicians. Nearly 50% of the pharmacy 
assistants reported they were interested in pursuing further training in community 
pharmacy, and 89% of the pharmacy manager/owners indicated their pharmacy 
encourage advanced training of assistants.[66] Furthermore, the survey reported 
pharmacy owners/managers and salaried pharmacists envisaged a greater role for 
assistants in the dispensary area and in providing advice on medicine and other 
health care.[66]  
 
 Roles of Pharmacists and Pharmacy Assistants  
 
Pharmacists are recognised by the Australian public as providing valued advice on a 
range of health issues.[54] In addition, pharmacists rated second in the 2014 Gallup 
Poll among the most trusted professionals,[73] and second for honesty and ethical 
standards according to the 2015 Roy Morgan survey.[74] The Australian public’s trust 
and confidence in pharmacists has increased vastly over the years.[75] In the recently 
published report by the Pharmacy Guild of Australia[76] on the survey of 3000 
consumers as a part of the Fifth Community Pharmacy Agreement Research and 
Development Program, 90% of participants reported being satisfied with the 
interaction they had with the pharmacists.  
 
Pharmacists are accountable for the advice and service provided in their 
pharmacies.[19] They are well positioned to identify clients who may benefit from 
information and advice on effective health care, and can provide them with valuable 
advice about medications, products and services. Pharmacists can also refer clients 
to other local health services when appropriate. Pharmacists have become 
increasingly involved in client-orientated services involving development of client 
profiles, client monitoring and client counselling.[61, 77]  
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The services offered by pharmacists differs from pharmacy to pharmacy in response 
to local needs. The most common preventative and chronic management services 
offered[63] are: 
 
 Asthma management support 
 Blood pressure monitoring 
 Bone density testing 
 Diabetes risk assessment and self-management support (including Diabetes 
MedsCheck) and National Diabetes Services Scheme (NDSS) Access Point 
 Cholesterol testing 
 Weight loss, sleep apnoea and smoking cessation programs 
 Product recalls and safety alert information and co-ordination 
 Continence support 
 Community health education/promotion (structured). 
 
The pharmacist in charge of the pharmacy business is responsible for ensuring 
pharmacy assistants’ functions are limited to those not requiring them to exercise 
professional judgement.[78] Pharmacy assistants perform various duties in the 
pharmacy independently or under the supervision of a qualified pharmacist.[66] 
 
Pharmacy assistants can provide general product knowledge and advice to the client 
and refer clients with symptoms or medical conditions or queries about the 
medications to the pharmacist. The duties of assistant in the dispensing area might 
include stock management, preparing and attaching dispensing and cautionary and 
advisory labels, gathering non-clinical information from clients and collating 
prescriptions.   
 
It has been suggested that working with suitably-qualified pharmacy assistants to 
perform routine technical tasks should reduce the burden of the pharmacist, thus 
increasing the time for professional contact with clients.[72] 
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 Value of Pharmacy Advice   
 
In addition to dispensing, pharmacies have become important providers of various 
client-centred healthcare services.[55, 77] Several of these activities present 
pharmacists with opportunities to identify and address health-related issues in their 
clients.[77] Pharmacists may provide various preventive interventions, such as lipid 
and osteoporosis testing. [79] As established in Section 2.2.2, pharmacists are a 
valuable member of the primary health care team.[79]  
 
Consumers’ satisfaction with pharmacy services has always been high. Convenience 
of location and health advice by the pharmacists have been rated highly, and 
reported as the primary reason for patronising a specific pharmacy.[73] In the US 
National Pharmacy Consumer survey, consumers (N=1201) who reported having 
filled at least one prescription in the past six months were asked about their 
satisfaction relating to a range of consumer experiences.[80] The top six response 
options (of 12) indicate communication was highly valued (Figure 2.3).[80] 
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Figure 2.3: Consumer Satisfaction with Pharmacy Services (N=1201)  
Adapted with permission from Stergachis et al.[80]  
 
An Australia-wide pharmacy survey by Hamilton and Tee (2010) investigated the 
forward-looking and value-adding services in pharmacies that could determine their 
potential effects on client service and client satisfaction.[81] The most positive 
factors were personalised services such as immunisation, risk reports and advice, and 
efforts made to meet each client’s requirement. Additionally, the ability of clients to 
access additional health information and thorough, but not excessive, consultation 
with supporting explanation by the pharmacists was claimed to add to the value of 
the pharmacies.[81]  
 
2.3. Effective Primary Health Care  
 
Health stakeholders, including government services, private health services and non-
government organisations, along with individual health professionals and consumers, 
play a major role in delivering effective primary health care.[45]  The primary health 
care system should encourage coordination between consumers and their carers to 
provide health care that is safe and of high quality.[45] Trust and established 
relationships between stakeholders, including consumers, are important to work 
towards the common goals of delivering effective primary health care.[45]  
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 Inter-Professional Care 
 
Inter-professional care is grounded in professional communication skills, mutual 
respect of the expertise of other health professionals, and referral networks.[45] 
Primary health care is facilitated by inter-sectoral cooperation and coordination at all 
levels, developing a balance between health promotion, preventive care and illness 
treatment, and developing multi-disciplinary teams drawn from a variety of 
disciplines, including medical, nursing, pharmacy, allied health, community aid, 
population health, and health promotion and education.[45] 
 
While pharmacy consultation and a GP consultation differ in their scope and intent, 
pharmacy offers a convenient encounter with the health system for many purposes. 
Pharmacies are positioned to become, and be recognised, as the most commonly 
accessed health service provider, with the capacity to promote symptom awareness 
and to offer support and/or referral to individuals with symptoms who have not 
sought diagnosis, advice or treatment.[82] 
 
 Referral from Pharmacy to General Practice  
 
In addition to being recognised as one of the first ports of call for health advice, 
referral to other health services is increasingly mentioned as an important strength 
of community pharmacy.[83] A number of studies evaluating the impact of 
collaboration of pharmacists and GPs resulting in positive client outcomes have been 
reported. 
 
Hassel et al.[83] explored the advice-giving behaviour of staff in community 
pharmacies. The researchers used an ethnographic style research strategy, 
combining pharmacists and client interviews with non-participant observation of 
medicines- and health-related interaction between pharmacy users and staff. From 
the observational data, several criteria were identified as important in pharmacists’ 
decisions to refer cases to general practice or other services. A pharmacist 
participating in the study said, “It depends on the symptoms you are treating, if it is 
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straightforward self-limiting ailment, then that’s actually quite straightforward to 
deal with. If there are other things that provide question marks in your mind, you 
refer.”[83] Furthermore, for some clients, the pharmacy was viewed as a ‘filter’ to 
the GP, someone to use before going to the GP, or someone who could advise a visit 
to the GP if one was thought necessary.[83] Findings from the study suggest that 
pharmacists often identify potentially serious symptoms that may be overlooked or 
ignored by clients. This study did not report if the clients consulted their GP after 
being advised by the pharmacist, and if so, whether further investigations were 
recommended or if a diagnosis was made.  
 
Bereznicki et al.[84] assessed the impact of an intervention initiated by community 
pharmacists that involved the provision of educational material and GP referral. The 
impact on asthma knowledge and self-reported asthma control and asthma-related 
quality of life was recorded in clients whose asthma was not managed well. The 
intervention pack included: a personalised letter from the pharmacist, referring the 
client to his/her GP; an asthma knowledge, asthma control and asthma-related 
quality of life questionnaire; and the dispensing details of the client to give to the GP. 
The researchers claimed their study provided evidence that community pharmacists 
could effectively identify clients who may have suboptimal management and refer 
such clients to their GP for review, and community pharmacists and GPs could 
effectively work together to improve client-reported outcomes in asthma.[84] 
 
Although there was no mention in that study of the proportion of participants who 
sought a review with their GP, it is assumed that the improvement in the asthma 
control in the intervention group was based on better medical management. As such, 
the study also provided evidence that community pharmacists were well placed to 
identify clients with suboptimal management and control of their asthma because of 
their access to computerised dispensing records and their frequent contact with the 
client. This facilitated easy referral of the clients to their GP for review.[84] 
 
In Australia, the Pharmacy Diabetes Care Program investigated the capacity of 
community pharmacies to identify, and refer to the GP, people in the community at 
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risk of Type 2 diabetes.[85] The study compared two screening methods managed in 
the pharmacy: risk assessment alone, and risk assessment followed by a finger-prick 
random or fasting glucose test. The GP referral form included the participant’s details 
and consent form, results from the glucose test (if applicable), and a request for 
further tests to be conducted by the GP.[85] GP referral from pharmacists and the 
uptake of referral was higher for the glucose-tested group, suggesting the addition of 
a clinical test provided results more meaningful to both pharmacists and clients. The 
findings from the study showed the pharmacy screening service had potential to 
identify a substantial number of people in the community who have undiagnosed 
type 2 diabetes.[85] 
 
A pilot study by Jiwa et al.[31] validated a cough questionnaire used to triage clients 
presenting in community pharmacies. The Pharmacy Cough Assessment Tool 
identifies clients with cough who may benefit from referral to a GP. Clients whose 
symptom profile warranted a referral were provided with a printed template referral 
letter along with the completed questionnaire to take to the GP. Of the 37 clients 
who were advised to consult their GP, seven attended their doctor. Although the 
referral uptake was not significant, of the clients who made an appointment to 
consult the GP, most were offered further investigation.[31] All 37 who were referred 
scored poorly on the quality of life questionnaire, indicating that people identified 
using this assessment tool could have benefited from GP consultation. 
 
Another proof-of-concept study by Jiwa’s team[23] explored the identification of 
pharmacy clients with high-risk bowel symptoms. This study tested the deployment 
of a self-administered questionnaire as an aid to advising pharmacy customers with 
bowel symptoms. The initiative involved a template referral letter issued when GP 
consultation was deemed appropriate. Of the eight patients with scores of concern 
on the intervention tool (the Patient Consultation Questionnaire, described in Section 
2.7.4.1), five visited their GP when referred by the pharmacists.[23] There was no 
control group to compare the referral rate and the GP visit rate.  
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2.4. Practice Change in Community Pharmacy  
 
Cognitive pharmacy services are “professional services provided by pharmacists, 
using their skills and knowledge to take an active role in contributing to client health 
through effective interaction with both clients and other health professionals”.[86] 
Community pharmacy in Australia has been at the forefront of this international 
trend toward the delivery of cognitive pharmacy services.[87] However, there is some 
evidence that actual practice often differs from the recommended delivery of 
services,[88] and there are substantial gaps between best evidence and the 
management clients receive.[89-91] Implementation of a particular behaviour 
requires an understanding of specific factors that influence the behaviour.[37] 
 
For successful implementation of any evidence-based practice, the barriers – which 
could be at the individual, organisational or/and national level – should be recognised 
and addressed.[88] A systematic review by Cabana et al. proposed the barriers 
affecting the change in practice as knowledge, attitude, resources and other external 
factors:[92]  
 
 Knowledge 
 Lack of awareness and familiarity or disagreement with the change 
 Lack of skills to implement a change 
 Attitude 
 Difficulty in changing ingrained practices  
 Feeling that new practice would not bring positive outcomes  
 Resources 
 Lack of staff  
 Lack of resources  
 Lack of managerial leadership 
 External barriers  
 Attitudes of clients who may resist a new practice  
 Environmental factors such as lack of time, organisational constraints 
 Structure of reimbursement mechanisms. 
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Research was conducted by Roberts et al. to identify the key components needed for 
the development of a practice change model for Australian community 
pharmacies.[87] The study developed and validated an instrument to allow the 
identification and quantification of facilitators of practice change, drawing on the 
experiences of those involved with existing community pharmacy services and 
programs.[87] Roberts et al.’s study identified a range of facilitators for change of 
practice in community pharmacies and items forming each factor (Table 2.3). 
 
Table 2.3: Facilitators (Factors) and Items Forming (facilitating) that Factor  
 
Factor Items 
Relationship with GP  Communication with GP 
 Good working relationship with GP 
 Cooperation with GP on key elements of change 
Remuneration  Payment is necessary 
 Incentive payments for pharmacies 
 Profitable for pharmacies 
 Key concern in deciding to implement change 
Pharmacy layout  Right pharmacy layout is necessary for implementation of 
change in practice 
 Designated pharmacy area for delivering service 
Patient Expectation  Motivated because customers expect it 
 Demand for services 
Staffing  Sufficient number of staff as a key factor in 
implementation of change in practice 
Communication and 
teamwork 
 Communication with staff member of proposed change 
 Importance of working as a team 
External support/assistance  External support for pharmacies to implement practice 
change 
Adapted with permission from Roberts et al.[87]  
 
Adherence to a change in practice may be hindered by a variety of barriers. A 
theoretical approach can help explain these barriers and help target interventions to 
address specific barriers. 
 
2.5. Behaviour Change in Community Pharmacy Practice 
 
Change in pharmacy practice, particularly to facilitate new primary healthcare 
services, requires consideration of behaviour change theory. Change is more likely to 
28 
 
be accepted and implemented if strategies are developed after identifying the 
barriers.[93] Numerous approaches that contribute to the understanding of the 
process of change have been reported:[88] 
 
 Learning theories suggest particular behaviours will be repeated if they are 
rewarded with incentives, and stopped if they are penalised  
 Social cognition models propose beliefs and attitudes as key to the way people 
behave 
 Organisational models of change examine stages that organisations go through 
in the process of change. 
 
The Theory of Planned Behaviour (TPB) is a Social Cognition model and is considered 
the direct determinant of behaviour. As such, it constitutes a theoretical framework 
for the explanation and prediction of social behaviour.[94]  
 
 Theory of Planned Behaviour 
 
Concepts referring to behavioural dispositions, such as attitudes, beliefs and social 
influence, have played an important role in understanding and predicting human 
behaviour. The TPB (Figure 2.4) is one of the most tested and robust social 
psychological models, designed to predict and explain human behaviour in specific 
context.[95, 96] The TPB is an extension of the Theory of Reasoned Action (Figure 
2.5).[95] According to the Theory of Reasoned Action, “a person's intention to 
perform a specific behaviour is a function of two factors: attitude (positive or 
negative) toward the behaviour and  the influence of the social environment (general 
subjective norms) on the behaviour.”[97] As in the Theory of Reasoned Action, a 
central factor in the TPB is the individual’s intention to perform a given behaviour. 
The TPB incorporates perceived behavioural control as a third factor that influences 
behavioural intention.[97]     
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Figure 2.4: Theory of Planned Behaviour 
Adapted with permission from Ajzen’s Theory of Planned Behaviour[95, 97] 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Theory of Reasoned Action  
Adapted with permission from Madden et al.[97] 
 
2.5.1.1. Intention 
 
The TPB proposes ‘intention’ is the immediate determinant of behaviour, because it 
reflects the person’s level of motivation and desire to exert effort.[98] The intention 
of a person to perform the behaviour depends on the person’s willingness to try and 
Attitude 
Behavioural 
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the effort required to perform that behaviour. The stronger the intention, the more 
likely the behaviour would be performed.  
 
2.5.1.2. Attitude 
 
The attitude toward the behaviour is determined by the person's belief that a given 
outcome will occur if he/she performs the behaviour, and by an evaluation of the 
outcome.[97] Attitude refers to the degree to which a person has a favourable or 
unfavourable evaluation or appraisal of the behaviour in question.[95] 
 
2.5.1.3. Subjective Norm 
 
The social or the subjective norm is the level of influence of what others think he/she 
should do, has on a person to perform a behaviour.[97, 99] In other words, subjective 
norm is the perceived social pressure to perform or not to perform the behaviour.[94] 
 
2.5.1.4. Perceived Behavioural Control 
 
Perceived behavioural control plays an important part in the TPB. In TPB, the 
perceived behavioural control, attitude and subjective norm hold the same level of 
influence on the behavioural intention, which in turn influences the behaviour. 
(Figure 2.5).[94] Perceived behavioural control reflects the ease or difficulty 
associated with performance, and the person’s confidence in performing that action. 
Preparation to perform an activity and effort the expended during performance can 
be influenced by self-efficacy beliefs.[100]  
 
The perceived behavioural control also has a direct influence on the behaviour. The 
effort expended to successfully perform a behaviour is directly proportional to the 
perceived behavioural control.[95]  
 
 Predicting Behaviour using the Theory of Planned Behaviour 
 
The TPB has been widely used to understand health professionals’ attitude, perceived 
barriers, beliefs and the influence of external factors in achieving best practice. The 
ability of the TPB to predict behaviour has been corroborated by numerous studies:  
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meta-analytic reviews across a range of behaviours,[101] health behaviours in 
general,[102-104] adherence to exercise,[98, 105] and prediction of participation in 
cancer screening.[106, 107] There are number of studies conducted in pharmacies to 
predict behaviour using this theory, as described below.  
 
Farris et al. studied the relationship between intention to change behaviour and 
provision of pharmaceutical care.[108] Pharmaceutical care is defined as “the 
responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a client’s quality of life”.[109] These researchers also quantified 
intention and behaviour to provide pharmaceutical care, and studied the relationship 
between intention and behaviour. The reported findings supported previous work 
that indicated that behavioural control has additional power in predicting goal-
oriented behaviours.[95, 110] The authors argued pharmaceutical care 
implementation programs considering perceived behavioural control in providing 
pharmaceutical care, rather than addressing individual factors, could be key in the 
success of the implementation program.[108] The behavioural measure employed 
was self-reported, and the causal model reported in this study requires further 
validation, given the changing nature of pharmacy practice. 
 
A pharmacy smoking cessation study conducted in the US[111] evaluated the 
knowledge and attitude of pharmacy technicians after they attended an education 
program. Community pharmacy staff are ideally situated to promote smoking 
cessation to clients, but barriers were identified for not providing this service in the 
pharmacy. Knowledge and attitudes of the pharmacy assistants were evaluated 
before and after a continuing education program. Both significantly improved after 
the program.[111] This is in line with the TPB stating that confidence, a factor of 
perceived behavioural control, influences the action of a person. Self-efficacy beliefs 
influence choice of activities and effort expended during performance.[95] 
 
Odedina et al.[37] developed a theoretical framework that explained pharmacists’ 
behaviour relative to the provision of pharmaceutical care. The implementation of 
pharmaceutical care in pharmacies involves change in the functions of pharmacists, 
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and change in the relationship of pharmacists with clients and other health care 
providers.[109] Odedina’s study confirmed the TPB, in that perceived behavioural 
control significantly predicted behavioural intention, and attitude and subjective 
norm also directly influenced behavioural intention. According to these authors, if 
pharmacists’ attitudes towards the behaviour are identified, and perceived 
behavioural control and influencing social norms are addressed, this will facilitate 
enhanced delivery of pharmaceutical care.[37] 
 
A study by Grimshaw et al. applied the TPB to community pharmacy behaviour, 
identifying the barriers to/facilitators of evidence-based practice, and examined the 
relationship between beliefs and intention to change behaviour relating to the 
treatment of vaginal candidiasis with non-prescription medicines.[112] The 
researchers developed a questionnaire based on the TPB, completed by community 
pharmacists. The pharmacists showed positive attitude towards supply of antifungals 
to symptomatic women. This study showed that the pharmacist’s attitude was the 
best predictor of behavioural intention. The pharmacy setting, pharmacist’s 
knowledge and customer characteristics (e.g. elderly, pregnant) also played an 
important role in decision-making.[112] 
 
 Willingness to Pay for Community Pharmacy-Delivered Cognitive 
Services 
 
Cognitive pharmacy services provided within pharmacies require effective use of 
skills and knowledgeable staff. This is achieved by active and adequate interaction 
with the client and other health professionals. Despite attempts to more broadly 
increase the community pharmacist’s role in health care, obstacles often preclude 
delivery of such quality-enhanced pharmacy services.[113] Along with heavy 
workloads, lack of reimbursement for clinical services is one of the most common 
reasons cited by pharmacists regarding their failure to provide such services.[38-41] 
Economic viability through public and private funding would be key in the long-term 
sustainability of such services in the pharmacies, especially in a budget-constrained 
health system.[114]  
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Health-related advice in Australian pharmacies is provided at no cost to clients, and 
without financial support from government or private health insurance.[114] This 
financial barrier is one of the most common reasons for pharmacists’ reluctance to 
provide more comprehensive cognitive services, the common perception being 
clients are not willing to pay for such services.[115] Contrary to that belief, there is 
evidence that more clients are willing to pay for pharmacists’ services today than 15-
20 years ago.[116] Few studies have attempted to investigate WTP for pharmacy 
services in Australia. 
 
A study evaluating client’s WTP for personalised asthma management trialled – at no 
cost to participants – in Australian pharmacies reported the participants valued the 
pharmacists’ services and were willing to pay.[114] In further analysis, the same 
researchers identified clients were willing to pay a median of AUD18.00 for 
consultation in a private area, and AUD22.80 for provision of comprehensive advice 
on asthma and related medication.[117]  
 
A recent study of 80 participants recruited from eight pharmacies in WA[118] 
determined WTP and cost-effectiveness pertaining to a pharmacy-based smoking 
cessation program that used digital ageing of the client’s image as a motivational 
intervention. The program was cost-effective, with an incremental cost-effectiveness 
ratio of AUD46 per additional quitter.[118] On average, participants indicated they 
were willing to pay AUD20.25 for the service.[118] 
 
Hanna et al.[115] determined the WTP of clients (n=130) and its relation to 
demographic variables for diabetes management in 14 community pharmacies across 
Sydney, Australia. WTP was assessed by asking how much the clients were willing to 
pay for initial and follow-up consultation, ranging from AUD0-80 in $10 increments, 
per 30 minutes of consultation.[115] The four scenarios assessed were 50 and 100% 
improvement in diabetes control after a 30-minute initial and 30-minute follow-up 
consultation. For 50% improvement following a 30-minute initial consultation, clients 
were willing to pay a median of AUD30, while for 100% improvement, they were 
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willing to pay AUD40. The WTP for a 30-minute follow-up consultation was AUD20 
for 50% improvement, and AUD30 for 100% improvement.[115] 
 
2.6. Bowel Disease 
 
This section explores the clinical presentation of bowel conditions, as a foundation 
for the clinical intervention reported in this thesis. The role of pharmacies in 
management of bowel symptoms in the community is then evaluated with reference 
to published research. 
 
Bowel symptoms, such as diarrhoea, constipation and rectal bleeding, are 
common.[4] Over a one-year period, almost one in four people in most developed 
countries experience lower gastrointestinal symptoms, such as rectal bleeding and 
diarrhoea.[2, 3] Similarly, it has been reported one or more gastro-intestinal 
symptoms are prevalent in 47% of women and 27% of men.[119] A number of bowel 
(colorectal) diseases share common clinical presentations, and certain symptom 
profiles significantly increase the risk of serious underlying conditions such as cancer, 
inflammatory bowel disease (IBD), large adenomatous polyps,[5] diverticular disease 
and irritable bowel syndrome (IBS).[6, 120] Other benign bowel diseases include 
haemorrhoids, anal fistula and anal fissure, all of which need to be managed 
conscientiously.[121] The symptoms of benign bowel disease often mimic those of 
malignant conditions, complicating diagnosis. Symptoms of particular concern, and 
that have been associated with colorectal cancer (CRC) are rectal bleeding, 
abdominal pain and abnormal bowel habits. CRC is also a major public health 
concern. 
  
 Diverticular Disease 
 
Colonic diverticulosis refers to bulging pockets of tissue (sacs) that push out “colonic 
lumen due to mucosal herniation through the colonic wall at sites of vascular 
perforation.” In diverticulitis, the diverticulum ruptures and becomes infected. 
Diverticular disease and its complications are responsible for nearly 40% of hospital 
emergency admissions for bowel pathology. The prevalence of colonic diverticulosis 
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increases with age, and the condition is more prevalent in developed countries.[122-
124] Diverticular disease affects more than 65% of people over the age of 80, whereas 
less than 10% of people younger than 40 will develop the disease.[123, 124]  
 
Non-symptomatic diverticular disease is frequently an incidental finding during an 
assessment for a different purpose using stool testing or colonoscopy.[122] While 
majority of patients with diverticulosis are asymptomatic, 20-30% will develop 
symptoms.[6] Patients with symptomatic diverticular disease present with abdominal 
pain, bloating and constipation.[6, 7, 122, 123, 125] Since the incidence of this disease 
increases with age, those presenting with symptoms are mostly the elderly.[6] [6, 
122] Another complication is haemorrhage, affecting 5-15%.[6] Inflammatory bowel 
disease, Crohn’s disease and ulcerative colitis, may have similar presentation to 
diverticulitis.[6] Figure 2.6 shows the diagrammatical representation of the natural 
history of diverticulitis, adapted to highlight the associated symptoms.[6] 
   
 
Figure 2.6: Natural History of Diverticulosis  
Produced using data from Fearnhead et al.[6] 
 
Diverticulosis 
25% symptomatic 75% asymptomatic 
Symptoms: 
Abdominal 
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25% haemorrhage 75% diverticulitis 
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follow-up required 
 
1/3 asymptomatic 
1/3 non-specific 
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25% recurrent or 
complicated 
diverticulitis 
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Diverticular haemorrhage, which is more common in the older age group, is not 
tolerated well by these individuals, leading to significantly high morbidity and 
mortality rates.[6] Diverticulitis ranges from uncomplicated diverticulitis, which is 
more common, to complicated diverticulitis, which requires surgical intervention.[6] 
The majority of patients with diverticulitis present with short duration of symptoms 
and may have recurrent attacks.[124]  
 
Diverticulitis impacts the health-related quality of life of patients. Studies show 
evidence of poor scores on SF-36 quality of life (QoL) questionnaire by patients with 
this disease.[126, 127] Specifically, diverticulitis was reported to have a negative 
impact on QoL scores relating to physical, psychological and social functioning.[126-
128] These manifest as compromised work productivity, sleep interruption, sexual 
dysfunction, depression, lack of motivation, anger and anxiety.[128] 
 
The severity of diverticulitis is often graded via Hinchey’s classification: the risk of 
death is less than 5% for most patients with Stage 1 or 2 diverticulitis, approximately 
13% for those with Stage 3, and 43% for those with Stage 4.[124] 
 
 Inflammatory Bowel Disease  
 
IBD is not a single entity, rather a collection of inflammatory disorders of the bowel, 
which include Crohn’s disease and ulcerative colitis.[129-132] These diseases are 
characterised by relapses and remissions.[133] The aetiologies of these diseases are 
at this time unknown.[133] They represent a collection of diseases where the lining 
of digestive tract becomes inflamed and damaged.[132] The incidence and 
prevalence of IBD has increased significantly in the past decade.[129] The prevalence 
of IBD is highest in developed countries, e.g. North America and Europe. However, 
IBD cases are emerging in developing countries like China, South Korea and India, 
possibly related to industrialisation of these countries.[134] The prevalence of 
ulcerative colitis worldwide ranges from 37 to 246 cases per 100,000.[129] The 
prevalence of Crohn’s disease worldwide ranges from 26 to 199 cases per 
100,000.[129] 
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Common symptoms in ulcerative colitis and Crohn’s disease are rectal bleeding, 
diarrhoea, abdominal pain and weight loss (Figure 2.7).[130, 132] The disorders share 
other points of similarity: features of genetic susceptibility, epidemiologic, 
immunologic, and other pathogenetic features. However, ulcerative colitis involves 
the colon (large intestine) only, whereas any part of the gastrointestinal tract may be 
affected in Crohn’s disease.[135] For most people with IBD, there will be periods of 
remission interspersed with flare-ups. The flare-ups are the active stage of the 
disease.[136] Although there is no cure for IBD, it can often be effectively managed 
with medication.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Diagnostic Criteria of Ulcerative Colitis and Crohn’s Disease  
Produced using data from Bernklev et al.[135]  
 
Crohn’s Disease Ulcerative Colitis 
Presence of at 
least three of the 
criteria 
Diagnostic criteria 
1. A history of diarrhoea and/or 
blood or pus in the stools 
2. Macroscopic appearance at 
endoscopy with continuous 
mucosal inflammation 
3. Microscopic features at biopsy 
compatible with UC 
4. Excluding criteria of CD at small 
bowel x-ray, ileoscopy, or biopsy 
Diagnostic criteria 
1 Typical clinical features, including 
abdominal pain, diarrhoea, weight 
loss 
2 Macroscopic appearance at surgery 
or endoscopy  
3 Radiological evidence of stenosis in 
the small bowel, segmental colitis, 
or findings of fistulae 
4 Histological evidence of transmural 
inflammation or epithelial 
granulomas with giant cell  
 
Presence of two 
or more of the 
criteria 
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IBD is chronic and debilitating, with a significant impact on health status,[137] activity 
limitation and restriction in participation.[138] A disease-specific symptom scale, the 
Inflammatory Bowel Disease Questionnaire, has been developed to assess quality of 
life of patients with IBD, and comprises four domains: assessing the bowel symptoms, 
systemic symptoms, emotional functions and social functions.[131, 137, 139]  
 
Using the Inflammatory Bowel Disease Questionnaire, researchers have identified a 
negative correlation between quality of life in IBD patients and variables such as 
unemployment and sick leave.[135] Indeed, work absenteeism and requirement for 
financial support add to the mounting cost of these diseases.[140, 141] 
 
Patients with IBD are at increased risk of developing CRC. Although IBD-associated 
cancer only constitutes 1-2% of all colorectal carcinomas, CRC is a common cause of 
death in IBD patients.[142, 143] 
 
 Irritable Bowel Syndrome 
 
IBS is characterised by chronic abdominal pain or discomfort associated with a change 
in bowel habit that cannot be explained by any organic or biochemical 
abnormality.[120] It is defined as a “group of functional bowel disorders in which 
abdominal discomfort or pain is associated with defecation or a change in bowel 
habit, and with features of disordered defecation.”[120, 144-146] The Rome III 
classification system characterises IBS in terms of multiple physiological 
determinants contributing to a common set of symptoms, rather than a single disease 
entity. Diagnosis is based on identifying positive symptoms and excluding “alarm 
features” such as weight loss, refractory diarrhoea, and family history of colon 
cancer.[120]  
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Symptoms that cumulatively support the diagnosis of IBS are:[120] 
 
 
• abnormal stool frequency 
• abnormal stool form (lumpy/hard or loose/watery stool) 
• abnormal stool passage (straining, urgency, or feeling of incomplete evacuation) 
• passage of mucus 
• bloating or feeling of abdominal distension. 
 
Population-based studies estimate prevalence of this condition at 7-22%, higher in 
women, and initial presentation commonly at 15-40 years of age.[7, 147-150] 
 
Patients with IBS exhibit similar degrees of impairment of QoL to those reported by 
those with IBD.[147] The natural history of IBS is one of relapsing symptoms.[147] 
The presence of co-morbid medical conditions and the extent to which their IBS 
symptoms affect their physical and mental wellbeing determine patients’ help-
seeking behaviour.[16] 
 
 Colorectal Cancer 
 
Bowel cancer, which includes cancers of the bowel or large intestine and cancers of 
the rectum and anus, is sometimes referred to as CRC.[151] It is the second-most-
common cancer diagnosed in males (after prostate cancer) and in females (after 
breast cancer) in Australia. The incidence of bowel cancer has been increasing each 
year since 1982, with 15,151 new cases diagnosed in 2011. In 2011, the age-
standardised incidence rate was 62 cases per 100,000 persons.[152]  It is also second 
only to lung cancer as the most common cause of cancer death in Australia.[151] 
There is currently a one-in-10 lifetime risk for males of being diagnosed with CRC by 
the age of 85 years, and a one-in-15 risk for females.[153]  
 
Lower bowel symptoms may be indicative of CRC, especially when persisting for at 
least four weeks in individuals aged ≥60 years, and for at least six weeks in those aged 
≥40 years, respectively.[154] Almost 40% of people aged 50 years and older harbour 
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adenomatous polyps; 2% of such adenomas will progress to cancer.[155] Prognosis 
is better if CRC is detected at an early stage. The progression from identifiable 
precancerous phase to CRC takes approximately 5-10 years. So there is opportunity 
for screening programs. When CRC is diagnosed at an early, localised stage, the five-
year survival rate is 91%, decreasing to just 9% for diagnosis involving distant 
metastases.[156, 157] In Australia, bowel cancer is not diagnosed at an early stage in 
the majority of cases.[156]  
 
Symptoms such as rectal bleeding, anaemia, change in bowel habit and abdominal 
pain are predictors of CRC and advanced adenomas.[158-162] Retrospective data 
suggest about 40% of patients with CRC have rectal bleeding, but the risk of CRC for 
a patient with rectal bleeding is thought to be relatively low.[163] Rectal bleeding has 
a positive predictive value of 3-7% for CRC and 4% for colonic adenomas.[163] The 
National Institute for Health and Clinical Excellence, UK, recommends urgent referral 
of clients aged over 40 years with six weeks of rectal bleeding accompanied by 
diarrhoea, and referral of clients aged 60 years or more with rectal bleeding for six 
weeks without anal symptoms or diarrhoea.[154] An estimated 28-41% of people 
experiencing rectal bleeding consult their GP.[3, 164] 
 
Clients with more severe chronic constipation are associated with a significantly 
greater risk of developing CRC and benign colorectal neoplasm over time, compared 
to chronic constipation-free patients.[165] 
 
The prognosis for CRC detected at early stage is good. Hamilton et al. reported in 
their recent study that colon cancer was one of the cancers for which the 
symptomatic patients would benefit in expediting the diagnosis.[166] Adenomatous 
polyps, generally accepted as non-obligate precursor lesions, are common in adults 
over age 50 years, but the majority of polyps will not develop into adenocarcinoma; 
histology and size determine their clinical importance.[167-169] 
 
The testing options for early detection of CRC and adenomatous polyps for adults 
aged 50 years and older are:[169] 
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 flexible sigmoidoscopy every 5 years, or 
 colonoscopy every 10 years, or 
 double-contrast barium enema every 5 years, or 
 computed tomographic colonography every 5 years. 
 Annual guaiac-based faecal occult blood test (FOBT).  
 
2.6.4.1. Faecal Occult Blood Test 
 
One screening test that is accessible and key to early detection of CRC is the FOBT, 
which can detect small amounts of blood in the bowel motion. This involves testing 
two or three motion samples. Samples are collected in the privacy of the patient’s 
home, deposited at an agency, and forwarded to a pathology laboratory for analysis. 
The results are sent to the patient and his/her GP. If the results are positive, further 
investigations are recommended.[170] 
 
Although this test is the most researched for bowel cancer, there are limitations in its 
availability via the National Bowel Cancer Screening Program in Australia. Since the 
program is limited to people aged 50, 55, 60, 65 and 74 years, it excludes a proportion 
of people at risk of CRC. The average age of a patient with CRC is 68 years.[171] 
Participation in the program is reportedly poor,[172] with barriers such as 
“inconvenience of the testing process, aversion to manipulating faeces, lack of 
perceived benefit of screening, fear of a diagnosis of cancer, cost, views about 
personal invulnerability, and cultural beliefs and attitudes.”[173] 
 
2.7. Help-Seeking Behaviour 
 
Seeking medical advice and initiation of treatment in the early stage of a disease 
improves the prognosis and QoL. It follows that late presentation or failure to seek 
medical help may delay the diagnosis and worsen the prognosis.   
 
Help seeking is a complex phenomenon that may be influenced by a multitude of 
factors including age, socioeconomic status, marital status, education, employment 
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status, level of health insurance, ethnicity, lack of perception of the seriousness of 
the disease, an assumption that the condition would clear up by itself or 
embarrassment.[8, 174-179] Several studies have shown delay in seeking medical 
consultation is common.[32-36] Along with the clients’ recognition and awareness of 
the symptoms, the understanding of the potential seriousness of the symptoms is 
also very important.  
 
 Bowel Disease and Help-Seeking Behaviour 
 
There is robust evidence to suggest many patients with colorectal disease present 
late with symptoms, and only a minority of patients seek timely medical advice for 
their symptoms, the rate of doctor consultation among these patients varying from 
14% to 41%.[3, 10-12] Of the 7-10 months’ median delay between onset of symptoms 
and diagnosis of CRC, at least three months is due to delay by the patient in seeking 
medical help; the rest is due to a delay in diagnosis.[159]  
 
A population-based telephone survey (n=1019) of people’s knowledge about CRC-
associated symptoms in the UK revealed delays in medical investigation due to 
ignorance of bowel cancer symptoms (50% of respondents), lack of appreciation of 
the significance of the symptoms (40%) and attributing bowel habit change to diet 
alterations (15%).[159]  
 
A number of community-based studies have reported the prevalence of rectal 
bleeding and the consultation rate of people who had rectal bleeding in the past 12 
months or during their lifetime (Table 2.4). A notable trend in the studies indicates 
that less than 45% of participants with rectal bleeding sought timely help. 
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Table 2.4: Prevalence and Help-Seeking Rate for Rectal Bleeding  
 
Study Country 
Age range 
(years) 
Sample 
Size 
Prevalence 
 
% Seeking 
Medical 
Help 
Talley et 
al.[11] 
United 
States 
20-64 1643 
15.5% 
Past 12 
months 
13.9% 
Crosland et 
al.[3] 
United 
Kingdom 
20-80 1200 
19% 
Past 12 
months 
41% 
Byles et 
al.[178] 
Australia >40 2619 
20% 
Lifelong 
30% 
Eslick et 
al.[14] 
Australia >18 338 
18% 
Past 12 
months 
31% 
Produced using data from Eslick et al.[14] 
 
In a British study of 3,264 patients with IBD-related faecal incontinence, the 
researchers claimed 74% of the sample reported faecal incontinence, but only 38% 
sought medical help for this symptom.[15] The reasons for not seeking help were 
perceived lack of interest and sympathy from healthcare professionals, 
embarrassment and unawareness of available help.[15] 
 
In a population-based study in the US to determine the factors associated with 
healthcare seeking behaviour of patients with IBS, William et al. reported only 49% 
sought medical care for abdominal symptoms associated with IBS in the past 12 
months.[16] The researchers noted patients whose work and social functioning was 
affected by the symptoms, thus scoring low on IBS-specific QoL scale, were more 
likely to have sought medical help for their symptoms.[16] 
 
Delayed diagnosis of serious colorectal pathology occurs due to delay in the client’s 
presentation to a doctor, delayed referral to a specialist, and finally, the delay in 
diagnosis.[44] A systematic review by Mitchell et al.[44] of the influences of pre-
hospital delay in the diagnosis of CRC points to the influences of social network and 
support as a potentially important factors in reducing delay.[44] Symptom awareness 
and clients’ interpretation of symptoms was a common theme across the studies 
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identified in the systematic review. Lack of knowledge about colorectal diseases 
and/or the availability of screening were major contributors to increased delay.[44] 
Furthermore, the authors observed an increased delay was also found in clients who 
self-diagnosed or self-medicated before presenting to a GP.[8, 44] They suggested 
people associate the symptoms to benign disease, and embarrassment of symptoms 
would deter reporting.[44] 
 
 Role of Pharmacies in the Management of Bowel Symptoms 
 
Published data suggest one in 15 people identify the pharmacist as a source of advice 
about bowel symptoms.[21] In Australia, three or more clients present per pharmacy 
every week seeking symptomatic treatment for bowel symptoms.[21] A study by 
Phillip et al. stated at the onset of diarrhoea, 16% would consult a pharmacist and 
only 8% would consult a GP.[180] Similarly, while rectal bleeding is common in the 
general population, only one-third of those with rectal bleeding in an Australian 
population consulted a GP about their condition, as has been noted in other 
populations.[14, 181, 182]  
 
Definitive diagnosis of persistent symptoms requires medical consultation.[13] Given 
that bowel symptoms such as diarrhoea, rectal bleeding and altered bowel habit can 
be attributed to self-limiting or benign illness, GPs differentiate between patients 
with benign symptoms and those with symptoms that could be due to a serious bowel 
condition.  
 
Pharmacists are well placed to help identify symptomatic clients in community 
pharmacies who should be encouraged to consult a medical practitioner. Despite 
this, in a survey of 167 registered pharmacists in WA, it was demonstrated that bowel 
symptoms indicative of serious disease were not recognised in a significant 
proportion of cases.[13, 24] A self-administered questionnaire with vignettes 
constructed around six clinical variables: age, gender, duration of symptom, rectal 
bleeding, change in bowel habits and weight loss, were completed by the 
pharmacists. They described their referral pathway for each of the nine vignettes 
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posted to them.[13, 24] When compared to the expert panel’s opinion, 63% of 
pharmacists disagreed on weight loss due to bowel symptoms as warranting a GP 
referral and 30% did not agree that rectal bleeding for four weeks duration merits a 
referral. Over 60% of pharmacists did not consider persistent diarrhoea in a 65-year-
old client as a likely symptom of significant bowel pathology which was in contrast to 
cancer guidelines.[13, 24] 
 
Discussing embarrassing symptoms has been reported as a barrier to seeking 
help.[183] For example, when pharmacists were probed on their views and beliefs 
about benefits of treating women with symptoms suggestive of vaginal thrush, the 
popular perception was around client embarrassment, influenced by lack of 
privacy.[25] The major challenge encountered by pharmacists in this situation is to 
obtain an accurate history and symptom details from the client.[25]  
 
Similar issues are expected to arise in consultations relating to bowel symptoms. 
Despite this, there appears to be a role for community pharmacy staff in the 
management/triage of clients with bowel symptoms. Pharmacies are accessible, and 
clients present for non-prescription medicine purchases. There is some evidence that 
a self-administered questionnaire can be an effective tool in supporting primary 
health care professionals to triage cases that warrant further investigation for 
colorectal pathology.[30] In order to explore the strength of evidence in this field, a 
comprehensive literature search was undertaken, as reported below. 
 
 Literature Search 
 
A comprehensive literature review was conducted to identify the risk factors for 
bowel disease. Studies reporting trials of published instruments were also reviewed 
to determine the effectiveness of questionnaires in identifying symptoms indicating 
risk of bowel disease. A search strategy was developed to source peer-reviewed 
English-language papers using CINAHL, Medline (Ovid) and Scopus databases. The 
search spanned January 1990 to October 2012. The search method is shown in Table 
2.5.   
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This literature search was reported in the following paper: 
Sriram D, Jiwa M, McManus A, Emmerton L, Parsons R. Development and validation 
of a clinical decision-making aid for screening bowel symptoms in community 
pharmacies. Journal of Evaluation in Clinical Practice 2014; 20: 260-6. 
 
Table 2.5: Literature Search Strategy and Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limiters: Adult, Human, English language, Peer reviewed 
 
 
Database Searched Search Terms Results 
CINAHL 
(Questionnaire OR Survey OR Advice 
OR “Cognitive Service” OR Referral) 
AND (Bowel OR “Bowel Symptoms”) 
574 
 
(“Bowel Symptoms” OR Bowel) AND 
“Primary Health Care” 
16 
(“Bowel Symptoms” OR Bowel) AND 
(Pharmacy OR Chemist OR “Drug 
store”) 
6 
(“Bowel symptoms” OR Bowel) AND 
(“Bowel disease” OR “Bowel 
pathology”) 
317 
Medline (Ovid) 
(Questionnaire OR Survey OR Advice 
OR “Cognitive Service” OR Referral) 
AND (Bowel OR “Bowel Symptoms”) 
36 
(“Bowel Symptoms” OR Bowel) AND 
“Primary Health Care” 
6 
(“Bowel Symptoms” OR Bowel) AND 
(Pharmacy OR Chemist OR “Drug 
store”) 
1 
(“Bowel symptoms” OR Bowel) AND 
(“Bowel disease” OR “Bowel 
pathology”) 
414 
Scopus 
(Questionnaire OR Survey OR Advice 
OR “Cognitive Service” OR Referral) 
AND (Bowel OR “Bowel Symptoms”) 
499 
(“Bowel Symptoms” OR Bowel) AND 
“Primary Health Care” 
94 
(“Bowel Symptoms” OR Bowel) AND 
(Pharmacy OR Chemist OR “Drug 
store”) 
17 
(“Bowel symptoms” OR Bowel) AND 
(“Bowel disease” OR “Bowel 
pathology”) 
388 
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The researcher (DS) and two co-investigators (MJ and AM) reviewed the titles and 
abstracts of the articles and reached a consensus on articles that met the inclusion 
criteria of: 
 
 Publication in English 
 Peer-reviewed research article (rather than letter or commentary) 
 Primary focus on bowel symptoms, duration of symptoms  
 Focus on primary health care 
 Reporting pharmacy as the setting for health advice  
 Reporting a screening questionnaire for bowel disease. 
 
The search produced 2,368 reports. Deletion of duplicates reduced the total to 1,243. 
Title and abstract review further reduced the search results to 110 articles. The 
literature search results are shown in Figure 3.1. Of the 110 identified reports, 14 
focussing on bowel symptoms were identified, and the significance, duration and 
associated risks of these symptoms were noted.[4, 119-121, 148-150, 154, 155, 161, 
162, 165, 180, 184]  
 
Review of the literature suggested the following symptoms indicate significant risk 
for chronic bowel disease and warrant consideration in a screening questionnaire: 
rectal bleeding, change in bowel habit, increased frequency in bowel motions, 
abdominal pain, abdominal discomfort, and incomplete defecation.[30, 148, 154, 
165, 185] The duration and frequency of the symptom(s), pain, loss of weight, 
anaemia and history of gastrointestinal disease were also considered key factors for 
diagnosis of bowel disease.[29, 162, 185]  
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Figure 2.8: Flow diagram of the Results of a Literature Search of Risk Factors of 
Bowel Disease 
 
 Questionnaires for Screening of Bowel Symptoms 
 
The Rome III Diagnostic Questionnaire for Functional Gastro-Intestinal Disorders was 
developed by the Rome Foundation, Inc. (US), based on Rome III diagnostic 
criteria.[144] The rationale behind the development of symptom-based diagnostic 
classification was the presence of symptom clusters that remain consistent across 
different gastrointestinal tract. These criteria can be used for reliable diagnosis and 
specific treatment.[144] The questionnaire applies a coding system and takes 15-20 
minutes to complete. This questionnaire is designed for clinical use, with a 
Search Terms 
“Bowel 
Symptoms” OR 
Bowel AND Tools 
OR Survey OR 
Questionnaire OR 
“Cognitive 
Service” Total 
identified -1,109 
Search Terms 
“Bowel 
Symptoms” OR 
Bowel  AND  
Pharmacy OR 
Chemist OR 
“Drug store”  
Total identified -
24 
Search Terms 
“Bowel 
Symptoms” OR 
Bowel  AND 
“Primary Health 
Care”   
Total identified 
- 116 
 Search Terms 
“Bowel 
disease” OR 
“Bowel 
pathology”  
Total identified 
-1,119 
1,243 articles for further screening 
1,133 records excluded 
after title and abstract 
screening  
Excluded 
466 
duplicates 
Excluded 
17 
duplicates 
Excluded 
47 
duplicates 
Excluded 
595 
duplicates 
110 relevant articles identified  
Database Searched 
CINAHL+ Medline (Ovid)+Scopus  
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psychosocial module and response format including Yes/No, five-point ordinal scales 
for conditional questions and seven-point ordinal scales for frequency questions. The 
questionnaire is subdivided into question and coding modules for oesophageal, 
gastro-duodenal, gall bladder/sphincter of Oddi, bowel, chronic abdominal pain and 
anorectal disorders.[144]  
 
Kolosky et al.[186] used the Rome III diagnosis questionnaire for functional 
constipation and IBS symptoms, the Hospital Anxiety and Depression Scale for 
assessing psychological distress, and the SF-12 to measure QoL, in a population-based 
study to differentiate IBS-constipation from functional constipation. A postal survey 
of 3,260 randomly selected Australians using this self-report instrument reported 
that abdominal pain associated with IBS-constipation resulted in more people 
seeking health care than patients with functional constipation. Lifestyle factors and 
psychological distress remained similar in both sub-types of constipation. This study 
also argued that the symptom cluster as classified in the Rome III questionnaire was 
somewhat superficial, except for the frequency of abdominal pain, and suggested 
differentiation based on symptom severity rather than cluster.  
 
Talley et al.[187, 188] developed and validated a Bowel Symptom Questionnaire to 
identify patients with functional gastrointestinal disease, IBS and functional 
dyspepsia. The questionnaire covers 46 gastrointestinal symptoms and questions 
exploring past and present health, a Psychosomatic Symptom checklist, health habit 
questions and socio-demographic items.[189] This instrument is 15 pages long and 
comprises 83 items. The instrument was completed by 467 patients before their 
clinical evaluation to determine the diagnostic value of an a priori symptom 
score.[187] The researchers developed a symptom score to identify and classify 
patients with functional gastrointestinal disease; however, further validation has not 
been reported.[187]  
 
The Elderly Bowel Symptom Questionnaire,[190] based on the Bowel Symptom 
Questionnaire, was developed for elderly patients aged 65 to 95 years of age, and 
has value in community and out-patient settings for identifying persons with chronic 
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gastrointestinal symptoms, including IBS. It takes approximately 20 minutes to 
complete.  
 
The Bowel Symptom Checker[191] (https://www.nhs.uk/symptom-checker/) 
developed by the National Health Service, UK, is a web-based screening instrument. 
This website prompts the individual to answer questions about his/her symptom(s), 
and based on the reply, consequent questions are prompted. The symptom checker 
then provides management advice, including referral to the GP, depending on the 
symptom pattern.[191] There is no available evidence regarding scientific validation 
of the symptom assessment questions.  
 
The CRISP (Colonoscopy Research into Symptom Prediction) Study [29, 161] 
developed and validated a bowel symptom questionnaire to be deployed before a 
patient’s specialist consultation. The CRISP study aimed to develop and assess the 
reliability of a bowel symptom self-administered questionnaire potentially relating to 
CRC. In a trial in Australia, this questionnaire was administered to 263 patients who 
were likely to have a colonoscopy, before they consulted a gastroenterologist or a 
colorectal surgeon. The researchers reported it as reliable in assessing bowel 
symptoms, and acceptable by patients to complete in the waiting room. It took 
approximately 15 minutes to complete. The patients from this study reported, on 
average, one extra symptom than elicited by the specialist,[192] which is consistent 
with other research.[193]  
 
Hippisley-Cox and Coupland[162] derived and validated a risk-prediction algorithm to 
quantify the absolute risk of CRC in patients. This prospective cohort study was 
carried out on primary care patients obtained using the QResearch database (version 
30) from practices in England and Wales. Over 2 million (n = 2,351,052) patients were 
included for development of the algorithm and 1,236,601 patients for validation of 
the algorithm. Patients included were free at baseline from CRC and without any 
symptoms of rectal bleeding, abdominal pain or weight loss in the last 12 years. The 
primary outcome was incident diagnosis of CRC in the next 2 years after study entry. 
The algorithm was based on a combination of risk factors: age, family history of 
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gastrointestinal cancer, anaemia, rectal bleeding, abdominal pain, appetite loss and 
weight loss in females. Similar risk factors were used for males, with inclusion of 
alcohol use and change in bowel habits. The authors claimed that while the algorithm 
is likely to be most applicable in that setting, it could be used elsewhere, e.g. by 
patients using a web calculator, provided caution is applied in the interpretation of 
clinical symptoms by non-health professionals. Since the diagnosis and analysis is 
algorithm based, the limitation of this method is inaccurate or missing data. Since the 
information for validation was obtained from the same clinical computer system as 
used for development of the algorithm, external validation is required. 
 
Hamilton’s review[194] of the CAPER (Cancer Prediction in Exeter) study reported the 
quantification of risk of cancer symptoms and primary care investigations. CRC was 
one of the six cancers investigated in that study. Bowel symptom plus threshold 
haemoglobin values contributed highly to the CAPER score, thus facilitating easy 
identification and a cue to GPs for further investigation. Khan[195] tested the 
feasibility of a paper-based assessment tool incorporating the CAPER score in 
patients presenting for GP consultation. The study protocol of the assessment tool 
included the GP calculating the CAPER score, a score of 35 or over prompting a 
referral, which might include FOBT, haemoglobin test and rectal examination.  The 
assessment tool compliance rate was low. Recommendations from the assessment 
tool were not routinely followed by the GP. In many cases, test results, such as 
haemoglobin level, were not recorded in the assessment tool. This study identified 
barriers in effective implementation at practice level, similarly to a study by 
Khammarina et al.[196] There were also barriers relating to the healthcare 
professionals’ action, which is in line with Cabana et al’s systematic review, which 
identified individuals’ knowledge, attitudes and behaviour as barriers to adoption of 
a change in practice[92].  
 
Khan’s study on implementation of assessment tool thus a change in practice, brings 
into focus the design and the delivery of assessment tools in the primary care. This 
reiterates the importance of identifying barriers for a change to be accepted and 
implemented.[93] 
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The findings from the CRISP study[192] and Fromme et al.[193] further establish the 
importance of a self-administered questionnaire for eliciting symptoms, especially if 
the patient is embarrassed or hesitant to discuss symptoms. 
 
Most of the above studies were developed with high sensitivity for CRC, and were 
tested in the GPs’ or colorectal specialists’ waiting rooms.[187, 192, 195] Another 
commonality is that most of the questionnaires took approximately 15-20 minutes to 
complete. There were no reported studies that reported the use of these 
questionnaires in a community pharmacy setting. 
 
One additional questionnaire was developed with high sensitivity for CRC and for use 
within general practice: the Patient Consultation Questionnaire (PCQ). This 
instrument is critiqued below.  
 
2.7.4.1. Patient Consultation Questionnaire 
 
Within general practice, the PCQ has been demonstrated as an efficient and objective 
self-administered instrument that prioritises colorectal referral, and has high 
sensitivity for serious colorectal pathologies.[5, 197] Prospective studies from the UK 
have validated the PCQ for prediction of CRC and prioritisation of CRC referrals.[5, 30, 
197, 198] The PCQ is a 60-domain questionnaire of bowel symptoms and symptom 
complexes, its duration, progression, medical and family history. The value of this 
questionnaire, compared to others, is that it offers a numeric score for the risk of 
colorectal pathologies. Each symptom has a score which depends on the patient’s 
age, type of bleeding, frequency and duration of symptoms. The PCQ data had to be 
entered into a computer software program to get a score ranging from zero to one 
hundred.[197]  
 
Rai et al. conducted a prospective study to validate the PCQ against the ‘two-week 
wait’ system introduced by the UK Government for the prioritisation of CRC 
referral.[197] The study was conducted on 3,128 patients, including those referred 
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by their GP for specialist consultation and those on the two-week wait referral list. 
The completed PCQs from 1,422 patients indicated the most common presenting 
symptom as rectal bleeding and change in bowel habits.[197] There were 83 
confirmed diagnoses amongst the 1,422 patients. Table 2.6 shows the risk of cancer 
with increasing PCQ score. A score of 70 and over equates to a risk ratio of 1:5 for 
CRC.[197]   
 
Table 2.6: Colorectal Cancer risk and PCQ score  
 
PCQ Weighted Numerical 
Score 
No. of cancers (%) Risk ratio for CRC 
<40 4 (0.8) 1 in 123 
40-49 3 (1.4) 1 in 74 
50-59 12 (5.4) 1 in 19 
60-69 11 (5.4) 1 in 18 
≥ 70 53 (18.7) 1 in 5 
Adapted with permission from Rai et al.[197] 
 
In a prospective study by Ballal et al. in a district hospital in Wales,[5] 3,457 bowel 
symptomatic patients who were referred by their medical practitioners to consult 
colorectal specialists completed the PCQ. This study was conducted to further 
validate the scores for prioritising referral of CRC. Patients underwent colorectal 
investigations, and sensitivity, specificity and accuracy of CRC detection (as 
determined by the score) were established. This study reported similar results to 
those of Rai et al.[197] with regard to the risk ratio for CRC. Scores in the range of 50-
59 corresponded to a risk ratio of 1:19, and 70 and over, a risk ratio of 1:8.[5] This led 
to the conclusion that the relative risk for CRC with a PCQ score in the range 50-59 is 
1:19, rising to a risk between 1:5 to 1:8 for patients with a score at or above 70.[5, 
197] 
 
Jiwa and colleagues used the PCQ in community pharmacy setting in a feasibility 
study for triage of clients who might be at high risk of CRC.[23]  Twenty-one WA 
community pharmacies used the PCQ to identify clients at risk of CRC. Pharmacy 
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clients with bowel symptoms completed the PCQ, and the completed questionnaire 
was posted to the researcher to determine the score using a programmed algorithm. 
A score of 50 was considered the threshold, above which the participants were 
referred to their GP. Referral advice was sent to the participants approximately one 
week after their pharmacy visit. The low PCQ scores were consistent with the profile 
of clients who seek over-the-counter treatment.[23, 199] Only eight patients were 
recommended to consult their GP, five of whom followed this advice.  
 
The researchers noted three main problems with implementing the PCQ in 
pharmacies: 
 
 The PCQ is a 60-domain questionnaire and takes approximately 10 minutes to 
complete. Therefore, it is expected to be impractical and burdensome for 
completion in a busy pharmacy setting. 
 PCQ scoring required input into a computerised scoring system. The algorithm 
was not available in a mobile platform at the time of the study, nor were 
pharmacists granted access to the algorithm, requiring data input by the 
researcher. This limited the application of the PCQ in the pharmacy, as the results 
and the referral could not be provided to the client immediately during 
consultation with the pharmacists. 
 The PCQ was developed to prioritise CRC referral. In practice, clients may present 
with multiple conditions, which although identified as benign and self-limiting 
using the PCQ, may benefit from the advice of a GP (e.g. severe haemorrhoids, 
persistent diarrhoea and recurrent constipation).[154, 155] 
 
With reference to the published literature on the PCQ and other instruments for 
bowel symptom screening, it is evident a simpler screening tool is needed, retaining 
high sensitivity for bowel disease, to triage clients presenting with bowel symptoms 
at pharmacies. A self-administered questionnaire would be ideal for a client 
presenting with embarrassing symptoms in a busy pharmacy. A simple decision-aid 
tool can help in standardising and streamlining the consultation process for bowel 
symptoms in the pharmacy. There is an opportunity to test the value of a simple 
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triage tool to help pharmacists and pharmacy staffs identify symptomatic patients 
who should be referred to a medical practitioner.  
 
2.8. Conclusion and Recommendations 
 
This review of published literature has established the value of community pharmacy 
in primary health care. Bowel symptoms are prevalent in the community, and a 
number of bowel diseases share common clinical presentations. Furthermore, certain 
symptom profiles significantly raise the probability of serious underlying conditions 
such as cancer, colitis, or large adenomatous polyps. Research has also established 
many people with colorectal disease present late with such symptoms, yet the public 
identifies pharmacies as good source of advice for their bowel symptoms. 
 
To improve the outcomes of symptomatic clients who might be at risk of bowel 
disease, they should be encouraged to consult the GP for a definitive diagnosis. There 
is evidence a self-administered questionnaire can be an effective tool in supporting 
the pharmacist to triage cases for further investigation for colorectal pathology. The 
available questionnaires for bowel symptoms have been developed for use in a 
different setting to pharmacy. For symptomatic clients who present in community 
pharmacies, it would be helpful to design and test validated tools that can be used 
by pharmacy staff to identify and encourage individuals to seek medical help. 
 
The following two chapters explore the development and application of a self-
administered questionnaire that facilitates identification of clients who might benefit 
from GP consultation, and encourages at-risk clients to seek medical review. 
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3. Development and Validation of a Bowel Symptom 
Consultation Guide 
 
3.1. Introduction 
 
It is evident from the review of published literature (Chapter 2) that community 
pharmacies are well placed to play a constructive and dynamic role in the provision 
of effective primary health care. Pharmacies have become important providers of 
various client-centred healthcare services, which present pharmacists with 
opportunities to identify and address health-related issues. Pharmacists also have the 
capacity to offer support and/or referral to symptomatic clients who would benefit 
from medical advice from a GP. Indeed, a number of studies have reported positive 
impact from the collaboration of pharmacists and GPs in patient management.[23, 
31, 83-85] 
 
Chapter 2 presents evidence around the common occurrence of bowel symptoms 
and their association with serious underlying conditions such as CRC, large 
adenomatous polyps, diverticular disease, IBS and IBD. Published data suggest that 
the majority of people identify pharmacists as a source of advice about bowel 
symptoms.[21] Pharmacies are accessible, and clients present for both prescription 
and non-prescription medicine purchases. Challenges, however, relate to conducting 
a private consultation with clients who are embarrassed about their signs/symptoms, 
and providing appropriate management of referrals for further investigation. 
 
There is evidence that a self-administered questionnaire can be an effective tool in 
supporting the primary health care professionals to triage cases that warrant further 
investigation for colorectal pathology.[30] Almost all bowel symptom questionnaires 
reported in Chapter 2 (Section 2.7.4) have been developed for use in other settings. 
Most have multiple domains and pages, and take approximately 15-20 minutes to 
complete. There are no reported studies that have used these questionnaires in a 
pharmacy setting other than the PCQ feasibility study, which is reported in detail in 
Section 2.7.4.1. The researchers found the 60-domain questionnaire (the PCQ), and 
its requirement of computerised algorithm for scoring, to be burdensome to deploy 
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in a busy pharmacy setting. Moreover, the PCQ was developed with high sensitivity 
for CRC and to prioritise CRC referral.  To improve the outcome of symptomatic 
clients who present in the pharmacy with bowel symptoms, there is a need for a 
simpler screening tool that retains high sensitivity for bowel disease, to identify who 
might be at risk and encourage them to consult their GP for a definitive diagnosis. 
 
This chapter outlines the steps involved in developing and validating a self-
administered clinical decision-making aid for use in pharmacies to help pharmacists 
and pharmacy staff to identify symptomatic clients who should be referred to a GP. 
The questionnaire was named the ‘Jodi Lee Test’ (JLT) to acknowledge the Foundation 
sponsoring this research.  
 
The Jodi Lee Foundation (www.jodileefoundation.org.au) was formed in Australia in 
honour of Jodi Lee, who died of bowel cancer at the age of 41 years. The Foundation’s 
mission is to “prevent bowel cancer by motivating people to take screening tests 
regularly, act quickly on symptoms and lead healthy and active lifestyles.”[200] 
Initiatives include awareness campaigns to educate Australians about the importance 
of early detection of bowel cancer, and a program for corporate business to screen 
employees for bowel cancer. In this drive for bowel cancer prevention, the 
Foundation offered a research fellowship to promote medical consultation by people 
presenting at pharmacies with bowel symptoms. 
 
A paper describing the study in this chapter has been published in the Journal of 
Evaluation in Clinical Practice, paraphrased and expanded upon in this chapter. 
Limited content from the published paper has been reproduced with the publisher’s 
permission (Appendix 3.1) 
 
Sriram D, Jiwa M, McManus A, Emmerton L, Parsons R. Development and validation 
of a clinical decision-making aid for screening bowel symptoms in community 
pharmacies. Journal of Evaluation in Clinical Practice 2014; 20: 260-6. 
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3.2. Aim and Objectives 
 
The aim of this research stage was to develop and validate a questionnaire for use 
with pharmacy clients presenting with bowel symptoms.  Specific objectives were to: 
 
 identify signs and symptoms that can be considered ‘red flags’ for bowel disease 
 construct a decision-aid tool for pharmacy staff to identify who would benefit 
from further medical consultation and 
 validate the identified signs and symptoms, and evaluate the tool’s sensitivity and 
specificity for symptomatic clients at risk of bowel disease. 
 
3.3. Method 
 
 Questionnaire Development 
 
The self-administered questionnaire was developed in three stages: application of 
evidence from the comprehensive literature search (Section 2.7.3), questionnaire 
construction, and statistical validation against an existing validated screening tool, 
the PCQ (Section 2.7.4.1). 
 
Given the limitations of the PCQ in pharmacy settings (noted in Section 2.7.4.1), the 
JLT was designed with the following features in mind: 
 
 The instrument had to be usable by all pharmacy staff that interacts with clients 
with bowel symptoms who present in the pharmacy for advice: pharmacy 
assistants to determine if the client requires consultation with a pharmacist, and 
pharmacists to determine if referral to the GP is warranted. 
 The instrument had to be simple, short, easy-to understand and self-completed 
by clients, especially if when embarrassed to discuss their symptoms in a busy 
pharmacy. The questionnaire was designed to be completed by the client using a 
paper copy, as this was considered appropriate for review and interpretation by 
the pharmacy staff. 
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 The instrument was intended to act as a guide to clinical decision making. This 
would facilitate easy interpretation of the responses and thus encourage 
pharmacists to give appropriate advice and referral during their consultation with 
the client. 
 A ‘checklist’ approach without score-calculation was determined to be more 
appropriate in a pharmacy setting rather than to compute a risk score. 
 
All symptoms and questions considered for inclusion in the questionnaire were 
reviewed by an expert panel, comprising a GP with special interest in bowel disease, 
a community pharmacy researcher, a public health practitioner and two practising 
community pharmacists, to enhance the face and content validity of the instrument. 
For the item-generation phase, a nominal group technique[201] was used. During the 
initial discussion, each member of the expert panel and the researcher presented 
their points in a round-robin fashion. The researcher recorded each item on a 
whiteboard in full view to each member. Free discussion ensued, during which time, 
opinions and clarifications were expressed and new items were added to the list. At 
the end of the discussion, all items generated for the questionnaire were recorded 
by the researcher (Appendix 3.2) Once the questionnaire was prepared, aspects of 
the Delphi process[202] were applied to identify essential components. The panellists 
had previously rated (and ranked) the items as part of their involvement in the initial 
item-generation discussion. Several rounds of iteration to reassess initial judgement 
of items took place. A revised version of the questionnaire was circulated, taking 
account of the comments and suggestions from the panel. This was conducted with 
a view to retaining the minimum number of relevant questions in the instrument that 
could elicit a decision about referral in a community pharmacy setting. Eliminating 
ambiguity in the wording and instructions was also considered. Appendix 3.3 
illustrates the suggestions resulting from each round of iteration. The process 
continued until consensus was reached on all parameters.   
 
3.3.1.1. Questionnaire Construction 
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Clarity, comprehensiveness and representativeness of each item were improved 
after several rounds of consultation between members of the expert panel. The 
panellists identified the questions (relating to high-risk symptoms) that would 
warrant referral to a GP, and an appropriate order for the questions. A decision was 
made to include constipation as a single symptom, due to evidence from literature 
that chronic constipation is associated with significantly higher prevalence and 
incidence of CRC and benign colorectal neoplasm.[165] The other symptoms included 
in the questionnaire were diarrhoea, rectal bleeding, alternating diarrhoea and 
constipation, and discomfort in the back passage, due to their strong association with 
bowel diseases in the literature.  
 
Changes to the draft version included removal of indicators unable to be determined 
in a pharmacy, such as ‘anaemia’. For clients with multiple bowel symptoms, ‘Tick all 
that apply’ was included in the question about symptoms.  ‘Is this symptom(s) 
associated with any pain?’ determined associated pain without localising the pain. A 
question concerning prior consultation regarding the presenting symptom(s) was 
retained to provide background information for the pharmacist and GP.   
 
Referral to the GP was indicated if one or more of the five symptoms (diarrhoea, 
rectal bleeding, alternating diarrhoea and constipation, discomfort in the back 
passage, constipation) were present for at least one week.  
 
 Validation 
 
Readability was considered, as the JLT was designed to be self-completed by the 
client; however, it was intended that pharmacy staff would assist those who required 
help to complete the JLT. The Flesh-Kincaid assessment system was used to check the 
readability of the questionnaire. The score is based on a 100-point scale: the higher 
the score, the easier it is to comprehend.[203] A score between 70 and 100 was the 
target.  
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The PCQ was used as a proxy independent measure of the endpoint, GP consultation. 
Approval was obtained to use an existing database of 120 PCQ responses from a 
previous feasibility study.[21, 23] This validation process involved the researcher (DS) 
completing a JLT from each client record in the PCQ database.[21, 23] In cases where 
the PCQ data or a corresponding answer in the JLT was unclear, two other researchers 
(MJ, AM) assigned the JLT responses. One hundred and eighteen PCQ records were 
translated into responses using the JLT. Two records from the original PCQ dataset 
were excluded due to the volume of missing information.  
 
The PCQ produces an integer score between 0 and 100 for the risk of bowel 
disease.[30] In the aforementioned pilot study of the PCQ,[23] a score of 50 was 
identified as the threshold score, above which, individuals were issued a referral for 
further investigation. The JLT, by comparison, was designed as a guide for the 
pharmacy staff member in decision making about client symptom management. The 
JLT assisted the clinical decisions by highlighting symptoms that persisted for at least 
one week, thus warranting clinical investigation.  
 
The two instruments (PCQ and JLT) were compared to identify clients who might be 
at risk of bowel disease and would benefit from referral to a GP. This was achieved 
by cross-tabulating their corresponding data. Thresholds for referral were identified, 
and the sensitivity and specificity of the JLT in suggesting referral were calculated. 
Sensitivity refers to the percentage of cases with a PCQ score above the threshold 
who also returned a positive JLT recommendation (i.e. cases recommended to 
consult a GP).[204] Specificity indicates the percentage of those with a low PCQ score 
(below the threshold) who also returned a negative JLT recommendation (i.e. cases 
who would not be recommended to consult a GP).[204] The ideal characteristics of 
the JLT are high sensitivity (to refer clients who have a high PCQ score and therefore 
require follow-up) and relatively modest specificity (to not refer those who are likely 
not to require follow-up). Threshold PCQ scores ranging from 5 to 65 were used for 
this exercise, to encompass the threshold score of 50 used in the published pilot 
study. [23] Thirty was used here as the threshold PCQ score to capture a range of 
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bowel diseases, while a score of 50 in the PCQ pilot study [23] was chosen to focus 
on CRC.[184]  
 
A receiver operator characteristic (ROC) curve was generated from sensitivity and 
specificity calculations to ascertain the relationship between the two tests. The ROC 
curve displays the trade-off between the sensitivity and specificity (false positive) 
across a series of cut-off points.[205] This curve is useful in evaluating the 
discriminatory ability of the JLT to correctly identify subjects who require referral and 
those who do not. It also suggests an optimal cut-off point for minimal 
misclassification of subjects in the referral and non-referral groups.[206] The area 
under the curve (AUC) is an overall measure of the diagnostic accuracy of an 
instrument.[205] The maximum AUC=1 means the instrument accurately 
differentiates between ‘true’ positive and ‘true’ negative. The AUC of this curve was 
calculated using the non-parametric Mann-Whitney U statistic.[205] Each black dot 
on the graph corresponds to an observation: the ‘true’ positive rate (sensitivity) and 
‘false’ positive rate (1-specificity).  
 
3.4. Results 
 
 Questionnaire Construction 
 
The final version of the JLT comprised eight questions, took approximately three 
minutes to complete, and mostly required tick-box responses from clients (Appendix 
3.4). 
 
 Readability 
 
Readability of the JLT, measured by Flesh-Kincaid grade level, was 4 (i.e. an average 
grade 4 student should be able to read the instrument). The Flesh-Kincaid reading 
ease assessment resulted in a score of 79.5, the reading level of a child nine years of 
age.[207, 208]  
 
 Validation 
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Table 3.1 illustrates the sensitivity and specificity of the JLT for each PCQ cut-off 
score. At the threshold score of 30, the sensitivity of the JLT was 100% and specificity 
was 65%.    
 
Table 3.1: Sensitivity and Specificity of the Jodi Lee Test Compared to the PCQ 
Threshold Score (n=118) 
 
PCQ Threshold 
Score 
JLT- Sensitivity (%) JLT- Specificity (%) 
5 68.8 100.0 
10 75.6 96.9 
15 81.9 84.8 
20 84.8 80.8 
25 88.5 69.7 
30 100.0 65.0 
35 100.0 61.2 
40 100.0 57.8 
45 100.0 54.7 
50 100.0 51.5 
55 100.0 49.1 
60 100.0 46.8 
65 100.0 46.0 
 
Table 3.2: The Relationship between the Jodi Lee Test (JLT) Recommendation and 
PCQ Threshold Score of 30 
 
n - number 
52 - ‘true’ negative, 0 - ‘false’ negative, 28 - ‘false’ positive, 38 - ‘true’ positive 
 
The cross-tabulation at the threshold score of 30 (Table 3.2) illustrates the ‘true’ 
positive (TP) and ‘true’ negative (TN) GP referral rates of the 118 subjects, where all 
38 cases with a high PCQ score (>30) would be referred, and 52 of the 80 subjects 
PCQ Threshold 
Score 
JLT Recommendation 
Total 
Referral Not 
Warranted 
Referral Warranted 
N % n % 
≤30 52 65 28 35 80 
31 + 0 0 38 100 38 
Total 52 66 118 
64 
 
with a low PCQ score (≤30) would not be referred, if using the JLT. The remaining 28 
cases with a low score would also be referred to their GP, according to the JLT.  
 
Figure 3.1 shows the ROC curve plotting sensitivity (y-axis) versus 1-specificity (x-axis). 
The area under the ROC curve was 0.94.  
 
Figure 3.1: Receiver Operator Curve (ROC) - JLT Sensitivity versus JLT Specificity  
 
 
3.5. Discussion 
 
This study reported the development of the JLT, a self-administered questionnaire to 
aid consultations of pharmacy staff (pharmacists and pharmacy assistants) with 
clients presenting with bowel symptoms that would benefit from medical referral. 
The literature review (Chapter 2) emphasised the importance of community 
pharmacy as a major, easily accessible source of health advice. The literature 
suggested the need to develop a simple, valid screening tool that could be used 
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within the pharmacy setting to assist with coordinated, cooperative health care 
between community pharmacists and GPs.  
 
The JLT requires minimal time commitment by the client and pharmacy staff, and was 
developed to be easily assimilated into everyday pharmacy practice. It was designed 
for self-completion by the client, with readability equivalent to school grade four (age 
around nine years). This should offer confidence to clients in conveying details about 
their bowel symptom(s), especially if they are embarrassed and/or have limited 
health literacy. 
 
Brevity in the questionnaire was essential to retain the JLT as a simple guide for use 
in a busy pharmacy setting, but it had to be highly sensitivity for bowel disease. 
Review of the literature indicates symptoms and their duration play an important role 
in determining risk of more serious bowel disease.[29, 162] History of gastrointestinal 
diseases, and loss of weight, were also considered key factors for diagnosis of bowel 
disease,[29, 162, 185] and were referred to in Questions 5 and 7, respectively, in the 
JLT. While other decision-making tools incorporate scoring systems, as was evident 
from the literature review (Section 2.7.4) and the PCQ, the JLT acknowledges the 
importance of clinical judgement by pharmacists and pharmacy staff in client 
consultations. As such, pharmacists and pharmacy staff may consider responses to 
the JLT questions collectively, with the client’s verbalised complaints or responses, in 
deciding if the client requires referral.  
 
In the validation exercise, the PCQ was used as a proxy independent measure of the 
endpoint, GP consultation. While the PCQ has been validated for serious bowel 
disease at high cut-off score, a lower cut-off may indicate emerging disease or other 
bowel conditions that require GP intervention, and are appropriately identified in a 
community pharmacy setting.[197] The JLT is more sensitive to less severe bowel 
symptoms than the PCQ. Fifty-seven percent of symptomatic people attending a 
pharmacy who completed a PCQ scored in excess of 30, demonstrating early signs of 
colorectal disease that might benefit from GP intervention.[154, 155, 184]  
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In this validation exercise, the JLT demonstrated high sensitivity of 100% and modest 
specificity of 65%. The high sensitivity may help in identifying clients at high risk of 
disease, while the relatively modest specificity may also identify clients who are 
unlikely to have serious bowel disease, but nevertheless would benefit from a GP 
consultation when reporting non-life-threatening pathologies. The JLT is not likely to 
suggest consultation for clients with short-lived self-limiting conditions that are 
appropriately managed with over-the-counter treatments.  
 
This ROC curve displays the full picture of trade-off between the sensitivity and 1-
specificity (false positive) across a series of cut-off points, each represented as a black 
dot (Figure 3.1). The larger the AUC, better is the performance of the instrument in 
question to correctly pick the ‘true’ positive and ‘true’ negative.[205] The large AUC 
of 0.94 indicates the favourable overall performance of the JLT to identify clients at 
risk of serious bowel pathology.  
 
3.6. Limitations  
 
In this study, the JLT was tested against the PCQ. In ideal research practice, clients 
would complete both the PCQ and the JLT, and criterion validity would be established 
by demonstrating similar outcomes from the application of both tests. In this study, 
the key questions in the JLT match some of the questions in the PCQ. Therefore, the 
scores of the PCQ were used to determine the sensitivity and specificity of the JLT.  
 
The other limitation of the developed questionnaire is that as many as 35% of cases 
identified by the JLT as warranting referral have a PCQ score of less than 30, 
suggesting these subjects are at low risk of serious bowel disease. As pharmacists are 
in a position to apply clinical judgement when using the JLT, they can override the 
referral recommendation if they deem the symptoms may be due to factors other 
than underlying (or developing) disease. This is particularly the case when considering 
answers to Question 6 (prior consultation GP regarding the presenting bowel 
symptom) and Question 7 (medication).  
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A modified nominal group technique and Delphi technique were used to generate 
items for the JLT questionnaire and to reach consensus among the members of the 
expert panel. Conventional methods of scoring and ranking the items were 
completed during the developmental phase of the questionnaire rather than during 
the Delphi Technique as it was essential to include all key clinical markers of possible 
bowel disease.  
 
Pharmacy staff were involved in the development of the JLT. There was however, 
no direct involvement of the clients in the design of the JLT. This was because the 
intervention was aimed at, and managed by, pharmacy staff . The readability of 
JLT was measured by Flesh-Kincaid grade 4 level, indicating that an average grade 4 
student (aged 10-11 years) should be able to read the instrument. 
 
3.7. Conclusion and Recommendations 
 
Any new screening test should demonstrate the ability to clearly delineate cases that 
require medical advice. The JLT exhibited high sensitivity for identification and triage 
of symptoms of bowel disease. In the current drive for health promotion initiatives 
within community pharmacy, an easy, user-friendly, valid triage instrument such as 
the JLT has the potential to improve pharmacy practice.  
 
The next step is a prospective evaluation of the JLT against the referral of clients who 
may be at risk of bowel disease to further confirm the validity of the JLT in practice. 
The issues listed in the limitations can be studied in detail during a prospective study 
to test the use of the JLT in community pharmacies. 
 
 
68 
 
4. Trial of the Jodi Lee Test (JLT) 
 
4.1. Background 
 
Building on the results and conclusions of Chapter 3 (describing development and 
validation of the JLT), a prospective observational study was proposed and conducted 
to trial the JLT. The key findings of this study are reported in a journal article prepared 
for submission in Current Medical Research and Opinion entitled A Model for Effective 
Assessment and Referral of Clients with Bowel Symptoms in Community Pharmacies, 
authored by Deepa Sriram, Alexandra McManus, Lynne Emmerton, Richard W 
Parsons and Moyez Jiwa. All authors were involved in the study design. DS conducted 
the study and RP provided statistical guidance.  
 
This article is reproduced in Section 4.2. Spelling and styles used for citations, 
headings and tables are aligned with the thesis. Supplementary information 
(considered beyond the length and scope of a scientific journal article) is included in 
Section 4.3. 
 
4.2. JLT Trial  
 
 Introduction  
 
Help seeking is considered to be the recognition of a health concern followed by a 
range of actions, one of which may be health service utilisation.[209] Interviews with 
people experiencing symptoms of bowel disease have shown that a significant 
proportion try to manage their own symptoms,[210] rather than consult a doctor, 
even when symptoms are persistent and subsequently found to be due to a life-
limiting condition.[176, 211]   
 
A number of bowel diseases share clinical presentations, and certain symptom 
profiles that are associated with serious underlying conditions such as cancer, 
inflammatory bowel disease or degenerative bowel conditions.[5] To improve 
outcomes, clients need to recognise the significance of their symptoms, and GPs need 
to accurately diagnose and manage bowel diseases.[27, 44] 
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Faecal occult blood test screening (FOBT), available via the National Bowel Cancer 
Screening Program in Australia, is limited to people turning 50, 55, 60, 65 and 74 years 
(the average age of a patient with colorectal cancer is 68 years).[171] Biennial 
screening for those aged 50-74 began in 2015 and is due to be completed in 2020. 
[170] Detection of blood in bowel motions (from the FOBT) prompts 
recommendations for further investigations such as colonoscopy.[170] At more than 
30 times the price of FOBT, colonoscopy is too expensive for a population-based 
screening tool. [170]   Although FOBT is a valid test for bowel cancer, participation in 
the program is reportedly poor[172], with barriers such as: “inconvenience of the 
testing process; aversion to manipulating faeces; cost; views about personal 
invulnerability; and cultural beliefs and attitudes”.[173] 
 
Community pharmacies are a recognised and used as common source of health 
advice by many Australians.[212] Results from a survey of patients attending general 
practice in Australia show that pharmacists were identified as the most likely health 
professionals, other than GPs, who might advise about bowel symptoms.[21] Three 
or more clients per week, on average, seek symptomatic treatment for bowel 
symptoms[21] in each of Australia’s 5450 pharmacies.[19] Interactions between 
pharmacists and their symptomatic clients therefore offer an ideal opportunity to 
explore how pharmacy staff can identify patients with possible emerging serious 
illness. 
 
However, a survey of pharmacists in Australia[13] demonstrated a lack of awareness 
of high-risk bowel symptoms. This finding recognises the requirement for better 
education to understand when to refer for further medical investigation. 
 
Research supports the use of self-administered questionnaires to help primary health 
care professionals identify cases that warrant further investigation for colorectal 
pathology.[30, 31, 192] The Jodi Lee Test (JLT) is a simple, short, client-completed 
questionnaire developed to aid consultation between pharmacy staff and clients with 
bowel symptoms.[213] The data provided can be reviewed by any pharmacy staff 
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who interact with clients: pharmacy assistants to determine when the client should 
be referred to the pharmacist, and pharmacists to determine when referral to a GP 
is required.[213] The key items in the JLT indicating the need for referral for GP 
assessment are the client’s symptom(s), symptom duration and history of 
gastrointestinal disease.[213] The JLT demonstrates high sensitivity (100%) and 
modest specificity (65%) for identification and triage of symptoms of bowel disease 
when compared to a validated tool, the Patient Consultation Questionnaire 
(PCQ).[213] By comparison, the PCQ assists GPs in prioritising referrals for colorectal 
conditions, and has high sensitivity for serious colorectal pathologies.[5, 197]  
 
The purpose of this study was to examine the feasibility and effectiveness of use of 
the JLT as a guide to pharmacy staff to identify clients with bowel symptoms 
warranting GP assessment (‘referral’). 
 
 Materials and Methods 
 
Ethical approval was granted by the Curtin University, Human Research Ethics 
Committee (HR19_2013). This study used a prospective pre-post design in 
community pharmacies in WA, and was conducted from May 2013 to March 2014. 
Prior to the commencement of the intervention, data were collected concerning the 
usual practice (UP) of pharmacy staff dealing with clients seeking assistance for bowel 
symptoms. Following the UP phase, the JLT was introduced to guide the pharmacy 
staff in their interaction with the client (the intervention: JLT phase). These phases 
are described below. The value of the JLT was assessed between the two phases of 
the study by comparing the referrals to, and subsequent contact by the client with, 
the clients’ GP for those considered to have signs of potentially serious disease. 
 
4.2.2.1. Sample Size 
 
The development and validation of the JLT (Chapter 3) study reported that 55% of 
clients who were screened using the JLT required GP referral.[213] For the purposes 
of this study, it was conservatively assumed the referral rate would reduce to 
approximately 35% after the pharmacist reviewed the completed questionnaire, 
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communicated with the client, and applied his/her clinical judgment, in line with the 
protocol for use of the JLT. In the JLT validation study, approximately 10% of eligible 
clients were referred to their GP when the pharmacist was not using a decision 
support aid.[21] In order to detect a difference of this magnitude in the proportion 
of clients referred for further investigation ‘using’ versus ‘not using’ the decision-
support aid (35% vs. 10%) with power=90% and α=0.05, 65 participants would be 
required in each arm of the trial. Allowing for an estimated 20% loss to follow-up, this 
number was adjusted to n=82 in each arm. Conservatively assuming that each 
pharmacy would recruit at least one participant each week, i.e. a one-in-three 
recruitment rate,[13] it was estimated that 20 pharmacies would be required to 
complete the study within the proposed timeframe. 
 
A convenience sample of 21 pharmacies in WA was recruited to take part in the study: 
17 in the Perth metropolitan area and four from regional towns. The locations of the 
pharmacies were selected to represent a range of socioeconomic areas. Data 
collection commenced with the UP phase; however, these data were not collected 
from two pharmacies, as they joined the study just prior to the commencement of 
the intervention. During the recruitment process, the pharmacies were provided with 
promotional flyers for the study which included the timeline and study protocol 
(Appendix 4.1). Written consent was gained from all staff members of the 
pharmacies, including pharmacy assistants, pharmacists, pharmacists-in-training 
(pre-registered pharmacists) and locums, prior to commencement of the study 
(Appendices 4.2 to 4.4).  Prior to commencement of each phase, the researcher 
conducted a training session on the research protocol for the staff of each pharmacy. 
Instructions were given on recruitment of clients and study documentation. A written 
instruction sheet was left with each pharmacy for further reference, and staff 
members were invited to report any queries or feedback (Appendix 4.5 and 4.6). A 
feature of the JLT is that the pharmacist applies his/her interpretation of the 
questionnaire responses; as such, there was no training in clinical management of 
individual clients 
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4.2.2.2. Baseline 
 
The staff members of the 21 pharmacies completed a baseline survey comprising, 
among other questions, an open-ended question concerning their role in 
management of clients with bowel symptoms. Data were coded using key words 
elicited from the responses, and the roles of pharmacy assistants and pharmacists 
were determined collectively across the pharmacies. 
 
4.2.2.3. Usual-Practice Phase 
 
Pharmacy staff recruited consecutive clients seeking advice for bowel symptoms or 
seeking medicines normally used to treat diarrhoea, constipation or haemorrhoids. 
Participating clients were to be aged at least 18 years and able to give written 
informed consent to take part in the study, which included contact by the researcher 
for follow-up after their pharmacy visit.  
 
The pharmacy staff continued their usual service in managing clients’ bowel 
symptoms. Consultations with consenting clients were documented by the 
pharmacists, recording the clients’ reported symptom(s), medication purchased, 
verbal referrals for further investigation, and reasons for referrals. The pharmacies 
aimed to recruit and follow-up a total of 82 participants for this phase over a period 
of 12 weeks. 
 
Follow-up of the recruited clients took place four weeks following their pharmacy 
visit. The researcher contacted clients by telephone to determine if their symptom(s) 
persisted, whether referrals were acted upon, and if so, investigations undertaken by 
the GP. Verbal consent for a second follow-up at a negotiated time was obtained from 
those with pending investigations to determine their ultimate diagnosis. Participants 
who were not contactable for follow-up after three attempts were deemed lost to 
follow-up. 
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4.2.2.4. Intervention (JLT) Phase 
 
Recruitment started four weeks after the completion of the UP Phase. The same 
eligibility criteria, client recruitment and follow-up processes were used for the 
Intervention Phase as for the UP Phase of the study. 
 
In this phase, the pharmacy staff, following client consent, deployed the JLT to guide 
decision making in their consultation. The JLT, a paper-based questionnaire 
comprising eight questions, was self-completed by clients in a private or semi-private 
area in the pharmacy (if available), with the assistance of the staff member if 
required. On reviewing the completed JLT, the attending pharmacy assistant decided 
whether or not to refer the client to the pharmacist; likewise, the pharmacist applied 
his/her clinical judgement regarding referral to the client’s GP. For cases warranting 
GP investigation, the pharmacist completed details on a standard referral letter, 
issued to the client with the completed JLT and verbal recommendations. Verbal 
recommendations included sale of medicines, instructions for use of these medicines, 
and relevant warnings. A carbon copy of the completed JLT was posted to the 
researcher in a reply-paid envelope following recruitment of each participant. The 
researcher contacted pharmacies twice weekly by telephone and email to monitor 
and discuss their progress. The recruitment and follow-up period for this phase was 
extended to 20 weeks to account for increased pharmacy workload during December 
2013 and January 2014.  
 
Similarly to the UP Phase, clients who were referred for consultation with a GP were 
contacted by the researcher four weeks after their pharmacy visit to determine if 
they had visited their GP, if any further investigation had taken place, and if a 
diagnosis had been made.  
 
4.2.2.5. Evaluation by Staff 
 
Within two weeks of the completion of the intervention phase, staff of the 
participating pharmacies was asked to complete a post-trial feedback questionnaire 
to assess the utility of the JLT. The questions included the usability of JLT, reasons 
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why the JLT had or had not been used during the consultation, intentions to continue 
using the JLT, if they would recommend it to their colleagues, and which (if any) other 
symptoms would benefit from a questionnaire such as the JLT. A copy of the JLT was 
attached to the post evaluation survey for the respondents to refer to especially if 
they had not used JLT for consultation 
 
4.2.2.6. Analysis 
 
The effectiveness of the JLT intervention was determined by: 
 
1. The proportion of clients who were referred to their GP following use of the JLT 
compared to UP 
2. Comparison of GP attendance rates for clients referred to the GP following use of 
the JLT compared to UP 
3. Diagnoses of colorectal pathologies in clients following the use of JLT compared 
to UP 
4. Feedback from pharmacy staff on the utility of the JLT. 
 
Demographic details of the study participants and baseline practice were 
summarised using standard descriptive statistics. Differences in referral rates and GP 
consultations were assessed using the chi-square and Fisher’s exact test. The SPSS® 
version 22 statistical software was used for all analyses. A p-value<0.05 was indicated 
a statistically significant association. 
 
 Results 
 
4.2.3.1. Baseline 
 
One hundred and ninety-one pharmacy staff, comprising 122 pharmacy assistants, 
62 pharmacists and seven pre-registered pharmacists, completed the baseline 
survey. The mean age for pharmacy assistants was 28 years (range: 15-62 years), and 
32 years (range: 22-56 years) for pharmacists. The pharmacists had around 10 years’ 
work experience in pharmacy, while the pharmacy assistants recorded approximately 
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six years. Twenty-one percent of the pharmacy assistants were tertiary educated, and 
44% had completed only up to year 12 or equivalent. Self-reported data from the 
participating pharmacies revealed pharmacy assistants typically gathered 
information about clients’ symptoms, history and lifestyle. The pharmacists offered 
advice on managing symptoms and lifestyle, and provided further information about 
the symptoms, medication and referral to a GP.  
 
4.2.3.2. Assessment of the JLT Intervention 
 
Eighty-four clients were recruited and followed up over 12 weeks in the UP Phase 
(Table 1); these comprised 60 (71%) females and 24 (29%) males. Twenty-one were 
lost to follow-up, and seven were excluded on the basis of age. Staff of 19 of the 21 
selected pharmacies recruited clients for this phase. 
 
Eighty clients were recruited and followed up over 20 weeks in the Intervention 
Phase, comprising 54 (68%) females and 26 (33%) males. Fourteen were lost to 
follow-up. Fifty of the 80 clients (63%) were initially identified on self-completion of 
the JLT as meriting referral to a GP. However, during the ensuing consultation 
between client and pharmacist, only 30 (38%) were confirmed by pharmacists as 
warranting referral. Common reasons why the pharmacists did not refer cases 
indicated as concerning by the JLT were that the client’s GP was aware of the 
symptoms for which he/she was seeking advice, or that the presenting symptom was 
an obvious side effect of a prescription medication the client was taking. 
 
The intervention was associated with a significantly higher referral rate compared to 
the UP Phase: 38% vs 20% (Table 1). The acceptance of the recommendation to 
consult a GP (i.e. attendance rate for GP consultation) was also higher during the 
Intervention Phase: 40% vs 6%. Three clients from each of the UP and the 
Intervention Phases who were referred to consult the GP were lost to follow-up. The 
p-value (Fisher’s Exact test) for comparison of the proportions of clients who were 
recommended to consult a GP (1/14 and 12/27, excluding those lost to follow-up), 
was p=0.031. More diagnoses were made for clients who consulted a GP following 
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the pharmacist’s referral using the JLT, while there was no definitive diagnosis for the 
one client from the UP group who consulted a GP.  
 
Table 4.1: Impact Evaluation: Usual-Practice Phase versus Intervention Phase  
  
 
   p=0.029 (chi-square) 
** p=0.017 (Fisher’s Exact) 
 
 
4.2.3.3. Pharmacy Evaluation 
 
Forty-seven pharmacy staff completed the feedback questionnaire. In this 
evaluation, each of the 19 participating pharmacies was represented by at least one 
full-time pharmacist and one pharmacy assistant. The respondents comprised 19 
pharmacists and 27 pharmacy assistants. Though only 21 (45%) reported using the 
JLT when consulting clients with bowel symptoms, 30 (64%) of the pharmacy staff 
agreed that the JLT could be incorporated in the pharmacy after reviewing the 
Variable Usual Practice Intervention 
Recruited 84 80 
Referred to 
General 
Practitioner 
17 (20%) 30 (38%)* 
Consulted 
General 
Practitioner 
1/17 (6%) 12/30 (40%)** 
Details of 
General 
Practitioner 
Consultation 
#55: No follow-up for 
diagnosis 
#05: Monitored by General Practitioner  
#07: Ultrasound  diverticulitis 
#13: Blood tests  monitored by General 
Practitioner 
#26: No further action  
#41: No further action 
#51: Dairy allergy 
#55: Monitored by General Practitioner 
#58: No follow-up for diagnosis 
#74: Blood and stool test  all clear 
#76: Stool test  all clear 
#80: Colonoscopy  monitored by General 
Practitioner 
#83: Colonoscopy  monitored by General 
Practitioner 
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attached JLT. Thirty three (70%) indicated they would use the JLT in future when 
managing clients with bowel symptoms. 
 
The effectiveness of JLT is illustrated by the following quotations from pharmacy 
staff: 
 
“Effective way to establishing client needs and current bowel symptoms” 
(pharmacy assistant). 
“Confirming ‘red flags’ for early detection of bowel signs and symptoms that 
warranted referral for medical advice” (pharmacist). 
“Establishing consistent practice in the pharmacy” (pharmacist). 
“Providing timely, effective professional advice and information to clients, 
including advice about consulting a GP” (pharmacist). 
“Helpful in reinforcing the case of referral when the client was initially hesitant 
to see the GP” (pharmacist). 
 
Additional feedback related to the JLT being simple and quick to use, easy to 
understand by the client, non-invasive, easier for clients who feel embarrassed to 
discuss their bowel symptoms, and a good checklist approach for quick response in a 
busy pharmacy. In critiquing the tool, some stated the study protocol booklet format 
was time consuming and a deterrent to the recruitment process. Reasons given by 
staff for not using the JLT were largely logistical, including workflow, and few clients 
perceived as eligible. Other conditions for which the pharmacy staff would accept a 
JLT-like questionnaire were urinary tract infections, asthma, vaginal candidiasis, 
cough, chronic pain, kidney problems, headaches, and upper gastro-intestinal 
symptoms. 
 
 Discussion 
 
This prospective study supports the use of the JLT, a brief self-administered 
questionnaire, as a clinical decision tool for pharmacy staff to identify symptoms that 
might require medical investigation, and serves as a written referral to the GP. The 
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staff in the pharmacy were made aware of clients who were presenting with 
symptoms that may require medical assessment. The client and the pharmacist were 
afforded the opportunity to discuss these in detail, and in some cases, referral was 
considered unnecessary. A reasonable assumption was made by the pharmacists that 
if a client had recently consulted a GP, the GP was almost certainly aware of the 
symptom(s) and was managing the client appropriately. Other clinical situations may 
have also led a pharmacist not to refer a client. 
 
In those cases where referral was warranted, the participants were advised on the 
need for a medical consultation and given a referral letter to take to the GP. Use of 
the JLT resulted in 38% of clients being referred to their GP, compared to 20% during 
UP. This result is in line with studies reporting that health questionnaires completed 
by patients frequently captured more positive symptoms than elicited during 
consultation.[193, 214] Our empirical evidence also indicates a greater proportion of 
the clients accepted the pharmacist’s referral, consistent with other studies that 
reported increased GP consultation after being encouraged by a pharmacist.[21, 215]   
 
The concept of applying a decision-support tool in pharmacy practice was novel to 
our participating pharmacy staff, and although it may not be applicable to all practice 
settings or situations, the JLT shows promise in guiding management of bowel 
symptoms. In particular, the documentation produced for cases warranting referral 
appears to hold value for clients, evidenced by their uptake of recommendations to 
consult their GP. Alternatively, for situations able to be managed in the pharmacy, 
the JLT highlights to the pharmacy staff member the presenting symptoms and their 
significance. 
 
As established in the baseline phase, the first point of contact for the client was 
commonly the pharmacy assistant. As such, prompting pharmacy assistants’ use of a 
simple, structured assessment tool can benefit the pharmacy workflow, in triaging 
clients to be referred to the pharmacist and supporting the provision of non-
prescription medicines; these are recognised roles for pharmacy assistants in 
Australia.[78] 
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Most of the pharmacy staff found the JLT to be a simple and effective assessment 
guide for management of bowel symptoms, and reported that clients managed to 
complete the questions unassisted. As such, its deployment did not burden pharmacy 
staff. The majority of burden related to client recruitment and consent for research 
purposes (follow-up).  
 
A randomised controlled trial is the ideal design to test pharmacy-led interventions; 
however, it was not feasible in this case for several reasons. Firstly, one of the 
objectives of the study was to identify if a change in referral practices of pharmacists 
could be achieved by introducing to them a structured questionnaire approach (the 
JLT) for these clients. Once the JLT is used for a particular client in a pharmacy, it 
would not be practical to revert to UP for a subsequent client. A cluster design where 
pharmacies applied only UP or the JLT would have avoided the issue of randomising 
clients, but differences between practices in terms of staffing and demographic 
profile may have confounded the analysis. For these reasons, a pre-post design was 
considered the most appropriate.  
 
The study protocol was not consistently applied in some pharmacies, highlighting the 
challenges of research in a naturalistic setting. Although the researcher closely 
monitored the study progress, adherence to the study protocol by individual staff 
was not able to be controlled. Ideally, this trial would have also included client 
feedback on the JLT to supplement developmental research in its design,[213] and 
validation of client outcomes using general practice data. Further research on the 
acceptability of the JLT directly from the client’s perspective is required to determine 
their expectations of pharmacy services when presenting with bowel symptoms. 
Though a practising GP was involved in the design and validation stage of JLT,[213] 
no GPs to whom the clients were referred to, were asked to give feedback on the 
written referral that was given to clients whose symptoms warranted further medical 
consultation. Loss to follow-up is also recognised as a limitation in outcomes-
focussed research. 
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Our findings suggest potential for wider application of the JLT as an optional practice-
enhancing guide to over-the-counter consultations in the community pharmacy 
setting. There is potential for the documentation to be adapted to guide 
management of other complex symptoms potentially warranting GP investigation 
and potentially associated with early-stage cancer. There is potential for future 
research on development and trial of a JLT-like questionnaire for screening of 
pharmacy clients presenting with symptoms indicative of conditions such as urinary 
tract infection, vaginal candidiasis and kidney problems. 
  
 
 Conclusion 
 
The JLT was found to be an acceptable assessment tool for the triage of bowel 
symptoms in the community pharmacy setting. Its effectiveness was demonstrated 
by prompting a higher rate of referrals in those who would benefit from a GP 
investigation, a higher rate of uptake of recommendations for referral and more 
clinical diagnoses compared to the usual model of consultation. As such, the JLT 
shows promise as an effective decision-making aid in the pharmacy to triage clients 
at higher risk of bowel cancer.  
 
4.3. Additional Information 
 
 Perceived Roles of Pharmacy Staff and Pharmacists 
 
Of the 191 questionnaires completed by pharmacy staff of the recruited pharmacies 
(Section 4.2.3.1), 25 had missing responses to the open-ended question exploring the 
role of pharmacy staff in the management of bowel symptoms. Table 4.3 represents 
the frequency of the 166 coded valid responses to the open-ended question 
described in Section 4.2.3.1. Pharmacy assistants perceived their role as eliciting as 
much information as possible from the client about his/her symptom(s), while 
pharmacists perceived their role in management of the symptom(s).  
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Table 4.2: Frequency of Data Code elicited from Responses of Pharmacy Staff on 
Their Role in Bowel Symptom Management 
 
Characteristics Pharmacists  
N=53 (%) 
Pharmacy 
assistants N=113 
(%) 
To gather as much information 
from the client about his/her 
symptom(s) 
27 (50.9) 79 (69.9) 
To elicit information about the 
duration of symptom(s) 
12 (22.6) 40 (35.4) 
To elicit information about 
presenting symptom(s) 
15 (28.3) 45 (39.8) 
To obtain information about pain 
or discomfort in the back passage 
0 (0) 2 (1.8) 
To obtain information about 
bleeding 
1 (1.9) 8 (7.1) 
To obtain information about the 
client’s lifestyle 
2 (3.8) 2 (1.8) 
To obtain information about the 
client’s diet 
0 (0) 7 (6.2) 
To ask about prior consultation 
with a doctor regarding this 
symptom(s) 
0 (0) 2 (1.8) 
To gather information about 
medication having or tried for the 
presenting symptom(s) 
6 (11.3) 22 (19.5) 
To gather information about the 
client’s medical history  
9 (17) 13 (11.5) 
To gather information about the 
client’s family medical history 
1 (1.9) 2 (1.8) 
To gather information about the 
client’s other regular medication 
9 (17.0) 25 (22.1) 
To give product advice 20 (37.7) 14 (12.4) 
To give lifestyle advice 16 (30.2) 8 (7.1) 
To give diet advice 5 (9.4) 4 (3.5) 
To give prevention advice 2 (3.8) 3 (2.7) 
To give general advice about the 
client’s symptom(s) 
41 (77.4) 48 (42.5) 
To either refer or get assistance 
from (another) pharmacist 
2 (3.8) 84 (74.3) 
To sell medication or offer 
treatment 
36 (67.9) 55 (48.7) 
To offer bowel scanning kit 2 (3.8) 3 (2.7) 
To refer to doctor 34 (64.2) 29 (25.7) 
To take to a private spot for 
consultation 
0 (0) 1 (0.9) 
 
Seventy-five percent of the pharmacy assistants (n=84) reported that they would 
refer the client to the pharmacist if they think the symptom warrants a pharmacist’s 
intervention. Sixty-four percent of the pharmacists (n=34) consider they would give 
verbal advice to consult a GP. Very few pharmacists (3.8%) and pharmacy assistants 
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(2.7%) reported that they would normally offer a faecal specimen-collection kit to the 
client. 
 
 Actor-Simulation study 
 
The perceived roles of the pharmacy staff on the management of bowel symptoms 
in their pharmacy is reported in the previous section (4.3.1), however there can be 
inconsistencies between real and reported behaviour.[216] Information given in 
surveys and questionnaires may not be in accordance with the actual (usual) 
behaviour in a natural setting.[216]  
 
Participant observation can elicit information to help verify information that is 
gathered from a survey.[216] Standardised patients are increasingly used to assess 
primary care practice.[217-221] An actor-simulation study was conducted at the 
baseline phase to ascertain the accuracy of the baseline survey conducted for the 
pharmacy staff. This aspect of the study was conducted to glean the normal 
procedures for managing patients presenting with bowel symptoms. 
 
4.3.2.1. Method 
 
Four scenarios relating to diarrhoea, constipation, rectal bleeding and alternating 
constipation and diarrhoea were prepared for this study (Appendix 4.7). These are 
common bowel symptoms, and there is evidence showing that one in 15 people 
identify the pharmacist as a source of advice for these symptoms.[21]    
 
A checklist approach completed soon after the actor-pharmacy staff interaction was 
taken for collection of data in this actor-simulation study. Electronic device 
malfunction was reported as the cause of data loss in few studies using recording 
instruments for collecting data. [217, 221] A checklist was developed for each of the 
four scenarios. It captured the consultation provided, history taking and 
management by the pharmacy staff during the actor visit (Appendix 4.8).  
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Ethical approval was granted by the Curtin University, Human Research Ethics 
Committee (HR19_2013). As indicated in Section 4.2.2, the pharmacy staff gave 
written consent before the commencement of the baseline phase of the JLT trial; this 
included consent for the actor-simulation study. This kind of consent is called the 
‘principle’ consent where the participant gives prior consent without knowing the 
exact day or time of the simulated-client’s visit.[222]  
 
Of the 21 pharmacies recruited for the prospective study, seven pharmacies were 
chosen randomly to represent the pharmacies from Perth metropolitan area and 
different pharmacy locations (shopping centre, medical centre, city/suburb stand-
alone).  Four actors (2 males and 2 females, aged approximately 30-45 years), were 
selected from a number of ethnic groups (Caucasian, African and Indian) and trained 
for one of the symptom scenarios. The scenario included the detail about the 
symptom, duration, medical history and medication taken for the presenting 
symptom. Each scenario also depicted who to talk to, how to sound when conveying 
the symptom, and what to say. Three training sessions were held for the actors by 
the researcher. They were trained on how to act as a pharmacy client with the bowel 
symptom and to observe and recall pharmacy staff’s action during the visit. 
Information on how to respond for different management suggestions by the 
pharmacy staff was also given to each actor. Training was followed by two practice 
sessions with an academic pharmacist and GP. 
 
Each pharmacy received one visit (one scenario) by all four actors at randomly 
assigned times over a period of 30 days. The pharmacy staff were not aware when 
an actor would present with his/her scenario. The interaction with the pharmacy 
staff was documented by the actor based on the checklist of questions soon after the 
consultation with the pharmacy staff. No audio-recording took place, in line with the 
ethical approval for this study. 
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4.3.2.2. Results 
 
There were 28 actor-pharmacy staff interactions. All actors were first offered 
assistance by the pharmacy assistant. All seven of the ‘alternating diarrhoea and 
constipation’ cases were referred to the pharmacists by the assistants, compared to 
six of the seven ‘rectal bleeding’ cases. Two cases each from the ‘constipation’ and 
‘diarrhoea’ cases were referred to pharmacists. In all but three ‘rectal bleeding’ 
scenarios, a medication was sold to the actor. Table 4.2 illustrates the responses 
documented by the actor for each symptom, and how the pharmacy staff questioned 
and managed each symptom.  
 
Six ‘constipation’ cases were managed by the pharmacy assistant without involving 
the pharmacist, while all seven cases of ‘alternating constipation and diarrhoea’ were 
managed by the pharmacist. In six ‘rectal bleeding’ scenarios, actors were referred to 
pharmacists; of these, three actors were advised to consult a GP at their earliest 
convenience. One pharmacist offered to book a GP appointment for the actor with 
the ‘rectal bleeding’ case scenario. 
 
Surprisingly, none of the staff asked the actors if they had discomfort (pain or a lump) 
in the back passage except for three cases with rectal bleeding scenario. None of the 
actors reported as being asked about weight loss by the pharmacy assistants or 
pharmacists. 
 
 
85 
 
Table 4.3: Actors’ Documentation of Questions and Management of their Bowel Symptom Scenario by Pharmacy Staff 
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Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No 
Constipation 
6 
(85.7) 
1 
(14.3) 
1 
(14.3) 
6 
(85.7) 
6 
(85.7) 
1 
(14.3) 
2 
(28.6) 
5 
(71.4) 
1 
(14.3)  
6 
(85.7) 
0      
(0) 
7  
(100) 
0      
(0) 
7  
(100) 
N/A N/A N/A N/A 
0      
(0) 
7  
(100) 
Diarrhoea 
2 
(28.6) 
5 
(71.4) 
3 
(42.9) 
4 
(57.1) 
6 
(85.7) 
1 
(14.3) 
3 
(42.9) 
4 
(57.1) 
2 
(28.6) 
5 
(71.4) 
0      
(0) 
7  
(100) 
0      
(0) 
7   
(100) 
0      
(0) 
7          
(100) 
0      
(0) 
7   
(100) 
4 
(57.1) 
3 
(42.9) 
Alternating 
Diarrhoea 
and 
Constipation 
3 
(42.9) 
4 
(57.1) 
1 
(14.3) 
6 
(85.7) 
7 
(100) 
0     
(0) 
7 
(100) 
0     
(0) 
4 
(57.1) 
3 
(42.9) 
0      
(0) 
7  
(100) 
3 
(42.9) 
4 
(57.1) 
0      
(0) 
7  
(100) 
0      
(0) 
7  
(100) 
5 
(71.4) 
2 
(28.6) 
Rectal 
Bleeding 
4 
(57.1) 
3 
(42.9) 
2  
(28.6) 
5 
(71.4) 
4 
(57.1) 
3 
(42.9) 
2 
(28.6) 
5 
(71.4) 
3 
(42.9) 
4 
(57.1) 
3 
(42.9) 
4 
(57.1) 
1 
(14.3) 
6 
(85.7) 
0      
(0) 
7  
(100) 
0      
(0) 
7  
(100) 
6 
(85.7) 
1 
(14.3) 
Total 28 28 28 28 28 28 28 28 28 28 
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 Additional Discussion 
 
Two additional sets of data have been presented in this section: self-perceived roles 
of pharmacy staff and pharmacists in managing bowel symptoms; and an actor-
simulation study to verify the normal procedures for managing patients presenting 
with bowel symptoms. 
 
Statements in surveys and interviews may not be in accordance with the factual 
behaviour.[216] In natural settings, the actual staff response is brought to light 
without being influenced by the awareness that the behaviour is being 
monitored.[222] Standardised patients’ assessments are a valid measure of quality 
of care given in primary care setting.[217, 223] The baseline survey reported in brief 
in Section 4.2.3.1 and in detail in Section 4.3.1 is the self-reported role of bowel 
symptom management perceived by the respondents: pharmacy assistants and 
pharmacists. The actor-simulation study is the standardised clients’ assessments to 
verify the perceived role to the actual behaviour in the natural setting. 
 
In the actor-simulation study, pharmacy assistants were confident in managing 
constipation and diarrhoea symptoms, but referred the actors for pharmacist 
consultation when symptoms involved alternating diarrhoea and constipation or 
rectal bleeding. This study verified the role of pharmacy assistant as usually the first 
point of contact for clients presenting in a community pharmacy. Ethnically-diverse 
actors were assigned to a single case and all pharmacies in the actor-simulation study 
received all cases. The risk of detection of simulated consultation by the pharmacy 
staff would be higher in rural setting where a ‘new face’ would be detected in the 
close-knit community.[223] The participating pharmacies for this study were from the 
metropolitan area and there was no reported detection of the simulated clients by 
the pharmacy staff. 
 
One of the limitation is that there was no covert recording during the consultation 
and therefore no validation of the documentation made by the actors. Systematic 
review by Rethans et al.[220] on actor-simulation studies in real practice reported 
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that studies that used electronic devices to record the consultation had the scope for 
failing due to technical failure of the device. As reported in the systematic reviews by 
Watson et al.[224] and Xu et al.[222] a checklist method was the most common 
method of documentation of the simulated-client’s visit. Nevertheless, there is 
potential for error in data due to memory and recall time.[222] The documentation 
on the checklist for this study was made by the actors as soon as they came out of 
the pharmacies, so as to minimise recall bias. It is recommended that in future 
studies, consideration could be given to a combination of checklist documentation 
and audio-recording for validation of data. 
 
The open-ended descriptions from pharmacy assistants and pharmacists regarding 
their perceived role in management of clients presenting with bowel symptoms 
should be interpreted with caution. Self-report is one way of collecting data for health 
research, but the response is influenced by the cognitive and technical factors in 
understanding and responding to the questions.[225] An open-ended question was 
used to reduce the bias that might be introduced by prompting response from 
pharmacy staff on management of bowel symptoms.  
 
4.4. Conclusion and Recommendation 
 
Findings from this JLT prospective study suggest there is potential for implementation 
of a questionnaire such as the JLT in pharmacies for screening and management of 
complex symptoms that might benefit from a medical consultation to initiate 
treatment at an earlier stage of a potentially serious pathology.  
 
Implementation of behaviour, such as quality-enhanced services in community 
pharmacy, requires understanding of specific factors that influence the 
behaviour.[37] Provision of services in pharmacies where the pharmacy staff identify 
and refer clients requiring further medical investigations based on their responses to 
questionnaire such as the JLT, requires understanding of the intention, and the 
factors that influence the intention, of pharmacy staff. Intention, which directly 
influences the behaviour, reflects the person’s motivation and desire to perform that 
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behaviour.[98] Factors influencing intention are the person’s perceived barriers, 
perceived social behaviour and attitudes about the outcome of the behaviour.[95] A 
study to examine the attitudes, beliefs and intention of the pharmacy staff towards 
changing practice to implement quality-enhanced services in the community 
pharmacy setting was proposed and conducted, and is described in the Chapter 5.  
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5. Intention of Pharmacy Staff to Change Behaviour 
 
5.1. Introduction 
 
It is evident from the review of the literature (Section 2.4) that for successful 
implementation of any evidence-based practice, understanding of the factors that 
influence behaviour (change of practice) is required. Multiple barriers may exist that 
hinder the successful application of knowledge into practice.[112] 
 
Designing strategies based on the TPB can assist adoption of a behaviour of interest, 
such as a change in practice among pharmacy staff.[1] According to this theory 
(Section 2.5.1), the intention that directly influences a behaviour reflects a person’s 
motivation and desire to perform an action.[98] The factors that influence this 
intention are:  
 
• PBC: ease or difficulty associated with the performance and confidence in 
performing an action; PBC also has direct influence on behaviour 
• Subjective Norm: perceived social pressure to perform or not to perform an 
action, and 
• Attitude: degree of evaluation or appraisal of the behaviour.[94, 95, 97-100] 
 
The TPB has been widely used to understand health professionals’ attitudes, 
perceived barriers, beliefs and the influence of external factors in achieving best 
practice. Numerous studies have used this theory for meta-analytic reviews across a 
range of behaviours, to predict general health behaviour, participation in cancer 
screening, and adherence to exercise.[98, 101, 103-107, 226] Section 2.5.2 presented 
evidence around use of the TPB to understand the relationship between influencing 
factors and the intention to change behaviour in pharmacies. Farris et al.[108] 
studied the relationship between intention to change behaviour and provision of 
pharmaceutical care, defined as “the responsible provision of drug therapy to 
improve the patient’s quality of life.”[109] Odedina et al.[37] developed a theoretical 
framework that explained pharmacists’ behaviour relative to the provision of 
pharmaceutical care. A pharmacy smoking cessation study evaluated the knowledge 
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and attitude of pharmacy assistants after they attended an education program.[111] 
Furthermore, Grimshaw et al. applied the TPB to examine the relationship between 
beliefs and intention to change pharmacists’ behaviour relating to the treatment of 
vaginal candidiasis with non-prescription medicines.[112] 
 
The development and implementation of the JLT (Chapter 4 - JLT trial) is an example 
of a quality-enhanced service in pharmacy that involved reviewing client responses 
to a symptom-based questionnaire that facilitates identification and triage of 
symptoms that might indicate the respondent is at risk of potential serious pathology. 
This value adds to (enhances) the usual service that pharmacy staff undertake when 
managing symptomatic clients. To facilitate successful implementation of a quality-
enhanced service using instruments such as the JLT, it is essential to examine the 
factors that influence the intention to change usual practice to quality-enhanced 
service. 
 
This component of the thesis provides understanding of how perceived barriers, 
confidence, positive or negative evaluation of a behaviour, and social pressure might 
influence the intention of pharmacy staff to change practice around the management 
of clients presenting with bowel symptoms. This chapter presents a study examining 
the intention of pharmacy staff, both pharmacists and pharmacy assistants, to 
change practice and provide quality-enhanced service. The quality-enhanced service 
in this study refers to the service where symptom complexes indicating serious 
underlying bowel pathology are identified and clients referred for further medical 
investigations based on a screening tool such as the JLT.  
 
5.2. Aims and Objectives 
 
The aim of this study was to assess the factors that influence pharmacy staff 
(pharmacists and pharmacy assistants) in their decision to provide a quality-
enhanced service for bowel symptom management. 
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The specific objectives were to: 
 
 evaluate the domains (Attitude, PBC and Subjective Norm) of the TPB framework 
that influence the intention of pharmacy staff to change practice and 
 compare their intention to change practice before and after the JLT trial (Chapter 
4). 
 
5.3. Methods 
 
 Study Design 
 
A cross-sectional survey (administered both pre and post intervention) was used to 
predict the intention of pharmacy staff to change practice when managing clients 
presenting with bowel symptoms.  
 
 Study Participants 
 
The staff of pharmacies recruited for the JLT trial (Chapter 4) consented to this study 
when they provided written consent to the JLT trial (refer to Appendix 4.1 for the 
information sheet and consent form). The participants were invited to complete a 
questionnaire based on the TPB at the baseline of the JLT trial, as described in Chapter 
4. Construction of the questionnaire is described in Section 5.3.3. 
 
Pharmacy staff were invited to complete the questionnaire again as part of the post-
evaluation measures (Section 4.2.3.3), approximately 30 weeks following completion 
of the baseline questionnaire. All staff who completed the post-JLT-intervention TPB 
survey were aware of how their consultation was intended to change when using the 
JLT as a decision-aid tool. 
 
 TPB-Based Questionnaire 
 
Questionnaire construction followed recommendations by Francis et al.[1] specific to 
the TPB. Items were generated to assess all domains specified in the TPB, with 
reference to the literature, with a five-point response scale. Demographic questions 
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were added to record the respondent’s age, gender, education, employment status 
in the pharmacy and years of experience in pharmacy. Pharmacists responded to 
additional questions relating to the location of the pharmacy and clientele. The 
questionnaire was pilot tested by four pharmacy staff, two pharmacists and two 
pharmacy assistants to assess readability and comprehension. These participants 
were from one of the recruited pharmacies. They repeated the exercise with the 
other respondents in the actual survey. 
 
Quality-enhanced service was termed ‘cognitive service’ in the questionnaire, as this 
is more common in the professional literature. Cognitive service was defined as 
“professional services provided by pharmacists, who use their skills and knowledge 
to take an active role in patient health, through effective interaction with both 
patients and other health professionals.”[86] The definition was provided in the TPB 
questionnaire for the benefit of pharmacy assistants. The pharmacy clients were 
referred to as ‘customers’ in the questionnaire for relevance to pharmacy assistants 
 
5.3.3.1. Intention 
 
Two questions – the intention to provide cognitive services to clients with lower 
bowel symptoms at some time in the future, and intention to change usual/current 
practice in the future – were included in the Intention domain. The construct for this 
domain was taken from Francis et al.[1] Recommendations from Conner and Sparks 
were considered when wording the questions.[227] These questions were coded 
using a five-point Likert scale ranging from “Strongly Disagree” to “Strongly Agree”. 
Other studies have used similar Intention questions, with “over the next 10 weeks” 
for an adherence to exercise study[98] and “likelihood of visiting a GP in the next six 
months” in a follow-up study on colorectal cancer care,[228] instead of “in the 
future”, as used in this study on pharmacy staff. Both questions measuring the 
different end-points were treated as individual questions in the analysis. 
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5.3.3.2. Perceived Behavioural Control (PBC) 
 
PBC factors were measured using five items in the method of Francis et al.[1] Staff 
members completed questions related to their ease of communication, knowledge 
and confidence and perceived barriers and burden with regard to managing clients 
presenting with embarrassing bowel symptoms. Ease of engaging with the client was 
determined using two questions about providing privacy and ability to elicit symptom 
information for embarrassing symptoms, and were coded on a five-point Likert-type 
scale ranging from “Extremely Difficult” to “Extremely Easy”. The two questions 
about respondents’ confidence in recognising warning signs and making 
recommendations were coded on a five-point Likert scale ranging from “Strongly 
Disagree” to “Strongly Agree”. “Providing cognitive services to customers with lower 
bowel symptoms would be a burden on pharmacy staff” was included as the fifth PBC 
question, following the definition of cognitive service. This was coded on a five-point 
Likert scale ranging from “Strongly Disagree” to “Strongly Agree”.  
 
5.3.3.3. Subjective Norm  
 
The subjective norm construct was measured by three items reported by Francis et 
al.[1] This domain determined the level of the influence of the client, other 
pharmacies and the owner/manager of the participant’s pharmacy on his/her 
intention to change practice. All three questions were coded on a five-point Likert 
scale ranging from “Strongly Disagree” to “Strongly Agree”. The owner/manager was 
instructed to omit the question about the owner/manager’s influence.  
 
5.3.3.4. Attitude 
 
Four questions assessed the staff member’s attitude towards providing cognitive 
services and giving recommendations for bowel symptoms. This too was derived from 
Francis et al..[1] One statement – “Pharmacists providing recommendation to 
customers regarding their lower bowel symptoms is consistent with good 
professional practice” – measured attitudes towards providing appropriate 
recommendations. The other three items were attitudinal questions about providing 
cognitive services to clients with bowel symptoms: “enhancing customer service”, 
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“providing even higher level of care” and “ensuring appropriate care”.  The questions 
were coded on a five-point Likert scale ranging from “Strongly Disagree” to “Strongly 
Agree”. 
 
 Statistical Analysis 
 
Data were analysed using the SAS® version 9.2 statistical software (SAS Institute Inc, 
Cary, NC, USA, 2008).  
 
The negatively-worded question for PBC, “Providing cognitive services (please refer 
to the definition given above) to customers with bowel symptoms would be a burden 
on pharmacy staff” was reverse-coded so the lowest score represented “no burden”. 
Mean scores were calculated for each domain, as the mean and median for each 
domain were close. Scoring details are provided in Appendix 5.1, and followed the 
methods of Francis et al.[1] Cronbach’s alpha was calculated to assess the internal 
consistency of questions within each domain. A Cronbach’s alpha coefficient of 0.7 
or above was considered acceptable.[229, 230] The two questions for Intention were 
not tested for internal consistency, as they measured intention for two different 
variables namely the intention to change behaviour in future, and the intention to 
provide cognitive services in future. These intention questions were reclassified as 
binary variables (agree or strongly agree to the intention versus disagree or 
undecided) on account of the distribution of responses. 
 
For purposeful selection of variables for regression analysis, univariate analysis was 
firstly performed.[231] Chi-square analysis was then used to assess the association 
between each of the questions and intention to provide the cognitive service. Some 
questions in the PBC domain were treated individually, while others were grouped.  
For the pair of questions relating to the ease of engaging with a client with 
embarrassing symptoms, the Cronbach’s alpha was 0.576, indicating both questions 
should be retained individually for analysis. Questions 3 and 4 were grouped as 
PBC_Confidence for the analysis. Question 5 of the PBC domain, the perceived 
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barriers in providing cognitive services, was also treated as an individual question for 
this univariate analysis.  
 
For both the grouped and individual variables in all domains, the responses were 
treated numerically (1-5, with 5 representing “strong agreement”). Where a domain 
was represented by more than one question, the average of the relevant questions 
was calculated to represent the level of agreement with the domain. The scores for 
each domain were classified similarly to the intention questions, as 4 or more versus 
less than 4. In this way, a score of at least 4 showed that there was at least general 
agreement with the domain.  
 
Multivariate logistic regression was used to identify which of the domains were 
independently associated with intention. The logistic regression model was 
developed using backward elimination to identify independent variables contributing 
significantly to the prediction of intention. Backward elimination is preferable to 
obtain the best subset of retained independent variables.[232, 233] However, in this 
analysis, both backward elimination and forward stepwise inclusion of variables[232] 
would give similar results due to the absence of missing values. The pairwise 
interactions between final variables that remained in the model were checked for 
statistical significance. Following convention, a p-value <0.05 was taken to indicate a 
statistically-significant association in all tests. 
 
5.4. Results 
 
 TPB Questionnaire 
 
The pharmacy staff who took part in the pilot test suggested changes in the order 
and some wording of the questions. The final TPB questionnaire comprised 14 
questions and took approximately 10 minutes to complete (Appendix 5.2). 
 
96 
 
Table 5.1 presents the questions for each of the three domains of the TPB and the 
questions to assess the intention to change practice and provide cognitive services, 
along with Cronbach’s alpha coefficients to assess internal consistency.   
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Table 5.1: TPB Questions to Examine Intention to Change Practice and provide cognitive services among Pharmacy Staff 
Theory of Planned 
Behaviour Domains 
Questions Cronbach’s Alpha  
Intention 
1. In the future, I will provide cognitive services to customers with lower bowel symptoms 
2. In the future, I will change my usual/current practice for customers with lower bowel 
symptoms 
Likert scale ranging from “Strongly Disagree” to “Strongly Agree” 
N/A 
Attitude 
1. Pharmacists providing recommendation to customers regarding their lower bowel 
symptoms is consistent with good professional practice 
2. Providing cognitive services to customers with lower bowel symptoms will allow 
pharmacists to provide an even higher level of care to patients  
3. Providing cognitive services to customers with lower bowel symptoms will enhance 
customer satisfaction even more 
4. Providing cognitive services to customers with lower bowel symptoms will make it even 
more likely that pharmacists will ensure people with lower bowel symptoms get 
appropriate care 
Likert scale ranging from “Strongly Disagree” to “Strongly Agree” 
0.884 
Subjective Norm 
1. I would like to provide cognitive services to customers with lower bowel symptoms 
because customers expect it 
2. I would like to provide cognitive services to customers with lower bowel symptoms 
because other pharmacies are doing it 
3. I would like to provide cognitive services to customers with lower bowel symptoms 
because the pharmacy owner/manager expects me to do it 
Likert scale ranging from “Strongly Disagree” to “Strongly Agree” 
0.734 
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Perceived Behavioural 
Control 
Ease of engaging with customer presenting with embarrassing symptoms 
1. For me to take a customer to a private space to speak about his/her embarrassing 
symptoms is  
2. For me to obtain the reason for the patient’s visit to the pharmacy with embarrassing 
symptoms is generally -   
Likert-type scale ranging from “Very Difficult” to “Very Easy” 
0.576 
Confidence in recognising and making recommendations for bowel symptoms 
1. I am confident in making recommendations to customers regarding their lower bowel 
symptoms 
2. I am confident in recognising signs, symptoms and risk factors (warning signs) of bowel 
disease that may require consultation with the general practitioner (GP) 
Likert scale ranging from “Strongly Disagree” to “Strongly Agree” 
0.759 
Perceived barrier  
Providing cognitive services to customers with lower bowel symptoms would be a burden 
on pharmacy staff 
Likert scale ranging from “Strongly Disagree” to “Strongly Agree” 
N/A 
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 Statistical Analysis 
 
One hundred and ninety-three pharmacy staff from 21 participating pharmacies 
completed the TPB questionnaire at baseline (pre-TPB). Their average age was 29.1 
(SD 10.3) years, with 16.1% male and 83.9% female (Table 5.2).  
 
Table 5.2: Demographic Characteristics of the Pharmacy Staff   
 
 
 
The concept of ‘intention’ (Questions 13 and 14) represented the respondents’ level 
of agreement that they would provide cognitive services (Q13) and change practice 
(Q14) for customers with lower bowel symptoms in the future. Of the 193 
respondents, 11 did not give a response to these intention questions. Those who 
strongly agreed showed a clear intention to either provide cognitive services (Q13) 
or change practice (Q14) (Table 5.3). 
 
Demographic Characteristics 
 
Response  (N=193) 
Number % 
Gender 
Male 31     16.1 
Female 161   83.5 
Age (15-62) Mean (SD) years 29.1  
Education Level 
Less than Year 10 3        1.6 
Year 10 or equivalent 27      14.3 
Year 12 or equivalent 54      28.6 
Diploma or equivalent 11  5.7 
Tertiary education 94  49.7 
Employment Status in the 
Pharmacy 
Pharmacist 62  32.5 
Pre-registrant 7  3.6 
Pharmacy assistant 122  63.2 
Location of Pharmacy 
Medical centre 134  72.4 
≤25 shops shopping centre 23  12.4 
> 25 shops major shopping 
centre 
7  3.8 
City, suburban shopping 
strip 
18  9.7 
Other 3  1.6 
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Table 5.3: Intention to Provide Cognitive Services (Q13) and to Change Practice 
(Q14) (n=182) 
 
 
 
Univariate associations between the questions and the ‘intention’ questions (provide 
cognitive services and change practice), demonstrate a number of significant 
associations (Table 5.4). 
 
 
 
Response 
Intention to Provide 
Cognitive Service 
Number (%) 
Intention to Change 
Practice  
Number (%) 
Strongly Disagree 3 (1.6) 10 (5.6) 
Disagree 4 (2.1) 16 (8.9) 
Neutral 27 (14.0) 60 (33.5) 
Agree 69 (35.8) 56 (31.3) 
Strongly Agree 79 (40.9) 37 (20.7) 
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Table 5.4: Univariate Analysis using Perceived Behavioural Control, Subjective Norm and Attitude to Predict Intention to Provide Cognitive 
Services 
 
Variable Intention to provide 
cognitive services 
n/N (%) 
p-value Intention to change 
practice 
p-value 
PBC Q1 and Q2 
Q1 (For me to take a customer to a private 
space to speak about his/her embarrassing 
symptoms is) 
 0.0851  0.8446 
Extremely Difficult, Difficult or Neutral (1-3.9) 8/28 (28.6) 5/26 (19.2) 
Easy or Extremely Easy (4-5) 71/154 (46.1) 32/153 (20.9) 
Q2 (For me to obtain the reason for the 
patient’s visit to the pharmacy with 
embarrassing symptoms is generally) 
 0.0250  0.2021 
Extremely Difficult, Difficult or Neutral (1-3.9) 9/34 (26.5) 4/32 (12.5) 
Easy or Extremely Easy (4-5) 70/147 (47.6) 33/146 (22.6) 
PBC_Confidence (average Q3 and Q4)  0.0015  0.0555 
 1-3.9 34/102 (33.3) 15/97 (15.5) 
 4-5 45/79 (57.0) 22/81 (27.2) 
PBC Q5 (Providing cognitive services to 
customers with lower bowel symptoms 
would be a burden on pharmacy staff) 
 0.7811  0.7145 
Strongly Disagree, Disagree, Neutral (1-3.9) 73/167 (43.7) 34/167 (20.4) 
Agree or strongly agree (4-5) 6/15 (40.0) 3/12 (25.0) 
Subjective Norm (average Q6, Q7 and 
Q8) 
 <0.0001  0.0082 
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 1-3.9 40/120 (33.3) 18/110 (15.1) 
 4-5 39/60 (65.0) 19/59 (32.2) 
Attitude (average Q9 to Q12)  0.0006  0.0449 
 <4 0/15 (0.0) 0/15 (0) 
 4-5 72/158 (45.6) 33/155 (21.3) 
 Q3- I am confident in making recommendations to customers regarding their lower bowel symptoms 
 Q4- I am confident in recognising signs, symptoms and risk factors (warning signs) of bowel disease that may require consultation with the (GP) 
 Q6- I would like to provide cognitive services to customers with lower bowel symptoms because customers expect it 
 Q7- I would like to provide cognitive services to customers with lower bowel symptoms because other pharmacies are doing it 
 Q8- I would like to provide cognitive services to customers with lower bowel symptoms because the pharmacy owner/manager expects me to do it 
 Q9- Pharmacists providing recommendation to customers regarding their lower bowel symptoms is consistent with good professional practice 
 Q10- Providing cognitive services to customers with lower bowel symptoms will allow pharmacists to provide an even higher level of care to patients  
 Q11- Providing cognitive services to customers with lower bowel symptoms will enhance customer satisfaction even more 
Q12- Providing cognitive services to customers with lower bowel symptoms will make it even more likely that pharmacists will ensure people with lower bowel 
symptoms get appropriate care 
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Questions 1 and 2 in the TPB questionnaire about perceived barrier in consulting 
clients with embarrassing symptoms and providing cognitive services as perceived 
burden (Q5) did not influence the intention of the staff to provide cognitive services 
and change practice. Tables 5.5 and 5.6 show the results of logistic regression analysis 
for the outcome variables ‘the intention to provide cognitive services’ and ‘the 
intention to change practice’, respectively. The PBC questions about confidence in 
identifying and making recommendations of ‘red-flag’ symptoms (average of Q3 and 
Q4) and subjective norm were independently associated with the intention to change 
practice by providing quality-enhanced service when dealing with people with bowel 
symptoms. 
 
Table 5.5: Multivariate Logistic Regression for Intention to provide Cognitive 
Services  
 
Variable Odds Ratio 95% Confidence Interval p-value 
PBC_Confidence*    
 <4 1 (reference)   
 4-5 2.79 1.45 – 5.37 0.0022 
Subjective Norm    
 <4 1 (reference)   
 4-5 4.07 2.00 – 8.29 0.0001 
         * PBC_confidence: Average of Q3 and Q4  
          Q3- I am confident in making recommendations to customers regarding their lower bowel     
symptoms 
          Q4- I am confident in recognising signs, symptoms and risk factors (warning signs) of bowel 
disease that may require consultation with the (GP) 
 
Table 5.6: Multivariate Logistic Regression for Intention to Change Practice 
 
Variable Odds Ratio 95% Confidence Interval p-value 
PBC_Confidence*    
 <4 1 (reference)   
 4-5 2.15 1.01 – 4.57 0.0458 
Subjective Norm     
 <4 1 (reference)   
 4-5 2.40 1.32 – 6.02 0.0073 
         * PBC_confidence: Average of Q3 and Q4  
         Q3- I am confident in making recommendations to customers regarding their lower bowel   
symptoms 
                   Q4- I am confident in recognising signs, symptoms and risk factors (warning signs) of bowel 
disease that may require consultation with the (GP) 
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Demographic variables and the location of pharmacy were not significantly 
associated with intention to either provide quality-enhanced cognitive services or 
change practice. 
 
Forty-seven participants completed the post-intervention TPB questionnaire, 23 (10 
pharmacists and 13 pharmacy assistants) of whom had also completed the baseline 
questionnaire. This participation rate was not representative of the original cohort, 
limiting the pre/post analysis. The proportion of “Strongly Agree” (46.8%) and 
“Neutral” (21%) responses increased slightly in the post-intervention for the 
intention to provide cognitive services (Q13) when compared to pre-JLT-intervention 
data (Table 5.7). However, the pattern of responses for the intention to change 
practice (Q14) was almost similar to the pre-JLT-intervention response, where 
“strongly agree” was 23.4% and “neutral” 36.2%. 
 
Table 5.7: Responses of Participants at post-JLT (n=47) for Intention to Provide 
Cognitive Services (Q13) and to Change Practice (Q14)  
 
 
 
 
 
 
 
 
Response Intention to Change 
Practice Number (%) 
Intention to Change 
PracticeNumber (%) 
Strongly disagree 1 (2.1) 0 
Disagree 2 (4.3) 6 (12.8) 
Neutral 10 (21.3) 17 (36.2) 
Agree 12 (25.5) 13 (27.7) 
Strongly agree 22 (46.8) 11 (23.4) 
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Table 5.8: Intention of Participants Who Completed Baseline and Post-TPB Survey     
(n=23) 
 
Intention Pre (% agree + strongly 
agree) 
Post (% agree + strongly 
agree) 
Q13 (In the future, I will 
provide cognitive services to 
customers with lower bowel 
symptoms) 
91.3% 74% 
Q14 (the future, I will change 
my usual/current practice for 
customers with lower bowel 
symptoms) 
43.4% 56.5% 
 
Cross-tabulation of response of the 23 participants showed that six respondents who 
had agreed to provide cognitive services (Q13) in the baseline survey, changed to 
either neutral (unsure) or disagreed to provide cognitive services in the post-JLT-
intervention TPB questionnaire, while two of them agreed to provide the service in 
the post survey when they were unsure in the baseline survey. The rest remained the 
same, agreeing to provide cognitive services in pre and post measures. Four of the 
respondents who were unsure or had disagreed to change practice (Q14) in the 
baseline survey agreed to change practice in the future during the post-JLT survey. 
Five respondents remained neutral in both baseline and post-JLT survey, and the rest 
of the respondents agreed to change practice in both baseline and post-intervention 
measures. 
  
While 10 respondents were confident in making recommendations (Q3) for clients 
with at-risk symptoms both in pre and post JLT-intervention survey, seven who were 
not confident in making recommendations in the pre-JLT intervention survey 
reported that they were confident in making recommendations in the post-JLT-
intervention survey. Five respondents remained neutral while just one reported 
he/she was not confident in making recommendations in the baseline and post 
survey. Nine pharmacy participants who were not confident in recognising ‘warning’ 
signs (Q4) in the baseline TPB survey reported that they were confident in recognising 
these signs in the post-JLT-intervention survey. One participant who was neutral in 
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the baseline reported that he/she was not confident in recognising the ‘red flag’ signs 
for bowel disease in the post survey.  
 
Seven participants of the 23 participants who completed both baseline and post-JLT-
intervention survey, did not think that they would provide cognitive service if the 
client preferred it (Q6). This was different from their baseline TPB survey where they 
had agreed to provide cognitive services because the “customers wanted it”. Other 
subjective norm questions about perceived social pressure: ‘because other 
pharmacies were providing it’ (Q7) and ‘because the owners of the pharmacies 
wanted it’ (Q8), was very similar to the baseline survey. 
 
Attitudinal rate towards providing cognitive services and changing practice among 
the respondents, was high in the post-JLT-intervention survey as was in the baseline 
survey. 
 
5.5. Discussion 
 
This study provides an understanding of how perceived barriers, confidence, attitude 
and social pressure influence the intention of pharmacy staff to provide quality-
enhanced services (cognitive services) and have potential to change their usual 
management of clients presenting with bowel symptoms. 
 
The Cronbach’s alpha coefficient provided an understanding of all possible 
combination of items within each domain. For the pair of questions relating to the 
ease of engaging with a client with embarrassing symptoms, the Cronbach’s alpha 
was 0.576, indicating both questions should be retained individually for analysis. 
Although ‘embarrassing symptoms’ was the common factor in both the questions, 
each measured a different parameter: ease of taking the client to a ‘private space’ 
and ease of ‘obtaining the reason of visit’. 
 
The PBC questions assessing the confidence of the respondents (Q3 and Q4) that 
measured the perceived self-efficacy of the respondents in identifying ‘red-flag’ 
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symptoms and making recommendations (p=0.002), and subjective norm (Q6 to Q8) 
about the perceived social pressures (p=0.002), were both independently associated 
with intention to provide cognitive services. Similarly, the PBC confidence, Q3 and Q4 
(p=0.046) and subjective norm (p=0.022) showed independent association with 
intention to change practice.  These findings are discussed below. 
 
PBC, particularly the self-efficacy questions about respondents’ confidence in 
recognising high-risk symptoms and making recommendations, had a significant 
influence on their intention to provide cognitive services. Even if their attitude 
towards delivering a service that is beneficial to the client was positive, lack of 
confidence might have a negative impact on their intention to perform it.[108] 
Greater self-efficacy will most likely lead to increased intention to deliver a cognitive 
service.[87, 108, 234] A questionnaire such as the JLT[213] that would assist in 
identification of ‘red-flag’ symptoms of the pharmacy client has potential to increase 
the confidence of the pharmacy staff. The post-JLT-intervention survey indicates an 
increase in confidence in the participants who completed both baseline and post-JLT-
intervention survey.  
 
Perceived burden of providing quality-enhanced services and the set-up of the 
pharmacy to facilitate private consultation with the client were not a significant 
influencing factor on the intention. This was reflected in the feedback from the 
pharmacy staff during the post-evaluation phase of the JLT trial (Chapter 4, Section 
4.2.3.3), where they reported that JLT deployment was not a burden and they would 
accept a JLT-like questionnaire for screening of urinary tract infections, asthma, 
vaginal candidiasis, cough, chronic pain, kidney problems, headaches, and upper 
gastro-intestinal symptoms. 
 
Similar to other studies that examined intention of pharmacy staff,[87, 235, 236] 
subjective norm emerged as the major influence on intention to provide quality-
enhanced service and change practice. Most of the pharmacy staff appeared to be 
willing to change practice and provide quality-enhanced services if clients (Q6 in the 
TPB questionnaire) preferred it or if other pharmacies were providing it (Q7 in the 
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TPB questionnaire). Pharmacists may feel more pressure to perform a behaviour that 
is beneficial to their clients and satisfy regulatory pressure.[237] Persuasion of peers 
can accelerate the diffusion of the service.[238, 239] In the present study, adoption 
and implementation of JLT may be influenced by the opinions of others within their 
professional network. Once a service, in this case the deployment of JLT for screening 
of bowel disease, is adopted by some individuals, it becomes increasingly likely that 
other members of that social/professional network will also adopt it.[240] Preference 
of the owner (Q8 in the TPB questionnaire) of the pharmacy also played a significant 
role in the intention of the staff. This again is reflected in this thesis where the owner 
of the pharmacy was the driving force in the deployment of JLT for screening clients 
presenting with bowel symptoms.  In the post-JLT-intervention TPB survey, the 
results showed trends similar to the baseline survey with regards to peer pressure 
and owner’s preference.  
 
The high attitudinal rating of pharmacy staff about outcomes when providing 
cognitive services suggests an appreciation of staff of the benefits of this type of 
practice. Although the attitudinal questions were associated with intention in the 
univariate analyses, they were not included in the multivariate analysis due to the 
generally positive responses. This high attitudinal rating is consistent with a 
pharmacy-based TPB study in the US by Farris and Schopflocher on community 
pharmacists’ assessment of pharmaceutical care[108] and the Herbert et al. study in 
Canada on pharmacists’ intention to provide medication therapy management 
service for Medicare beneficiaries.[241] Farris and Schopflocher acknowledged the 
small sample size and potential self-reported bias in their survey, while Herbert et al. 
considered possible sampling bias. Behavioural decision-making models such as the 
Theory of Reasoned Action and TPB mostly rely on self-report.[101] While Gavaza 
et.al. reported considerable variation between self-reported behaviour and actual 
behaviour,[242] Armitage and Connor[243] showed few effects of social-desirability 
when self-reporting the TPB components. Future studies aimed at measuring the 
actual behaviour and validating the attitude[244] should be conducted. In the present 
study, the high attitudinal rate was reflected in the JLT-intervention study (Chapter 
4) with increase in the referral rate and a greater proportion of clients accepting the 
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pharmacist’s referral and consulting a GP, when the pharmacy staff based their 
consultation of bowel symptomatic client on the client’s response to the JLT.    
  
At the pre-JLT-intervention survey (n=193), pharmacy staff were generally positive 
about their intention to provide quality-enhanced service and to change practice. The 
post-JLT-intervention survey response from the participants who completed both 
baseline and post survey (n=23) indicated a decrease in the percentage of positive 
response for providing cognitive services in the future. Although the respondents did 
not think that providing cognitive services was a burden (Q5) in the baseline TPB 
survey (n=193), the recruitment for JLT intervention (Chapter 4, Section 4.2.4) and 
adherence to study protocol (Chapter 4) was considered as an issue. This could have 
been due to the paperwork involved for ethical purposes: consent form, information 
sheet, and for research purposes: the notes page. The responses of pharmacy staff 
to the post-JLT-intervention TPB survey could have been largely influenced by the 
study protocol they had to follow when recruiting clients for the JLT trial (Chapter 4), 
which they thought was cumbersome. Nevertheless, the 23 respondents were more 
positive about changing practice, which was reflected in the pharmacy evaluation 
study of the JLT (Chapter 4, Section 4.2.3.3), where the pharmacy staff reported that 
using the JLT when consulting with clients with bowel symptoms established a 
“consistent practice”. 
 
The two ‘intention’ questions measured intention for two different variables namely 
the intention to change behaviour in future, and the intention to provide cognitive 
services in the future. Recommendations by Conner and Sparks[227] for developing 
multiple intention measures, was considered when wording the questions. The word 
intend which was the term recommended by Francis et al.[1] was replaced by “in the 
future, I will”.  
 
The demographic characteristics and the location of the pharmacy did not 
significantly influence future intention to change practice or provide quality-
enhanced services. This was in line with a study conducted by Herbert et al.[241] on 
predicting intention of pharmacy staff to provide medication therapy management 
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service for Medicare beneficiaries. The study reported that the location of pharmacy 
and education level were not significant predictors for intention to provide service. 
Past experience was reported as significantly influencing the attitude, subjective 
norm and PBC. In the present study, the participants were not asked about their past 
experience in providing cognitive services. 
 
  Limitations 
 
The results of this study should be interpreted with caution for the following reasons: 
behavioural intention measures were self-reported. Behavioural decision-making 
models such as the TPB often rely on self-report.[101] As discussed above, evidence 
suggests that individuals may provide socially-desirable answers in terms of attitude 
and intention.[101] Additional research to further validate the observed behavioural 
change is required.  
 
The post-JLT-intervention survey of respondents’ intention to provide cognitive 
services and change practice was conducted to examine the change in intention and 
the influencing factors of their intention from the pre-JLT-intervention responses. 
The other purpose was to examine the longer-term behavioural change, beyond the 
study period. The response rate for the post-intervention survey was lower than 
expected, and limited the comparison of pre- and post- responses. This low response 
rate could have been due to change in pharmacy staff over the period of the study, 
research fatigue, and/or staff not using the JLT during the intervention declining to 
complete the post-intervention survey, despite the researcher’s encouragement. 
Providing incentives could improve the participation rate and motivate participants 
to sustain interest throughout the study.[245]  
 
5.6. Conclusion 
 
This study examined if the constructs of the TPB influenced the intention of pharmacy 
staff to provide quality-enhanced (cognitive) services and change from their practice. 
The pre-JLT-intervention survey results suggest the pharmacy staff had a positive 
attitude towards providing cognitive service. Lack of confidence in making a clinical 
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assessment was considered a barrier in providing cognitive services, whereas greater 
adoption of the enhanced cognitive services by other pharmacists and the client’s 
preference were perceived as driving adoption of these services. 
 
This is valuable information for efficient implementation of interventions in 
community pharmacies. Screening tools such as the JLT, when used in pharmacies, 
are intended to facilitate identification of complex symptoms that could be 
associated with serious underlying pathology. This may increase the confidence of 
pharmacy staff to provide screening services in their pharmacies. As established in 
previous chapters, early intervention for identification and triage of clients who might 
benefit from further medical investigation should enable treatment to be initiated at 
an earlier stage, thus improving prognosis. 
 
Adherence to change in practice may be hindered by economic reasons. Lack of 
reimbursement for clinical services is one of the most common reasons cited by 
pharmacists regarding their failure to provide cognitive services.[38-41] A study to 
determine the monetary value for a quality-enhanced service, where pharmacy staff 
use a questionnaire such as the JLT to identify and triage clients who might be at risk 
of a serious underlying condition, was proposed, keeping the prospects of 
implementation of JLT in mind. The next chapter (Chapter 6) describes the WTP study 
conducted for a quality-enhanced service in community pharmacy. 
112 
 
6. Willingness to Pay for a Quality-Enhanced Service in 
Community pharmacies 
 
6.1. Introduction 
 
It is evident from the review of published literature (Chapter 2) that community 
pharmacies are important providers of client-centred, value-added healthcare 
services, which present pharmacists with opportunities to identify and address 
health-related issues and offer support and/or referral to symptomatic clients who 
have not sought medical advice. A number of studies have reported positive impact 
from the collaboration of pharmacists and GPs in patient management.[23, 31, 83-
85] 
 
Economic viability through public and private funding would be key in the long-term 
sustainability of cognitive services in the pharmacies, especially in a budget-
constrained health system.[114] Chapter 2 presented evidence that studies 
attempting to investigate WTP in Australian pharmacies, showed clients were willing 
to pay for quality-enhanced services offered in pharmacies. WTP is defined as the 
(maximum) sum of money an individual is willing to contribute for a specified health 
gain.[246]  
 
This chapter outlines a WTP study for a quality-enhanced service such as the JLT 
(described in Chapters 3 and 4), whereby pharmacists offer advice and, if warranted, 
provide written referral to the GP, following consideration of a client’s responses to 
a self-administered questionnaire about the presenting symptom(s).  
 
The WTP study is presented in Section 6.2 of this chapter as a published Research 
Brief, reproduced with the publisher’s permission (Appendix 6.1):  
 
Sriram D, McManus A, Emmerton L, Jiwa M. Will Australians pay for health care 
advice from a community pharmacist? A video vignette study. Research in Social and 
Administrative Pharmacy 2015; 11(4): 579-83. 
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No changes have been made to the content of the published paper, including tense. 
The formatting and numbering of the headings, tables and reference have been 
changed to sync with the thesis requirements. The authors acknowledge statistical 
advice from Dr Richard Parsons, School of Pharmacy, Curtin University. There was no 
competing interest declared by the authors.  
 
6.2. Willingness to Pay  
 
 Introduction 
 
People living in Australia who are concerned about symptoms are able to consult a 
community pharmacist without making an appointment and at no charge. 
Alternatively, if they choose to consult a general practitioner (GP), they may also do 
so without incurring a fee-for-service at some practices in Australia.[247] However, 
in the 2014 federal budget, the Australian Government proposes to introduce a AUD7 
co-payment levy for GP consultations.[248] Experts are concerned that: 
 
Vulnerable groups, including children, Indigenous people, older people and the 
financially disadvantaged, may delay seeking treatment for serious illness — or even 
serious worry — with consequent health compromise.[248] 
 
While consumer co-payments introduced in other countries have demonstrated 
minimal impact on consumer behaviour,[248] the impact of similar charges in the 
Australian healthcare system is unclear. Furthermore, it is possible that payment to 
other healthcare providers could also come under consideration.[249] This raises an 
interesting question about consumers’ perceived value of health-related 
consultations. In the case of community pharmacists, the first hypothesis was that 
most people would continue to expect consultation at no cost. However, the 
researchers wished to explore willingness to pay (WTP) for an advanced model of 
pharmacy consultation that would better determine the need for, and coordinate 
with, GP consultation. The second hypothesis, therefore, was that Australians are 
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more willing to pay for a service that includes systematic assessment of symptoms 
and formal referral to a medical practitioner if necessary. 
 
The aim of this study was to deploy a survey-based method to determine monetary 
valuations of a standard pharmacy consultation versus quality-enhanced service 
(QES). Few studies that have attempted to investigate WTP show that 13-57% of 
people are willing to pay for services in pharmacies, depending on the type of 
pharmacy service provided.[250] 
 
 Methods 
 
The project was approved by the Curtin University Human Research Ethics 
Committee (HR19_2013). The researchers selected assessment of bowel symptoms 
as the basis to test the hypotheses, following evidence that pharmacies are well 
utilised for purchase of medicines for diarrhoea, constipation and rectal bleeding.[21] 
A recently-published decision-aid tool to manage customers presenting with bowel 
symptoms to a community pharmacy [213] was the inspiration for the QES. 
 
6.2.2.1. Vignettes 
 
A video-vignette based Willingness to pay (WTP) survey was adopted. Vignettes are 
often used to elicit information about values, beliefs and perceived societal norms 
from participants. The use of video clips to deliver information to research 
participants makes vignettes more realistic, helps to engage the interest of research 
participants, and makes any variations in the vignettes more obvious.[251]  A major 
advantage of this methodology is allowing comparison of different respondents’ 
behaviour over the same set of scenarios and estimating the independent effects of 
specific information on a person’s judgements.[13] 
 
The two video vignettes depicted a pharmacy customer supposedly with lower bowel 
symptoms being consulted by the pharmacists  
 
115 
 
1. Video 1: standard (current) practice, using verbal approach to get symptom 
information and for giving advice/referral; duration 50 seconds (Appendix 
6.3) 
2.  Video 2: quality-enhanced service (QES), depicting greater privacy, 
systematic assessment of symptoms based on the decision-aid tool, and 
referral to a GP if necessary; duration 75 seconds. (Appendix 6.5) 
 
The script for each video is included in Appendix 6.2 and 6.4. Adult English-speaking 
consumers whose age and gender profile closely matched recent census data were 
recruited for this study from across WA[252] using the services of Qualtrics, an online 
survey organisation. Participants viewed both videos online, and then completed a 
brief WTP questionnaire online. Consent form for participants is attached as 
Appendix 6.6.  
 
6.2.2.2. WTP Questionnaire 
 
The Contingent Valuation Method (CVM), which is a survey-based, hypothetical, 
direct method to determine monetary valuations of effects of health technologies or 
interventions, was applied.[253] WTP elicited by the Contingent Valuation Method 
directly refers to the expense or cost that equals the valuation of the presented 
health outcome.[254] The WTP questionnaire comprised questions about the 
participants’ understanding of the scenarios depicted in the two video vignettes, their 
perception of the service provided in each video, and their WTP for each service, 
including the sum they would consider paying for the QES depicted in Video 2. (Figure 
6.1) Content and face validity were confirmed by a panel comprising a general 
practitioner, a community pharmacy researcher and a public health practitioner 
(authors MJ, LE and AM), and then by pilot testing with 10 volunteers. Refinements 
to the questionnaire were made following each validation phase. Self-reported 
demographic data were age, gender, marital status, education level, employment 
status, annual household income, and postcode of residency.  
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1. Did you notice a difference in the way the man was dealt with in Video 1 compared 
to Video 2?  
2. Which consultation do you think was longer?  
3. In which video was the man offered more privacy? 
4. Assuming that the man had the same problem in both the videos, which 
consultation do you think was more helpful in providing advice? 
5. If you were the man in the video, which type of service/consultation would you 
prefer? 
6. If you were the man in Video 1, would you be willing to pay for the service you 
received in the pharmacy? If yes, how much would you be willing to pay? 
7. If you were the man in Video 2, would you be willing to pay for the service you 
received in the pharmacy?  If yes, how much would you be willing to pay?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Willingness to Pay Survey 
 
6.2.2.3. Data Analysis 
 
A sample size of approximately n=110 is adequate for regression analysis to detect 
an independent variable exhibiting an effect size of r=0.3-0.5.[255, 256] Descriptive 
statistics were used to report the study sample and identify the proportion of the 
consumers who were willing to pay. Logistic regression was used to explore the 
influence of demographic data on their responses. For all statistical testing, a 
significance level of p<0.05 was adopted. Analyses were conducted using SPSS® V22. 
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 Results 
 
The target number of 175 participants completed the WTP survey. The WTP 
questionnaire is attached as Appendix 6.7. The sample was representative of the WA 
population regarding their age and gender profile. 
 
Seventy-nine percent of participants (n=139) perceived a difference in the service 
offered in the two videos, and 82% (n=144) acknowledged that the consultation 
length in Video 2 was longer than Video 1. Forty-one percent of participants (n=72) 
were not willing to pay for either service. Twenty-eight percent (n=49) of participants 
were willing to pay for the QES (Table 6.2), indicating a median payment of AUD15 
(range $1-$75). In comparison, 11% (n=19) of participants were willing to pay for the 
standard service, indicating a median payment of AUD10 (range $1-$50). Eighty-two 
percent of the people who were willing to pay (n=40) preferred the 
service/consultation depicted in Video 2 (QES) and 88% of the participants thought 
that the consultation offered in video-2 (QES) was more helpful in providing advice. 
 
Education status was the only demographic variable that significantly influenced a 
positive attitude to WTP for the QES. Holders of a trade certificate or diploma were 
less willing to pay compared to the high school education level or tertiary education 
level (odds ratio 0.265). 
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Table 6.1:  Demographic Characteristics of Willingness to Pay Survey participants  
                    (N=175) 
 
Demographic variable 
Frequency 
(n) 
Percent 
(%) 
Gender 
Male 84 48.0 
Female 
Total 
91 
175 
52.0 
100 
Employment status 
Unemployed 33 18.9 
Employed full time 56 32.0 
Employed part time 29 16.6 
Student 10 5.7 
Pensioner 
Other 
Total 
32 
15 
175 
18.3 
8.6 
100 
Education level 
Year 12 and less 72 41.1 
Trade certificate/ TAFE/ diploma 
Tertiary 
Total 
54 
49 
175 
30.9 
28 
100 
Age Range (years) 
18-29 31 17.7 
30-59 99 56.6 
60+ 
Total 
44 
175 
25.1 
100 
Annual Income (AUD) 
Less than $40,000 
36 20.6 
$41,000-$80,000 60 34.3 
$81,000 - $120,000 30 17.1 
$120,000 -$160,000 20 11.4 
More than $1,60,000 8 4.6 
I prefer not to answer this question 21 12.0 
Total 
Marital Status 
Single 
175 
 
36 
100 
 
20.6 
Married 108 61.7 
Separated 5 2.9 
Divorced 14 8.0 
Widowed 4 2.3 
Never Married 8 4.6 
Total 175 100.0 
 
In the regression analysis, the 19 participants who were willing to pay for the 
standard service were excluded, as the majority of these indicated they were also 
willing to pay for the QES. Of particular interest was the profile of the participants 
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who were not willing to pay for the standard service and were willing to pay for QES 
or were unsure about paying for QES (n=58, i.e. 9+24+25), compared with those who 
were not willing to pay for the QES (n=79). Binary logistic regression revealed no 
significant association between the socio-demographic variables and a change in the 
decision towards a positive response for the QES model. 
 
Table 6.2: Willingness to Pay for the Standard Service Vs the Quality-Enhanced    
service  
 
 Video 2 (Quality-Enhanced Service): 
Willing to pay? Total 
Yes No Not sure 
Video 1 (Standard 
Service): Willing to 
pay? 
Yes 
Count 16 2 1 19 
% of 
Total 
9.1% 1.1% 0.6% 10.9% 
No 
Count 
24 72 25 121 
% of 
Total 
13.7% 41.1% 14.3% 69.1% 
Not 
Sure 
Count 
9 5 21 35 
% of 
Total 
5.1% 2.9% 12.0% 20.0% 
Total 
Count 
49 79 47 175 
% of 
Total 
28.0% 45.1% 26.9% 100.0% 
 
McNemar Test p<0.001 
 
 Discussion 
 
These data offer some support for the primary hypothesis, insofar as most (121/175, 
69%) of this representative sample of Western Australians were not willing to pay for 
the standard service. There was also some support for the second hypothesis, as 
almost one-third (49/175, 28%) indicated WTP for a QES. An equally large proportion 
was ambivalent about their WTP for the QES (47/175, 27%). This is consistent with 
previous reports from pharmacies about the services for which consumers are willing 
to pay.[21, 116] 
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An unexpected finding was that income was not a significant factor in determining a 
person’s WTP. This may reflect economic circumstances in WA, where tradespeople 
have comparatively high incomes.[257] Interestingly, the participants were also 
willing to pay more than the proposed AUD7 GP co-payment. It is hypothesised that 
this may be related to the convenience of attending a community pharmacy, where 
there is no need to make an appointment. Therefore, it is speculated that WTP may 
reflect the value placed on convenience as much as on the perceived expertise of the 
community pharmacist. 
 
The key limitation to the study is the measurement of WTP, an inherently subjective 
concept. Experience of the service, face-to-face, by a consumer experiencing 
symptoms of concern, may elicit a perceived value of the service that differs from 
that indicated in a theoretical exercise.[116] Despite this, theoretical WTP studies are 
a cornerstone of exploratory research in the development of new services or 
products, and the findings suggest significant consumer acceptance of a user-pays 
pharmacist-led service in triage of symptoms. A prospective study of the feasibility 
and clinical value of the QES described in this paper is underway. Further research is 
warranted to develop suitable decision support tools that could support a QES for the 
majority of customers who might seek health advice at a community pharmacy. 
 
 Conclusion 
 
The majority of Western Australians may be willing to pay for a consultation service 
at a community pharmacy that offers enhanced privacy and a time-intensive 
experience, with documented GP referral where required.  
 
 Additional Limitations from the WTP Study 
 
The participants who completed the survey were representative of the English-
speaking Western Australian population in terms of age and gender. Other 
demographic characteristics such as the educational status or socio-economic status, 
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were not taken into account during recruitment. This could limit generalisability of 
the results.  
The same male actor was used in two scenarios used to measure respondent 
reactions (due to funding constraints). This was not considered an issue, as the 
scenarios focussed on showcasing different pharmacy services rather than gender or 
age of the client. Results should therefore be read with caution as it is possible an 
observer effect could have influenced respondent views.  
Based on the limitation of sample size and unknown characteristics of the subjective 
nature of the WTP study, further research should be conducted to confirm the 
findings 
 
 Updates to the published article 
 
At the time of writing the article, the Australian government’s proposal of the co-
payment towards GP consultation levy was being considered however, it has been 
abolished due to changes in federal policy. The results reported in this study about 
the WTP by Australian public for quality-enhanced service, are not affected by this 
decision. 
 
The next chapter discusses the results of the literature review and the key findings 
reported in Chapters 3-6, and how they address the research questions. 
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7. Discussion 
 
7.1. Overview 
 
This chapter draws together the extant literature and key findings reported in 
Chapters 3-6. This body of research was conducted with the intention of early 
detection of bowel disease in community pharmacies. A comprehensive literature 
search reported in Chapter 2 set the stage for the thesis, with evidence supporting a 
need for early detection of bowel disease.  
 
Chapter 3 described the development and validation of a screening tool (the JLT) that 
would facilitate the easy identification and triage of pharmacy clients who might be 
at risk of bowel disease. Building on the results and conclusion of the Development 
and Validation of JLT reported in Chapter 3, a prospective observational study 
(Chapter 4) was conducted to examine the feasibility and effectiveness of the JLT as 
a guide to pharmacy staff to identify clients with bowel symptoms warranting referral 
to a GP. Data were collected concerning the ‘usual practice’ of pharmacy staff when 
consulting clients presenting with bowel symptoms. The JLT was then introduced to 
guide the consultation of clients with bowel symptoms after the UP phase. Data 
regarding advice and management of clients based on their response to the JLT 
questions were collected in this ‘intervention phase’. The value of the JLT was 
assessed between the two phases of the study by comparing the referrals to, and 
subsequent consultation with GP, recommendations made by the GPs, and 
evaluation of the JLT by the pharmacy staff. 
 
Chapter 5 provided an insight into how perceived barriers, confidence, attitude and 
social pressure influence the intention of pharmacy staff to provide quality-enhanced 
service (cognitive services) and have potential to change their usual management of 
clients presenting with bowel symptoms. This study explored the factors that might 
influence the intention of pharmacy staff to provide a service using a screening tool 
such as the JLT as a guide to the consultation with their pharmacy clients. The 
questionnaire developed to be completed by the pharmacy staff was based on the 
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TPB. According to the TPB, intention, which is determined by attitude, perceived 
social pressure, perceived barrier and self-efficacy, is the direct determinant of the 
behaviour.[95] Intention reflects the level of motivation of the person to perform the 
behaviour. Attitude is the degree of evaluation of the behaviour: perceived 
advantages or disadvantages in performing the behavior while the subjective norm, 
is the perceived social pressure to perform the behaviour and PBC is the perceived 
barriers, level of ease and confidence in performing the behaviour.[95] Data were 
collected from the pharmacy staff who participated in the JLT trial described in 
Chapter 4. This study helped determine the factors that influenced the intention of 
the pharmacy staff to provide quality-enhanced service for clients presenting with 
bowel symptoms.  
 
 Chapter 6 was a study of the WTP for a quality-enhanced service in community 
pharmacy. This study was conducted to determine monetary valuations of a standard 
pharmacy consultation versus quality-enhanced service where the pharmacists offer 
advice and written referral to the GP, with reference to response to a self-
administered questionnaire completed by the client regarding the presenting 
symptom. This study used video vignettes to demonstrate these two services to the 
participants. The two video vignettes depicted a pharmacy customer being consulted 
by the pharmacists using standard practice and quality-enhanced service. Members 
of the public recruited for this study viewed both videos online, and then completed 
a brief WTP questionnaire online.  
 
7.2. Discussion based on Research Questions  
 
Nine research questions formed the basis of the thesis. Reflections on these research 
questions are presented below. 
 
1: Could community pharmacy help to identify clients who might be at high risk of 
bowel disease? 
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The literature review (Chapter 2) provided evidence around the initial research 
questions that community pharmacy could be an ideal primary care setting for testing 
interventions for early detection of bowel disease and triage of high-risk clients to 
appropriate care. 
 
Pharmacies have become the most accessible points of contact for individuals within 
the Australian healthcare system due to their wide distribution in urban, regional and 
rural areas. They are well placed to play a constructive and dynamic support role in 
the provision of effective primary health care.[55] The primary health care reform 
aims at creating a more integrated primary health care system, ensuring that 
consumers receive high quality and equitable care.[48] This increases the opportunity 
for community pharmacies to play an increased role in achieving this.  
 
Certain common bowel symptom profiles significantly raise the probability of serious 
underlying conditions such as cancer, colitis, or large adenomatous polyps. Research 
has established many patients with colorectal disease present late with such 
symptoms, yet the public identifies pharmacies as good source of advice for their 
bowel symptoms.[3, 10-12]   
 
2: Do pharmacy staff know which clients should be encouraged to consult their GP 
based on symptoms? 
 
Pharmacists are accountable for the advice and service provided in their 
pharmacies.[19] Pharmacists have become increasingly involved in client-orientated 
services including development of client profiling, monitoring and counselling.[61, 
77] The pharmacist in  charge of the pharmacy business is responsible for ensuring 
pharmacy assistants work within their levels of skill and knowledge .[78] 
Pharmacy assistants can provide general product knowledge and advice to clients but 
must refer clients with symptoms, medical conditions or queries about the 
medications to the pharmacist.[66]  
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Despite pharmacists being well placed to help identify symptomatic clients 
presenting to community pharmacies who would benefit for consultation with a 
medical practitioner, in a survey of pharmacists in Australia, it was demonstrated that 
bowel symptoms indicative of serious disease were not recognised in a significant 
proportion of cases.[13, 24]  One of the major challenges that pharmacists face in 
discussing client symptoms that could be considered personal and/or embarrassing, 
is being able to obtain an accurate history and symptom details from their clients 
within a ‘traditional’ pharmacy setting.[25] Evidence supported the need for an 
effective and evidence-based screening tool to support pharmacy staff to triage cases 
that warrant further investigation for colorectal pathology. 
 
3: What are the available screening and triage tools for bowel symptoms? 
 
A number of studies reported the development and use of bowel symptom 
questionnaires, such as the Rome III Diagnostic Questionnaire for Functional Gastro-
Intestinal Disorders,[144] Bowel Symptom Questionnaire to identify patients with 
functional gastrointestinal disease, IBS and functional dyspepsia developed by Talley 
et al.[187, 188], bowel symptom questionnaire developed during the CRISP study,[29, 
161] and a risk-prediction algorithm developed by Hippisley-Cox and Coupland.[162] 
There were few that reported the development of questionnaires with high 
sensitivity to CRC and testing for use by a GP or a colorectal specialist; examples are 
the PCQ and the CRISP study.[187, 192, 195] Jiwa and his colleagues studied the 
feasibility of using PCQ for screening pharmacy clients[21, 23] which is also reported 
in a recent systematic review by Lindsey et al.[258] There were no reported studies 
that developed bowel symptom questionnaires with high sensitivity for bowel 
disease for use in a community pharmacy setting. The literature suggested the need 
to develop a simple, valid screening tool that could be used within the pharmacy 
setting as part of the continuity of care health care model. 
 
4: Could a simple, easy-to-use, self-administered questionnaire (the JLT) be 
developed to identify pharmacy clients who might be at risk of bowel disease? 
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Based on the evidence presented in Chapter 2, there was a need for a screening tool 
for use in a pharmacy for management of clients presenting with bowel symptoms, 
with the following characteristics: 
 
 Self-administration, to reduce the workload of pharmacy staff in gathering 
appropriate information for effective management of symptoms 
 Facilitation of accurate information gathering, especially when the client is 
embarrassed to discuss his/her symptoms 
 High sensitivity for bowel disease  
 Facilitation of decision making without a need for computerised scoring 
calculations 
 Ability to present ‘an assessment’ to the client at the time of consultation 
 Easy and efficient identification of clients requiring further medical 
assessment 
 Effective referral of identified clients to appropriate medical care. 
 
Chapter 3 reported the development of a self-administered, decision-aid screening 
tool for use in the community pharmacies was developed to help pharmacists and 
pharmacy assistants identify clients presenting with bowel symptoms who should be 
referred to a GP. The questionnaire, named the JLT to acknowledge the foundation 
sponsoring this research, the Jodi Lee Foundation, was developed to be simple and 
requiring no score calculation, and to assist identification and referral process. The 
final questionnaire comprised eight questions and was developed to be easily 
assimilated into everyday practice without adding burden with regard to time and 
process.  
 
5: Could the JLT be a valid tool in identifying clients at risk of bowel disease in a 
pharmacy and be encouraged to consult a GP?  
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Statistical validation of the JLT was undertaken against a validated screening tool, the 
PCQ to assess its sensitivity and specificity. The large area under the curve of 0.94 
indicates the favourable overall performance of the JLT to identify patients at risk of 
bowel pathology.  
 
Few studies[25, 192] have reported symptom history taking and getting symptom 
details especially when clients are embarrassed to talk about their symptoms, as one 
of the major barriers the pharmacy staff face during a consultation. A triage tool such 
as the JLT would facilitate easy and accurate information gathering about the 
presenting symptoms and history taking. This would alert the pharmacists to ‘red flag 
symptoms’ which would benefit from further medical consultation. 
 
The advantage of the JLT is that it can be completed very quickly and facilitates 
decision making for GP referral by the pharmacist simply, without the need for 
complex calculations, which was the case with the scoring system in the PCQ.[197] 
The design of the tool incorporates the views of pharmacists and GPs. The JLT has 
high sensitivity and low specificity; the high sensitivity may help in identifying clients 
at high risk of disease, while the low specificity may also identify clients with lesser, 
non-life-threatening pathologies and unlikely to have bowel disease, but 
nevertheless would benefit from a GP consultation. The JLT may also standardise the 
consultation process of pharmacy staff with clients presenting with bowel symptoms.   
 
Following the development and validation of a bowel questionnaire with high 
sensitivity for bowel disease exclusively for pharmacy setting, the next step was to 
trial the questionnaire in community pharmacies. 
 
6: Could the JLT be an effective assessment tool for pharmacy clients presenting 
with bowel symptoms, assisting the pharmacy staff to identify at-risk clients and 
provide a referral to consult their GP?  
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This prospective study, reported in Chapter 4, supports the use of the JLT to identify 
symptomatic pharmacy clients who might require further medical investigation, and 
refer them to appropriate care. The present empirical evidence indicated a higher 
rate of referral in the intervention group. These findings are in line with studies that 
indicated structured symptom checklist and screening tools are an effective method 
to elicit symptoms that would benefit from medical consultation.[193, 214, 259, 260]  
 
Although the deployment of the JLT was not considered onerous by pharmacy staff, 
the majority of burden to the pharmacy staff was related to client recruitment for 
research purposes. One of the main reasons given by the staff for the slow 
recruitment during the intervention phase was the size of the booklet, which 
consisted of the information sheet, consent form and other paperwork to be 
completed by the staff. Even though the JLT was a short questionnaire, requiring less 
than three minutes to complete, the information sheet and consent form for ethical 
purposes, and notes pages to be completed by the pharmacy staff for research 
purposes, added to the bulkiness of the booklet and was reportedly a deterrent to 
recruitment. A similar challenge with engagement by research pharmacists was 
reported in a study by Emmerton et al.[261] about the experiences of community 
pharmacists involved in the delivery of a specialist asthma service in Australia, in 
which bulky research documentation deterred the potential participants from taking 
part in the study.[261]  
 
The concept of applying a decision-support tool in pharmacy practice was accepted 
by most of the pharmacy staff. They found the JLT to be a simple and effective 
assessment guide for management of bowel symptoms. The deployment of the JLT 
as a standalone intervention tool did not burden the staff, as most of the clients 
completed the JLT unassisted. The pharmacy assistants benefitted from the use of 
the JLT, as it structured the workflow and guided them to refer appropriate clients to 
the pharmacists. The JLT intervention was associated with a significantly higher 
referral rate compared to the UP Phase: 38% vs 20%. These clients were then clinically 
managed by the pharmacists. 
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7:  Could use of the JLT and referral from pharmacies encourage clients to consult 
their GP? 
 
The present study reported that greater proportion of referred client consulted their 
GP for further investigations. The acceptance of the recommendation to consult a GP 
(i.e. attendance rate for GP consultation) was also higher during the intervention 
phase than the UP phase: 40% vs 6%. The study reported more diagnoses being made 
for clients who consulted a GP following the pharmacist’s referral using the JLT. 
 
The JLT was found to be an acceptable assessment tool for the triage of bowel 
symptoms in the community pharmacy setting. Findings from this JLT prospective 
study suggest there is potential for implementation of questionnaire such as the JLT 
in pharmacies for screening and management of complex symptoms. There is 
potential for the documentation to be adapted to guide management of other 
complex symptoms potentially warranting GP investigation and potentially 
associated with early-stage cancer, such as pain or urinary tract infections. 
 
This brings the focus on the knowledge, confidence, attitude, perceived barriers and 
social pressure in influencing the intention to comply with a change in practice.  
 
8: Do attitude, perceived barriers and influence of other people affect the intention 
of pharmacy staff to perform an activity? 
 
Identifying the perceived barriers, the most influencing social norms and attitude of 
pharmacy staff for providing quality-enhanced services, and addressing these 
concepts, would enhance the implementation of such services.[37] The relationship 
of intention with individual domains of attitude, subjective norm and PBC was studied 
using univariate analysis. Providing quality-enhanced service was not perceived as a 
burden by pharmacy staff. The pharmacy staff did not relate the pharmacy layout as 
a barrier to providing quality-enhanced service. In other words, keeping 
implementation of the JLT in mind, pharmacy staff did not consider the use of 
questionnaires such as the JLT burdensome in their day-to-day functioning of the 
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pharmacy. Furthermore, they should not have to make any major structural changes 
to the pharmacy to deploy the JLT to clients presenting with bowel symptoms. The 
post-JLT-intervention survey response from the participants who completed both the 
baseline and post-JLT-intervention surveys (n=23) indicated a slight decrease in the 
percentage of positive responses for intention to provide a cognitive service. As 
discussed in response to research question 6, although the respondents did not think 
that providing a cognitive service was a burden, recruitment for the JLT intervention 
and adherence to the study protocol were considered an issue. Responses by 
participating pharmacy staff to the post-JLT-intervention TPB survey on intention to 
provide cognitive services could have been influenced by the study protocol they had 
to follow when recruiting clients for the JLT trial, although they were positive in their 
response for changing practice to a more “consistent practice”, as established in the 
pharmacy evaluation study (Section 4.2.3.3). 
 
Interestingly, perceived confidence level in identifying and giving appropriate 
recommendations played an important part in the intention of the pharmacy staff in 
providing quality-enhanced services and change their usual practice. This brings into 
focus a questionnaire such as the JLT that would facilitate in easy identification of 
‘red-flag’ symptoms of pharmacy clients. Feedback on the JLT by the pharmacy staff 
post-intervention (Section 4.2.3.3) pointed out that they accepted the JLT as a simple, 
easy-to-use questionnaire that “confirmed the ‘red-flag’ for early detection of bowel 
signs and symptoms that warranted referral for medical advice” and “helped 
reinforce the cases for referral”. The JLT has potential to increase confidence of the 
pharmacy staff in accurate identification of clients who would benefit from further 
medical consultation. The post-JLT-intervention survey also indicated an increase in 
confidence in the participants who completed both the baseline and post-JLT 
intervention surveys. Greater self-efficacy would most likely lead to increased 
intention to deliver a quality-enhanced service.[108, 234]  
 
All three social norm factors – pharmacy clients, other pharmacies and owner of the 
pharmacy – positively influenced the intention of pharmacy staff to provide quality-
enhanced service. In the hope of facilitating implementation of JLT, these findings of 
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the influence of social norms on intention of pharmacy staff play a vital role. Similar 
to other studies that measured the intention of pharmacy staff by applying the 
TPB,[235, 262] social norm was a strong influence on their intention. The pharmacy 
staff felt under pressure to provide quality-enhanced service and thus change their 
usual practice, if it was beneficial to the client. The influence of the owner and peer 
pressure also played an important role on their intention to provide quality enhanced 
service and change in practice. Persuasion of peers can accelerate the diffusion of the 
service.[238, 239] Implementation of the JLT with a focus on increasing client 
expectations and convincing owners to adapt quality-enhanced service is more likely 
to be successful than without. Adoption and implementation of the JLT may also be 
influenced by the opinions of others within their professional network. Once a 
service, in this case, the deployment of JLT for screening of bowel disease, is adopted 
by some individuals, it becomes increasingly likely that other members of that 
social/professional network will also adopt it.[240] 
 
Pharmacy staff in this study showed a positive attitude towards provision of quality 
enhanced service. However, intention to provide quality enhanced service and 
change practice was very high in this study, leaving very little potential for change in 
attitude. This was reflected in the post-JLT-intervention TPB study, which again 
showed positive attitudes towards providing a cognitive service and changing 
practice. This finding is consistent with a pharmacy-based TPB study in the US by 
Farris and Schopflocher on community pharmacists’ assessment of pharmaceutical 
care[108] and the Herbert et al. study in Canada on pharmacists’ intention to provide 
a Medicare medication therapy management service.[241] In the present study, the 
high attitudinal rate was reflected in the JLT trial (Chapter 4), with increase in the 
referral rate and a greater proportion of clients accepting the pharmacist’s referral 
and consulting a GP, when the pharmacy staff based their consultation of bowel 
symptomatic client on the client’s response to the JLT.    
 
Economic viability through public and private funding could be key in the long-term 
sustainability of such services in the pharmacies.[114]  
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9: Will Australians pay for healthcare screening and triage service from a 
community pharmacy? 
 
One-third of the 175 participants were willing to pay a median amount of AUD5 for a 
quality-enhanced service where the consultation between pharmacists and client 
was based on the client’s response to a symptom screening tool. An equally-large 
proportion was ambivalent in their WTP for quality-enhanced service. This suggests 
a realistic fee is appropriate for quality-enhanced service in community pharmacies. 
This is consistent with other studies that have attempted to investigate the WTP for 
pharmacies services in Australia.[114, 117, 118] Interestingly, the participants 
acknowledged the longer consultation time in quality enhanced service and majority 
found the advice given in the video depicting the enhanced service in pharmacy, 
more helpful.  
 
The findings in this theoretical WTP study suggested significant consumer acceptance 
of a user-pays pharmacist-led service in triage of symptoms. This could be an 
economically-viable option for pharmacy staff if they provide JLT-based quality-
enhanced service, even if it is not government funded. 
 
7.3. Limitations 
 
A randomised controlled trial is the ideal design to test pharmacy-led interventions, 
but in this case, the objective of the JLT-intervention study was to identify if a change 
in practice of pharmacists could be achieved by introducing to them a structured 
questionnaire consultation approach for their clients. The practicality of alternating 
between JLT-led consultation and UP in a busy pharmacy with multiple staff 
consulting the clients was one reason for not conducting a randomised controlled 
trial. Clustered randomisation instead of client randomisation was not applied, due 
to differences in practice in terms of staffing and demographic profile, which would 
confound the analysis. A pre-post prospective study was considered appropriate for 
this study. 
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Recruitment to health research in primary care remains a hurdle.[263] There are 
published systematic reviews of factors that have an impact on recruitment process 
for health research.[245, 263-265] Strategies to boost recruitment should be one of 
the priorities when developing a study. An unfortunate side-effect of ethical 
committees, which play a hugely valuable role in protecting the participant and the 
study, is the paperwork that comes with it, which could be burdensome to the client 
and the pharmacy staff.[263] A less daunting and more acceptable format for carrying 
out this quality-enhanced service in the pharmacy could be the JLT presented in a 
letter-pad format. Following the post-evaluation phase of the JLT-intervention study 
(Chapter 4), the JLT was formatted into a letter-pad style questionnaire (Appendix 
7.1) and distributed to the participating pharmacies for future use. No data were 
collected about the use of the JLT in the letter-pad format, as it was outside the scope 
of the study.  
 
The other reason for slow recruitment during the intervention phase of the JLT trial 
study (Chapter 4) was the added burden to the pharmacies of seasonal changes. This 
study was conducted from May 2013 to March 2014. Recruitment for the 
intervention phase, which coincided with the Christmas holiday season, was 
considerably slow due to the shift in focus of the pharmacies. Since it is highly unlikely 
to avoid long periods with no added burdens such as audits, seasons with other 
priorities such as festivities in this retail business,[266] it becomes important to 
maintain flexibility and acknowledge the other commitments of participating 
pharmacies.  
 
The study protocol was not consistently applied in some pharmacies, highlighting the 
challenges of research in a naturalistic setting. Although the staff of the participating 
pharmacies were trained in the protocol and significance of a screening tool such as 
the JLT in early detection of bowel disease, non-compliance with the protocol could 
not be controlled in some pharmacies, even when the researcher closely monitored 
the study progress. Low compliance with the assessment tool was also reported in 
the CAPER study,[195] where the recommendations made by the assessment tool 
were not routinely followed by the participating practitioner.  
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There was no direct involvement of the clients in the design and evaluation of JLT. 
This was on the account of the intervention being managed by the pharmacy staff. 
The readability of JLT was measured by Flesh-Kincaid grade level, indicating that an 
average grade 4 student should be able to read the instrument. Although feedback 
from pharmacy staff about the JLT was positive in terms of standardising the 
consultation for clients presenting with bowel symptoms, no direct feedback to 
assess the client’s acceptability was obtained. The pharmacy staff reported that the 
JLT was easy to complete and clients managed the form unassisted. Further research 
on the acceptability of JLT directly from the client is required to determine their 
expectations towards pharmacy when presenting with bowel symptoms. 
 
Behavioural decision-making models such as the TPB (Chapter 5) often rely on self-
report.[101] Evidence suggests that individuals may provide socially-desirable 
answers in terms of attitude and intention.[101] Additional research to further 
validate the observed behavioural change is required.  
 
The response rate for the post-JLT-intervention behavioural survey (Chapter 5) was 
lower than expected, and limited the comparison of pre- and post- responses of the 
intention to change behaviour and provide cognitive service. The majority of 
pharmacists and pharmacy staff involved in this study participated enthusiastically, 
which is reflected in their ‘attitudinal responses’ to surveys, but a few could not 
sustain that motivation. 
 
Providing incentives could improve the participation rate and motivate participants 
to sustain interest throughout the study.[245] 
 
7.4. Implementation of the JLT 
 
The process of introducing a new service could be daunting. To achieve successful 
implementation of the JLT in community pharmacies, effective engagement of 
pharmacy staff, resources, policy makers and researchers is required.[87] Roberts et 
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al. identified seven key facilitators of practice change in Australian community 
pharmacies[87] that were addressed in the present study:  
 
 Inter-professional communication: The JLT facilitated identification of 
symptomatic clients and triggered a referral process for the client to consult a GP. 
This early intervention, at a point where clients may be seeking symptomatic 
relief from a pharmacy medicine, has potential to initiate early treatment and 
thus improve prognosis. A less daunting and more acceptable format for carrying 
out this cognitive service in the pharmacy could be the JLT presented in the 
aforementioned letter-pad format. Though the JLT based consultation provided 
a written referral to engage the client without any direct communication between 
pharmacists and the GP, the JLT trial reported in Chapter 4 indicates that the 
acceptance to this kind of referral by the client resulted in increased rate of 
consultation with the GP which again resulted in increased diagnosis after GP 
consultation 
 Remuneration: Findings from the WTP study suggest that people might be willing 
to pay for a service in the pharmacy, whereby a screening tool such as the JLT is 
used for triage of clients at high risk of bowel disease. A full cost-benefit analysis 
would be ideal to assess the economic-viability of providing quality-enhanced 
service where JLT is used for screening of bowel disease in community pharmacies 
 Pharmacy layout: Although the study by Roberts et al. identified the presence of 
a private consultation area as a key facilitator,[87] the TPB study (Chapter 5, 
section 5.5) indicated that providing privacy during consultation with clients with 
embarrassing symptoms was not considered difficult by the pharmacy staff.  
 Client expectation: Subjective norm was identified as a significant influencing 
factor for the intention to provide quality-enhanced service in the TPB-based 
study (Chapter 5, section 5.5). Pharmacy staff value the clients’ expectations and 
needs.[267] This act of working towards fulfilling expectations and needs of the 
clients is a facilitator in implementation of the service. Studies determining 
clients’ feedback about the JLT would be ideal to obtain information about their 
expectations. 
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 Staff: Skills and knowledge of the staff was a key facilitator for implementation of 
a service, as identified by Roberts et al..[87] This was reflected in this present 
study by the self-efficacy of staff in identifying high-risk symptoms, and their 
confidence in making recommendations, both significant influences on their 
intention to provide quality-enhanced service as well as change practice. The staff 
reported in their feedback of the JLT that they found it to be a simple-to-use 
questionnaire that confirmed the ‘red-flag’ symptoms that warranted GP 
consultation. The JLT can potentially increase confidence in identification and 
triage of high-risk bowel symptoms. 
 Communication and teamwork: Roberts et al.’s study identified a leadership role 
by the owner and pharmacists and engaging the entire pharmacy by active 
communication as key facilitators for implementation of a service. The TPB study 
in this thesis reflects on owners influencing the intention of staff to provide 
quality-enhanced service and to change practice. Implementation strategies for 
the JLT should consider the importance of owners and managers being aware of 
the need to include the entire pharmacy team towards the common goal of 
successful implementation. 
 
Overall, findings from this thesis suggests the validated assessment tool, JLT is an 
acceptable tool for triage of bowel symptoms in the community pharmacy. It has high 
potential in standardising the consultation of pharmacy clients presenting with bowel 
symptoms.  In the current drive for health promotion initiatives within community 
pharmacy, an easy, user-friendly, valid triage instrument such as the JLT has the 
potential to improve pharmacy practice. 
 
Potential future research is discussed in the following chapter. 
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8. Conclusion and Recommendations 
 
 
8.1. Conclusion 
 
The complex intervention, as described in this thesis, clearly reflects the steps of the 
MRC framework (Figure 8.1). The review of published literature in Chapter 2 
established the value of community pharmacy in primary health care. It also 
established the gap in research on early identification of bowel symptomatic clients 
in community pharmacies. To improve the outcome of clients presenting at 
pharmacies for management of their bowel symptoms, they should be encouraged 
to consult the GP for definitive diagnosis. The PCQ study reported in Section 2.7.4.1 
assessed the feasibility of a bowel symptom management intervention in community 
pharmacy. For symptomatic clients who present in community pharmacies, there was 
a need to design and test validated tools that can be used in the pharmacies to 
identify and encourage them to seek medical help. 
 
The development and validation of the JLT, outlined in Chapter 3, fills the gap in the 
literature with a self-administered questionnaire that successfully identifies 
pharmacy clients who may well be suffering from bowel conditions that would 
benefit from medical advice instead of self-management. The reports of prospective 
observational study of the JLT, described in Chapter 4, shows that pharmacy staff 
found the JLT to be a simple and effective assessment tool for management and 
triage of bowel symptoms.  The findings highlight that guided communication around 
symptoms is effective in alerting health professionals and clients to the need for 
clinical consultation. With evidence stating that a substantial number of individuals 
in the community manage symptoms without seeking medical help,[268] a pharmacy 
service with symptom management based on a decision-making tool such as the JLT 
should demonstrate value in triage of clients with underlying health conditions. 
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Figure 8.1: Thesis based on Medical Research Council Framework
Theoretical and Feasibility 
Phase 
Modelling/Development 
Phase 
Evaluation Phase Evaluation Related to 
Long-Term 
Implementation 
Long-Term 
Implementation 
Chapters 7 and 8 
 
 Discussion of the overall 
thesis 
 Recommendations on 
basis of study findings 
Chapters 5 and 6 
 
 Understanding intention 
to change practice in 
pharmacy for long term 
implementation 
 Measuring monetary 
value for pharmacy 
advice 
Chapter 4 
 
 Prospective 
Observational study of 
JLT to evaluate its 
effectiveness in 
identifying clients at risk 
of bowel disease 
 Measuring acceptance of 
referral to GP by 
pharmacy client 
Chapter 3 
 
 Development of 
decision-aid 
screening tool (Jodi 
Lee Test) 
 Validation of JLT 
for identification 
and triage of clients 
with risk of bowel 
disease 
Chapter 2 
 Identified available 
relevant evidence 
 Assessed feasibility 
of bowel symptom 
management 
intervention in 
community 
pharmacy 
Continuum of increasing evidence 
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Intention of pharmacy staff to change practice, outlined in Chapter 5, found the 
confidence level of pharmacy staff, and social pressure from client, peer group and 
the owner, strongly influenced their intention to provide quality-enhanced service 
such as the JLT screening service, in their pharmacies. The WTP study, reported in 
Chapter 6, showed that clients may be willing to pay for a service where a 
questionnaire such as the JLT is used to identify ‘red-flag’ symptoms which require 
further medical investigation. 
 
Overall, this thesis has demonstrated the development, validation and a prospective 
observational study of a self-administered bowel questionnaire, JLT for use in 
community pharmacies for triage of clients who might be at risk of bowel disease. 
 
8.2. Recommendations 
 
The findings of this study may inform intervention efforts for early detection and 
referral of symptomatic clients who present to community pharmacies. Community 
pharmacy staff are well placed to play a dynamic support role in effective primary 
health care as they are the most accessible points of contact within the healthcare 
system.[55] This makes them the key focal point for interventions aiming at screening 
and referral to appropriate care. Pharmacy clients value pharmacists’ advice and 
consider positively suggestions to seek GP referral.[21, 215, 269]  
 
Early intervention in pharmacies where clients may simply be seeking symptomatic 
relief from a pharmacy medicine, has the potential to be extended to other symptom 
complexes associated with early-stage of serious pathology.  
 
 Recommendation 1: Standardised Consultations 
 
During the post-evaluation phase of the JLT trial (Section 4.2.3.3), the pharmacy staff 
reported that they would accept a JLT-like questionnaire in the pharmacy for 
conditions such as urinary tract infection, vaginal candidiasis, kidney problems and 
headaches.  
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There is potential for development of JLT-like questionnaires and testing of these self-
administered screening tools in community pharmacies. This would expand the role 
of pharmacy staff in identifying and referring clients who would benefit most in 
further medical consultation. Standardised consultation in pharmacies would benefit 
the clients and guide them to appropriate care.  
 
 Recommendation 2: Staff Training 
 
Findings from Chapter 5 provided an insight into the intention, attitude and perceived 
barriers and social pressures in delivery of quality-enhanced services and changes to 
usual practice. The results suggest the participating pharmacy staff had a positive 
attitude towards proving cognitive services. Lack of confidence in making a clinical 
assessment was considered a barrier in providing cognitive services. Future 
intervention studies could concentrate on addressing the self-efficacy of pharmacy 
staff in identification and triage of symptoms indicative of serious underlying 
pathology, via training, a study package, information materials and screening tools 
such as the JLT.  
 
 Recommendation 3: Uptake Enhanced Services 
 
Findings from Chapter 5 also suggested that greater adoption of the enhanced 
cognitive services by other pharmacists and endorsement by the owner of the 
pharmacy could be the driving force in successful implementation of cognitive 
services. Effective engagement of pharmacy owners and staff has the potential to 
achieve successful implementation of evidence-based pharmacy research. 
 
 Recommendation 4: Client satisfaction 
 
Client satisfaction was another influencing factor for the intention of pharmacy staff 
to provide cognitive service. It would be worthwhile to find the client’s feedback 
about the JLT to elicit information about their expectations. Consideration should 
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also be given to creating public awareness about symptoms and continuity of care for 
various conditions.  
 
 Recommendation 5: Reducing administration 
 
Research-related burden is only an issue during the evaluation of a new intervention. 
Studies using standardised pharmacy clients might be a way to reduce administration 
burdens that usually hinder recruitment process. Ongoing implementation would 
require considerably reduced burden from paperwork and contact with researchers. 
 
 Recommendation 6: JLT should be used routinely 
 
There is scope to trial the JLT in the letter-pad format developed during the 
evaluation process of the JLT. Should that prove effective, JLT could be adopted as 
routine part of care for clients presenting with bowel symptoms. 
 
To avoid adding an administrative burden on participants, studies can be conducted 
on the feasibility of deploying the JLT in an electronic version. 
 
 Recommendation 7: Pharmacy involvement in health care 
 
The research identified scope for facilitating greater involvement of pharmacy 
assistants in pharmacy operations outside the dispensary. This would require 
additional training pharmacy assistants in appropriate protocols for administration of 
tools such as the JLT. It should also be noted that all involved should be clear about 
their role in the assessment and referral processes (e.g. definitive diagnosis is not 
feasible within a pharmacy; the pharmacist contributes to the continuity of care 
across the health care system, in this case, using a valid screening tool). 
 
Overall, this thesis has demonstrated that a screening tool such as the JLT is a viable 
method to support pharmacy staff in triage of clients at risk of bowel disease. This 
instrument, and the findings regarding validation and evaluation, are offered to the 
142 
 
academic community with a view to further research into the contribution of 
community pharmacy to primary health care and effective continuity of care. 
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Appendix 3.2: Nominal Group technique for JLT Item Generation 
 
Ten ideas were generated at the conclusion of the discussion.  
1. Symptoms to be included: 
a. Rectal bleeding 
b. Alternating diarrhoea and constipation 
c. Diarrhoea 
2. Duration of symptoms 
3. Importance of GP consultation for the presenting symptom 
4. Name of the questionnaire – to be clarified 
5. Inclusion of weight loss in the questionnaire 
6. Medical history 
7. Inclusion of pain ‘meter’ 
8. Medication taken by the client  
9. The key questions that would aid the pharmacists and their staff to make a better 
informed decision about referring to GP 
10. Tick-type format for questionnaire with simple wording 
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Appendix 3.3: Aspects of Delphi Technique- Suggestions Following 
Each Round of Iteration 
 
Suggestions Recorded After Round 1 of Iteration 
1. Change wording of ‘pain’ question and order to question 5. 
2. All symptoms to be present as one question. 
3. Name of the questionnaire to acknowledge the foundation sponsoring the 
researcher. 
4. Add bowel-related issues to question 8 as a prompt to help the client. 
5. Change the wording of weight loss question so as not to indicate the 
presenting symptom as illness. 
6. Symptom questions should be followed by the duration. 
7. Duration should be followed by the ‘GP consultation’ question. 
 
Suggestions Recorded After Round 2 of Iteration 
1. Avoid sub-division for symptoms - make it simple. 
2. Have ‘discomfort (soreness, itch, lump)’ as a separate symptom question. 
3. Move ‘GP consultation’ question to question number 6. It is to be used as 
additional information for the pharmacists, and should not be a major 
deciding factor for referral to GP unless the client was buying medication 
prescribed by the GP. 
4. Change the wording for ‘usual bowel habit’ question for simplicity. 
 
Suggestions Recorded After Round 3 of Iteration 
1. Change wording of the ‘GP consultation’ question and prompt as a following 
question when the client had last seen the doctor. ‘Last seen’ to be included 
to give the pharmacists information about the recurring symptom. 
2. Remove the word ‘tummy’ from the ‘pain meter’ question to make it a 
general pain meter for the presenting symptom. 
3. Change the order of questions to include symptoms first followed by 
duration, ‘usual bowel habit’, ‘pain meter’, ‘weight loss’, ‘GP consultation’, 
medical history, medication taken. 
 
Suggestions Recorded After Round 4 of Iteration 
1. Changes to wording for ‘medical history’ and ‘medication’ questions. 
 
There were formatting improvements that included colour, font size and 
highlighters to indicate the key questions for alerting the pharmacists and their 
staff. 
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Appendix 3.4: Jodi Lee Test 
 
Q1. Are you experiencing any of the following symptoms?           (tick ALL that apply) 
Diarrhoea (loose, watery and frequent bowel motions)  
Constipation  
Alternating constipation and diarrhoea  
Bleeding from the back passage  
Discomfort at your back passage (soreness, itch, lump)  
 
Q2. How long have you had these symptoms? 
Less than 1 week  
1 week or more  
 
Q3. Is this unusual for you? 
Yes  
No  
Q3a. If yes, in what way is it unusual? 
 
__________________________________________________________________ 
__________________________________________________________________ 
 
Q4. Is this symptom(s) associated with any pain? 
 
 
 
 
Yes  
No  
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Q4a. If yes, what is the pain like?     (circle the number that describes the pain) 
 
  
 
 
Q5. Have you lost weight unexpectedly in the past 4 weeks?  
 
  
 
      Q5a. If yes, approximately how much weight have you lost?     ___kg 
 
Q6. Have you talked to a doctor about this symptom(s)? 
   
 
 Q6a. If yes, when was the last time you talked to the doctor about this symptom(s)? 
 ________________________________________________________________ 
 
Q7.   Have you had any bowel problems in the past 12 months?  
 
 
 
 
 
 
Q8. Please list any medication that you are currently taking (including medicines bought 
without a prescription, and natural products). 
 __________________________________________________________________ 
Yes  
No                         
Yes  
No  
Haemorrhoids (Piles)  
Colitis 
Polyps 
Cancer 
Other   _________________ 
 
_ 
      None                 Mild      Moderate   Severe  Worst imaginable 
0      1  2 3           4          5          6          7          8          9 10 
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Appendix 4.1: Flyer  
 
 
 
Early detection of Bowel Disease in Community Pharmacies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timeline for Pharmacies participating in Early Detection of Bowel Disease 
in Symptomatic Patients 
 
 Establish Baseline of Current Pharmacy Practice 
 Recruit pharmacies into study. Need a minimum of 25 pharmacies. 
 Fill out team surveys to show current practice of detection of bowel 
disease in pharmacy.  Participants include all pharmacists, pre-
registration pharmacists and all team members that are accredited to 
work in the S2/S3 area. 
 
Key:    
P1- Simulated actor consultation in pharmacy and usual practice documented 
     
P2- Implementation of JLT in pharmacy      
    
P3- Post intervention ‘usual practice’       
   
 
 
Baseline 
4 
P 1 
4 
P 2 
4 
P 3 
4 
4-5 weeks 5 weeks Till sample 
target 
reached 
Till sample 
target 
reached 
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 Recruit Patients into Name collection/control phase 
 Mystery shop of 5 to 10 random pharmacies to see their current 
practice. 
 Recruit 2-3 participants/week into study.  Participants are asked to 
participate in phone survey (follow-up call) regarding their symptoms.  
Participants will be given $5 off the cost of their purchased item as 
incentive to participate in phone survey.  Follow up by Deepa Sriram of 
Curtin Innovation Health Research Institute within 4 weeks of patient 
consent. 
 
 Recruit patients to Jodi Lee Test Intervention phase 
 Participating pharmacies asked to trial the intervention tool designed to 
ascertain Early Detection of Bowel Disease in Symptomatic Patients 
(Jodie Lee Test Intervention Tool) in general Community Pharmacy 
practice. The Pharmacists will be asked to advice the participants based 
on their response to JLT.  Participating pharmacies asked to 2-3 
participants/week into study 
  The consented participants who complete the JLT will be followed up by 
Deepa Sriram of Curtin Innovation     Health Research institute within 4 
weeks of patient consent. Participants will be given $5 off the cost of 
their purchased item as incentive to participate in this phase. 
 
Thank You for your time  
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Appendix 4.2: Instructions to Pharmacy Staff for Usual Practice 
 
PHASE 2- Control Phase/Name Collection Phase 
Instruction for Staff members 
You have to recruit customers with lower bowel symptoms like 
diarrhoea, constipation rectal bleeding, for this phase of the study.  
Eligible participants are 
 Customers 18 and over who can give informed consent. 
 Who present in the pharmacy for advice or medication for lower 
bowel symptoms (Diarrhoea, Constipation, Rectal Bleeding)-
preferably not prescription medication for their presenting 
symptoms. 
What you would be asked to do 
 When a customer presents with the above mentioned symptoms, 
tell him/her about the study and if willing, give them the booklet 
with information sheet and consent form to complete. 
 The participant has to just give his/her name and best contact 
details for this bit of the study and I would follow them up after 4 
weeks.  They can have the main copy of the consent form - tear 
the consent form off and give to the customer. 
 They get $5 off their purchase if they sign the consent form 
 The Staff who deals with that particular customer should 
complete the notes page in the booklet. 
 Carry on with your usual management of the symptom. 
 Booklet should be posted back to Deepa Sriram. 
For further information please contact 
Deepa Sriram  
Email- d.sriram@curtin.edu.au   
Tel No- 94565473, 0431890299 
Curtin University 
Thank you for your participation
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Appendix 4.3: Instructions to Pharmacy Staff for JLT Phase 
 
JLT Phase - Intervention Phase 
      
Instruction for Staff members 
You have to recruit customers with lower bowel symptoms like 
diarrhoea, constipation rectal bleeding, for this phase of the study.  
Eligible participants are 
 Customers 18 and over who can give informed consent 
 Who present in the pharmacy for advice or medication for lower 
bowel symptoms (Diarrhoea, Constipation, Rectal Bleeding)-
preferably not prescription medication for their presenting 
symptoms. 
 
What you would be asked to do 
 When a customer presents with the above mentioned symptoms, 
tell him/her about the study and if willing, give them the booklet 
with information sheet and consent form to complete. 
 The participant has to complete the consent form and the Jodi 
Lee test (JLT) for this bit of the study and I would follow them up 
after 4 weeks.  They can have the main copy of the consent form 
and the JLT- tear the main copy consent form  and JLT –pages 3, 
4 and 5 off and give to the customer. 
 Check the completed JLT and if there is a tick in the highlighted 
boxes, the client will get a referral. Sign page 7 and tear and give 
the main copy to the client. 
 Even if the completed JLT warrants a referral,  you can decide by 
clinical judgement if the client requires a referral from further 
questioning or from the responses to Jodi Lee test (JLT), eg, Q6 
and Q8. 
 They get $5 off their purchase if they sign the consent form. 
 The Staff who deals with that particular client should complete 
page 6 in the booklet. 
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 Carry on with your usual management of the symptom. 
 Booklet should be posted  back to Deepa Sriram. 
For further information please contact 
Deepa Sriram  
Email- d.sriram@curtin.edu.au   
Tel No- 94565473, 0431890299 
Curtin University 
Thank you for your participation 
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Appendix 4.4: Baseline Booklet 
 
 
Booklet Cover page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Early Detection of Bowel Disease 
In Community Pharmacy 
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Booklet Back page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THANK YOU FOR YOUR PARTICIPATION IN THIS RESEARCH PROJECT 
For further information, please contact 
Deepa Sriram 
Email :  d.sriram@curtin.edu.au 
Tel: 08-92669581 
Curtin Health Innovation Research Institute (CHIRI) 
Curtin University 
GPO Box U1987 
WA 6845 
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Baseline Booklet 
Information Sheet 
 
Early detection of Bowel Disease in symptomatic patients attending community pharmacy 
This pharmacy is currently participating in the research study conducted by a PhD candidate 
from Curtin University. We are asking for your help in trialling an assessment tool (Jodi Lee 
Test - JLT) to support pharmacy staff to advice customers who present with lower bowel 
symptoms.  
 
What will I be asked to do? 
 Complete four short questionnaires. This will be at baseline and after each of the 3 short 
phases of the study. Each questionnaire would take 5-10 minutes to complete. 
 Provide your usual service for a mystery shopper. About five actors will present at the 
pharmacy with specific problems. You are invited to consult them as per your normal 
practice. The actor will document the consultation once he/she is out of the pharmacy 
and relay it to the researcher. The data will be used by the researcher to determine the 
current practice by offering a case scenario. Though you will not be aware of the exact 
date or time when the actors would present themselves, once the consultation is 
finished, you will be informed by the researcher of the ‘actor consultation’. 
 Recruit eligible customers to the study those who are over 18 years of age and able to 
provide informed consent, who attend a participating community pharmacy to seek 
advice and/or request to buy a product to manage a current symptom of bowel disease 
that includes diarrhoea, constipation and/or rectal bleeding. You will also be invited to 
document your interaction with those customers. 
 
 
What will happen 
During my first visit to your pharmacy I will explain  
 The study and the intervention tool (JLT) 
 How to recruit participants 
 How to record interaction with participants 
 
 
How will my privacy be protected? 
We believe it is extremely important to keep your personal information confidential. The 
researchers will need to collect personal data about you, which may be sensitive. Examples 
of such data include your name, contact details, date of birth and other relevant information. 
However, personal information will be kept private and confidential. It will be stored securely 
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and only authorised persons, who understand the confidential nature of the information, will 
have access to it. 
Any data that is required for data analysis will be securely exported to Curtin University and 
given a number so that your identity will not be apparent.   
The results of the research will be made available to other health professionals through 
medical journal, meetings or conferences, but you will not be identifiable in any of these 
communications. 
 
 
Can I decline to take part or withdraw if I change my mind? 
Participation in this study is purely voluntary. You may decline to take part or withdraw from 
this study at any time. 
All pharmacy customers will receive the same quality of service that is available in pharmacies 
regardless of participation in this project. Where you deem that a client should consult a 
General Practitioner for any reason, they will be urged to do so notwithstanding the focus of 
this project. 
The JLT offered will not replace clinical expertise.  It is designed to guide your discussion with 
the patient.  
 
 
Are there any risk or benefits? 
There are no risks involved in this study. 
The questionnaire that you complete at every study end point will help the researcher 
evaluate change in pharmacy practice. We anticipate that having your practice observed may 
have an impact on your current practice. At each stage of this study, we offer a different 
intervention. In order to identify the impact on your practice, we are inviting you to complete 
a short questionnaire to help identify which intervention was most helpful. This will help 
researchers understand how patients are advised about their lower bowel symptoms in this 
setting and what might help staff to advise them most appropriately. You may find this 
observation a little challenging, however, all the information you offer will be will be de-
identified in any reports or publications or presentations from this study.   
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For more information about the study please contact 
Ms Deepa Sriram 
Curtin Health Innovation Research Institute/Curtin University 
Phone: 92669581 
Email address: d.sriram@curtin.edu.au 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The study has been approved by the Curtin University Human Research Ethics Committee 
(Approval Number-HR 19/2013). The committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral carers. Its main role is to protect participants. If 
needed, verification of approval can be obtained by either writing to the Curtin University 
Human Research Ethics Committee on telephone number, c/- Office of Research and 
Development, Curtin University of Technology, GPO Box U1987, Perth 6845 or by telephoning 
9266 2784 or by emailing hrec@curtin.edu.au. 
All study participants will be provided with a copy of the Information Sheet and Consent Form 
for their personal records. 
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Consent Form 
Early detection of Bowel Disease in symptomatic patients attending community 
pharmacy 
This pharmacy is currently participating in the research study conducted by a PhD candidate 
from Curtin University. We are asking for your help in trialling an assessment tool (Jodi Lee 
Test - JLT) to support pharmacy staff to advice customers who present with lower bowel 
symptoms.  
By completing the consent form below, you certify that you: 
1. Have read and understood the information provided regarding the above mentioned 
study and have had an opportunity to ask questions. 
2. Are willing to participate by completing four questionnaires, actor consultation and 
recruiting eligible participants for the study. 
 
 
Name    _________________________________  
Pharmacy Name _____________________________________________ 
Pharmacy Address  
 
 
 
 
Signature 
Date   
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About you 
 
1. What is your age as of your last birthday? 
 
2. What is your gender 
Female 
Male 
 
3. Highest level of Education… 
Less than Year 10 
Year 10 or equivalent 
Year 12 or equivalent 
Diploma or equivalent 
Tertiary education 
What are your formal qualifications? 
 
 
4. Employment status in the pharmacy: 
 Pharmacist 
 Full-time 
           Owner 
  Part Time/ Locum/Casual 
 Pre-Registrant Pharmacists 
 Pharmacy assistant 
 
5. How long have you worked in a community pharmacy setting (years)? 
 
 
 
6. What is your role in managing customers with lower bowel symptoms (eg., 
constipation, diarrhoea, rectal bleeding) ? 
Please provide as much details as possible  
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Please answer the following question if you are a pharmacist 
 
7. When you are at work, how many other pharmacists also are present at your practice 
at the same time? 
None, I am the sole pharmacist 
One other pharmacist 
2-4 other pharmacists 
5 or more other pharmacists 
 
8. The location of this pharmacy 
Medical Centre 
Local shopping centre (<25 shops) 
Major shopping centre (>25 shops) 
City, suburb or Town-centre strip  
Other (please specify) 
Pharmacy Assistant please go to page 8 and complete Page 8 and 9 
 
Pharmacists/locums and Managers/owners, please go to Page 7 and complete page 7, 8 and 
9 
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_____________________ 
 
9. The majority of your customers are : 
Seniors 
Young families 
Working adults  
Young people 
 
10. Approximately how many customers attend the pharmacy with symptoms before they 
consult their GP per day?  
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Pharmacy Questionnaire 
Please do not consult any member of the team when filling in this questionnaire 
 
3. For me to take a customer to a private space to speak about his/her embarrassing 
symptoms is 
Extremely difficult   1 2 3 4 5  Extremely easy 
 
4. For me to obtain the reason for the customer’s visit to the pharmacy with embarrassing 
symptom is generally 
Extremely difficult   1 2 3 4 5  Extremely easy 
 
5. I am confident in making recommendations to customers regarding their lower bowel 
symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree  
 
6. I am confident in recognising warning signs of bowel disease that may require 
consultation with the general practitioner (GP) 
Strongly disagree  1 2 3 4 5 Strongly agree  
 
Cognitive pharmaceutical services can be defined as professional services 
provided by pharmacists, who use their skills and knowledge to take an 
active role in patient health, through effective interaction with both 
patients and other health professionals. 
 
7. Providing cognitive services (Please refer to the definition given above) to customer 
with lower bowel symptoms would be a burden on pharmacy staff 
Strongly disagree  1 2 3 4 5 Strongly agree  
 
8. I would like to provide cognitive services to customers with Lower bowel symptoms 
because customers expect it 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
9. I would like to provide cognitive services to customers with Lower bowel symptoms 
because other pharmacies are doing it 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
10. If you are the owner/manager of this pharmacy please move to question 9 
 
I would like to provide cognitive services to customers with Lower bowel symptoms 
because the pharmacy owner/manager expects me to do it 
Strongly disagree  1 2 3 4 5 Strongly agree 
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11. Pharmacists providing recommendation to customers regarding their lower bowel 
symptoms is consistent with good professional practice 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
12. Providing cognitive services to customers with lower bowel symptoms  will allow 
pharmacists to provide an even higher level of care to patients  
Strongly disagree  1 2 3 4 5 Strongly agree 
 
13. Providing cognitive services to customers with lower bowel symptoms will enhance 
customer satisfaction even more 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
14. Providing cognitive services to customer with lower bowel symptoms will make it even 
more likely that pharmacists will ensure that people with lower bowel symptoms get 
appropriate care 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
15. In the future I will provide cognitive services to customers with Lower bowel symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
16. In the future I will change my usual/current practice for customers with lower bowel 
symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree 
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Appendix 4.5: Control Group Booklet 
 
Participant Information Sheet  
 
We are interested in the best way to provide advice people who come into a Pharmacy with 
lower bowel symptoms. We are very interested in your opinion. 
 
Who can participate? 
You are eligible to participate if you are over 18 years of age and able to provide informed 
consent. 
 
What will you be asked to do? 
 
1. You will be asked to provide your name, address and a contact telephone 
number.  This information will ONLY be used for study. It will not be used for any 
other purpose and will be destroyed at the end of this research.  
2. A researcher named Deepa Sriram, will telephone you in the next 4 weeks  to ask 
you a few brief questions about whether you have sought any more advice about 
your symptoms. This will take approximately five (5) minutes. 
3. As a token of appreciation for your time in participating in the telephone survey, 
you will receive a $5 discount from your purchase in this pharmacy. 
 
How will my privacy be protected?   
We believe it is extremely important to keep your personal information confidential. As 
noted before, the information you provide to us will only be used for this research. After the 
research project is finished, it will be destroyed. You will not be named in any publication and 
any results will be summarised as percentages or proportions of the total number of 
participants in this study.  
 
Can I decline to take part in this study or withdraw if I change my mind? 
Participation in this study is voluntary. You may decline to take part or withdraw from this 
study at any time.   
Are there any risk or benefits?  
There are no risks involved in this study. You will continue to receive the usual service from 
this pharmacy. Your answers will help researchers to find better ways to help patients with 
bowel symptoms.  
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What if I have questions once I have completed the study? 
If you would like a copy of this questionnaire for your own information or would like further 
information on the study, please contact: 
 
Ms Deepa Sriram 
Curtin Health Innovation Research Institute (CHIRI) 
Curtin University 
Building 609 
GPO Box U 1987 
Phone: 92669581 
Email id: d.sriram@curtin.edu.au 
 
 
 
 
 
 
 
 
The study has been approved by the Curtin University Human Research Ethics Committee 
Approval Number HR19/2013. The committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral cares. Its main role is to protect participants. If 
needed, verification of approval can be obtained by either writing to the Curtin University 
Human Research Ethics Committee on telephone number, c/- Office of Research and 
Development, Curtin University, GPO Box U1987, Perth 6845 or by telephoning 9266 2784 
or by emailing hrec@curtin.edu.au. 
 
All study participants will be provided with a copy of the Information Sheet and Consent 
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Participant Consent Sheet  
 
This pharmacy is currently participating in a study conducted by the Curtin Health Innovation 
Research Institute. The study seeks to identify people who present at a pharmacy with lower 
bowel symptoms. Your participation is voluntary. 
 
By completing the consent form below you certify that you: 
1. Are over the age of 18 years. 
2. Have read and understood ‘participant information sheet’. 
3. Have had any questions answered about this study to your satisfaction. 
4. Are willing for a member of the research team to telephone you in the next 4 
weeks.  
 
Please note:  It is important we are able to contact you by phone and by mail so we would 
appreciate you making sure your details are complete and correct.  
 
 
 
 
 
 
 
 
 
 
 
 
Your signature: __________________________   Date: ________________  
 
Name of Pharmacy_________________________________________________________ 
 
Signature of Pharmacist: _____________________________________________________ 
 
 
First Name  
Surname  
Mailing Address  
Suburb  Post Code  
Telephone 
number/s 
 Date of Birth __/_
_/__
__ 
Best time to call 
                                                    You will be called by Deepa  
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The study has been approved by the Curtin University Human Research Ethics Committee 
Approval Number HR19/2013. The committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral cares. Its main role is to protect participants. If 
needed, verification of approval can be obtained by either writing to the Curtin University 
Human Research Ethics Committee on telephone number, c/- Office of Research and 
Development, Curtin University, GPO Box U1987, Perth 6845 or by telephoning 9266 2784 
or by emailing hrec@curtin.edu.au. All study participants will be provided with a copy of 
the Information Sheet and Consent 
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For Pharmacy Staff - Please document the consultation with the customer 
 
Date ____/____/______ 
 
Name of the Patient  
 
 
1. What symptoms were reported by the patient? 
 
 
 
 
2. What questions did you ask?  
 
 
 
 
 
 
3. Was any medication sold?      Yes   No  
 
If yes, what were the medication sold? 
 
 
 
 
 
 
4. Did you refer the patient to consult their GP?           Yes   No  
 
If yes, Why? 
 
 
 
 
5. How long did this consultation take (time in mins)? __________________ mins 
6. Did you give any other advice to the patient? Please comment. 
 
Thank You for your support 
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Name:  __________________________ 
 
Pharmacy: __________________________ 
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Appendix 4.6: JLT Booklet 
 
Participant Information Sheet  
 
You have been asked to volunteer in this study because you were seeking treatment 
for a particular bowel symptom or condition. This study seeks to explore the best 
way to advice people who present with bowel symptoms. 
 
Who can participate? 
 You are eligible to participate if you are 18 years of age  
 Over able to provide informed consent. 
What will you be asked to do? 
1. You will be asked to provide your name, address, a contact telephone number 
and the name of your general practitioner. This information will allow us to do 
follow up calls ONLY for the purpose of this study. 
2. You will be asked to answer a brief questionnaire about your lower bowel 
symptoms. This will take you approximately 3 minutes to complete.  
3. Approximately 4 weeks after you complete this survey, we will telephone to ask 
you a few brief questions about what you have decided to do about your 
symptoms. This will take approximately 5 minutes. 
4. You will receive $5 voucher for use in this pharmacy to cover your time today and 
when we call you next month for follow-up. 
5. When we call you next month, if you have been to see a GP on the pharmacist’s 
advice, we will call your GP for information about your bowel symptoms. 
 
How will my privacy be protected? 
We believe it is extremely important to keep your personal information confidential. 
As noted before, the information you provide to us will only be used for this research. 
After the research project is finished, it will be destroyed. You will not be named in 
any publication and any results will be summarised as percentages or proportions of 
the total number of participants in this study.  
 
Can you decline to take part or withdraw if you change my mind? 
Participation in this study is purely voluntary. You may decline to take part or 
withdraw from this study at any time. 
197 
 
Are there any risk or benefits? 
The completed questionnaire will show if you would benefit from talking to a 
doctor. 
There are no risks involved in this study.  However, you may feel a little anxious if 
the pharmacist suggests that you make an appointment with your doctor. If that 
happens or you have any concerns please do not hesitate to discuss with the 
pharmacist.  
 
What if you have questions once you have completed the study? 
If you would like a summary of the result of this project, please contact: 
Ms Deepa Sriram 
Curtin Health Innovation Research Institute (CHIRI) 
Curtin University 
Building 609 
GPO Box U 1987 
Phone: 9266 9581 
Email id: d.sriram@curtin.edu.au 
 
 
___________________________________________________________________________ 
 
The study has been approved by the Curtin University Human Research Ethics Committee 
(Approval Number HR19/2013). The committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral cares. Its main role is to protect participants. If 
needed, verification of approval can be obtained by either writing to the Curtin University 
Human Research Ethics Committee on telephone number, c/- Office of Research and 
Development, Curtin University of Technology, GPO Box U1987, Perth 6845 or by telephoning 
9266 2784 or by emailing hrec@curtin.edu.au. 
All study participants will be provided with a copy of the Information Sheet and Consent 
Form for their personal records. 
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Participant Consent Sheet  
This pharmacy is currently participating in a study conducted by the Curtin Health 
Innovation Research Institute. The study seeks to identify people who present with lower 
bowel symptoms and participation is purely voluntary. 
 
By completing the consent form below you certify that you: 
1. Are 18 years and over 
2. Have read and understood the participant information sheet. 
3. Have had any questions answered about this study to your satisfaction. 
4. Are willing for a member of the research team to telephone you in the next 4 
weeks.  
5. Are willing for us to contact your GP if your pharmacist refers you to 
them about your bowel symptoms. 
 
Please note: It is important we are able to contact you both by phone and by mail so 
please ensure these details are both complete and correct. 
Personal Details 
First Name
 ______________________________Surname_________________________  
Address ______________________________________________________________ 
Suburb   ____________________________    Post Code_____________________ 
Gender  Male     Female     
Telephone  ____________________________________  
Date of Birth __ __/__ __/__ __ __ __ 
Best Time to call     ________________________________________________ 
(you will be called by Deepa Sriram) 
 
GP details 
Name of GP   ____________________________________  
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Name of Medical Centre _____________________________________   
Name of Pharmacy ______________________________________________________ 
 
Signature: ________________________ Date: ________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________________________ 
 
The study has been approved by the Curtin University Human Research Ethics Committee 
(Approval Number HR19/2013). The committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral cares. Its main role is to protect participants. If 
needed, verification of approval can be obtained by either writing to the Curtin University 
Human Research Ethics Committee on telephone number, c/- Office of Research and 
Development, Curtin University of Technology, GPO Box U1987, Perth 6845 or by telephoning 
9266 2784 or by emailing hrec@curtin.edu.au. 
All study participants will be provided with a copy of the Information Sheet and Consent 
Form for their personal records. 
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Jodi Lee Test (JLT) 
Q1. Are you experiencing any of the following symptoms?           (tick ALL that apply) 
Diarrhoea (loose, watery and frequent bowel motions)  
Constipation  
Alternating constipation and diarrhoea  
Bleeding from the back passage  
Discomfort at your back passage (soreness, itch, lump)  
 
Q2. How long have you had these symptoms? 
Less than 1 week  
1 week or more  
 
Q3. Is this unusual for you? 
Yes  
No  
Q3a. If yes, in what way is it unusual? 
 
__________________________________________________________________ 
__________________________________________________________________ 
 
Q4. Is this symptom(s) associated with any pain? 
 
 
 
Q4a. If yes, what is the pain like?     (circle the number that describes the pain) 
 
  
 
Yes  
No  
      None Mild      Moderate   Severe  Worst imaginable 
0      1  2 3           4          5          6          7          8          9 10 
 
201 
 
Q5. Have you lost weight unexpectedly in the past 4 weeks?  
         Q5a. If yes, approximately how much weight have you lost?  _____________ kg 
 
Q6. Have you talked to a doctor about this symptom(s)? 
   
 
 
 Q6a. If yes, when was the last time you talked to the doctor about this symptom(s)? 
 ________________________________________________________________ 
 ________________________________________________________________ 
 
Q7.   Have you had any bowel problems in the past 12 months?  
 
 
 
 
 
 
Q8. Please list any medication that you are currently taking (including medicines bought 
without a prescription, and natural products). 
 __________________________________________________________________ 
 __________________________________________________________________ 
  __________________________________________________________________ 
 
 
Yes  
No  
Yes  
No  
Haemorrhoids (Piles)  
Colitis 
Polyps 
Cancer 
Other   _________________ 
_ 
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For Pharmacy Staff  
 
Date ____/____/______ 
 
Name of the Patient  
 
 
1. Did the JLT indicate this person should be referred to a GP? 
 
Yes        
No  
 
2. Did you refer this person to a GP? 
 
Yes        
 No  
 
Document your reasons 
 
 
 
 
3. Did you give the JLT referral letter to the person? 
 
Yes        
No  
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Referral Letter 
 
Dear Doctor 
This patient attended this pharmacy today. Based on the symptom reported they have 
been advised to consult you for further investigation. See attached questionnaire. 
With kind regards 
 
Pharmacy- 
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Appendix 4.7: Bowel Symptom Scenarios 
 
Scenario: Constipation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Setting the scene- talk to the first person and ask for assistance for constipation, 
please check the name plate to see if you are being served by a Pharmacy assistant or 
pharmacist or student or any other staff member.... 
 
What you say  
1. I have been having constipation for about 3 days 
2. Got slight discomfort and slight tummy pain (just below your chest) 
3. What can I do…..is there anything I can take 
 
 
Pharmacy assistant might refer you to pharmacists or student-pharmacists 
 
 
 
 
 
 
 
Whoever serves you might ask these following questions. The reply for them are in 
maroon font 
 For how long have you been constipated? For about 3 days 
 Are u not going to the toilet at all? Going to the toilet everyday but not fully 
cleared, not emptied satisfactorily. 
 Bloated? Yes, slightly 
 Eating ok? yes 
 Drinking water? Yes 
 Any change in diet lately? No 
 Any family history? No 
 Do you have any pain or lump or any kind of discomfort when passing motion? No 
 Are you using any other medication – using ventolin (about once a 
month….whenever have to take) 
 Are you taking any medication for this problem? No 
 Have you had this kind before – sometimes, and on few occasions have had 
laxatives 
 Have you seen a GP regarding this issue?- No  
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We now have these choices: 
1. medication suggested : buy the pdt (pharmacist might say things like this: 
Anal fissure or Haemorroid. This might be just to ease the bleeding) 
2. Recommendation to consult a GP- If not resolved in 3-4 days, see GP 
3. Both - same reply as stated above 
4. No recommendations 
5. Other recommendations 
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Scenario: Diarrhoea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Setting the scene- talk to the first person and ask for assistance for diarrhoea, 
please check the name plate to see if you are being served by a Pharmacy assistant 
or pharmacist or student or any other staff member.... 
You are embarrassed to discuss this…talk in a quiet voice when discussing 
 
What is your condition (u just say Diarrhoea, and wait till they ask other questions)  
4. I have had diarrhoea for 2 days now 
5. Been drinking water… 
6. There is no vomiting 
7. I go to the toilet 4-5 times a day and it is watery 
8. What can I do…..is there anything I can take 
 
 
Pharmacy assistant might refer you to pharmacists or student-pharmacists 
 
 
 
 
 
 
 
Whoever serves you might ask these following questions. The reply for them are in 
maroon font 
 When did it start? I have had it for about 2 days 
 Is it getting worse? No 
 Any other symptoms? No 
 Is there any blood- No 
 Any mucous? No 
 Does it continue after you finish going to the toilet? Or is there any leakage - No 
 Do you think it could be because of any food you ate)- No, but I had gone out for 
dinner 2-3 days back 
 Anyone in the family having it? No 
 Any travel? No 
 How often do you go to the toilet? About 4-5 times /day 
 Do you have any pain or lump or any kind of discomfort when passing motion? – 
No 
 Are you using any other medication –Multivit. Have been having for a while…had 
no issues 
 On antibiotic? No 
 Any significant weight loss over the past 4 weeks? – No 
 Have you felt excessively tired?- not particularly 
 Have you been diagnosed with (haemorrhoids it is also called piles) or polyps or 
any other bowel disease?- No  
 Have you seen a GP regarding this issue?- No  
 Are you taking any medication for this problem? No 
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We now have these choices: 
6. medication suggested : buy the pdt  
7. Recommendation to consult a GP- oh, is it serious?! Can I wait since I have to go 
away for a week regd work or Oh, how soon do you think I should see a doc, can it 
wait till after I come back from a work trip next week? 
8. Both - same reply as stated above 
9. If pharmacists says “I can get the appt for you now so that you can go before your 
trip”- just say that you would do it yourself 
10. No recommendations 
11. Other recommendations 
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Scenario: Alternating Constipation and Diarrhoea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Setting the scene- Setting the scene- talk to the first person and ask for assistance, 
please check the name plate to see if you are being served by a Pharmacy assistant or 
pharmacist or student or any other staff member.... 
You are embarrassed to discuss this… talk in a quiet voice when discussing 
What you say  
9. I have constipation and diarrhoea…on and off…pattern is completely different… 
10. Been having it for a while now…hmmm…say about 3-4 weeks.. 
11. I will be constipated for 2-3 days then for the next few days will be frequent 
motions. It would settle down for some time then the same pattern would 
happen…. 
12. What can I do…..is there anything I can take 
 
 
Pharmacy assistant might refer you to pharmacists or student-pharmacists 
 
 
 
 
 
 
 
Whoever serves you might ask these following questions. The reply for them are in 
maroon font 
 How long have you been having it?  It has been there for a while ….say…3-4 weeks 
 Any bloating? No 
 Loss of appetite? No 
 Is this been your normal pattern for bowel motions? No, regular bowel movement 
 Do you have any pain or lump or any kind of discomfort when passing motion? – 
No 
 Are you using any other medication – using ventolin (about once a 
month….whenever have to take) 
 Have you taken any medication? No, I thought it would settle down 
 Have you seen a doc or got advice anywhere else for this? No, thought it would 
settle down….now this is becoming a consistent pattern…that is why I came here 
to get something for this. 
 Are you taking any medication for this problem? No 
 How often do you go to the toilet? When I have diarrhoea, I go about 4-6 times 
 Any significant weight loss over the past 4 weeks? – No 
 Have you felt excessively tired?- not particularly 
 Have you been diagnosed with (haemorrhoids it is also called piles) or polyps or 
any other bowel disease?- No  
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We now have these choices: 
12. medication suggested : buy the pdt (diagnosis could be IBS) 
13. Recommendation to consult a GP- oh, is it serious?! Can I wait since I have to 
go away for a week regd work or Oh, how soon do you think I should see a 
doc, can it wait till after I come back from a work trip next week? 
14. Both - same reply as stated above 
15. If pharmacists says “I can get the appt for you now so that you can go before 
your trip”- just say that you would do it yourself 
16. No recommendations 
17. Other recommendations 
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Scenario: Rectal Bleeding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Setting the scene- talk to the first person and ask for assistance for rectal bleeding, 
please check the name plate to see if you are being served by a Pharmacy assistant 
or pharmacist or student or any other staff member....You are embarrassed to 
discuss this…talk in a quiet voice when discussing 
 You have noticed blood when to go to the toilet 
What you say  
13. I have noticed blood in the toilet paper the last few days  
14. I have been noticing it for a week now. 
15. Could you please help me? 
 
 
Pharmacy assistant might refer you to pharmacists or student-pharmacists 
 
 
 
 
 
 
 
Whoever serves you might ask these following questions. The reply for them are in 
maroon font 
 When did it start? I started noticing it for about a week 
 What kind of blood, fresh or not? Hmm…not able to say….not sure 
 Large amount of blood or not? Less in the toilet paper 
 What colour was the blood- normal….. red…….. I guess 
 Does it continue after you finish going to the toilet? - No 
 Have you had a change in bowel habit like constipated or having loose motion 
(Diarrhoea)- No, everything’s pretty normal. I’m pretty regular 
 How often do you go to the toilet? Most days About 1-2 times /day 
 Do you have any pain or lump or itchiness or any kind of discomfort when 
passing motion? – No 
 Are you using any other medication – using ventolin (about once a 
month….whenever have to take) 
 Any significant weight loss over the past 4 weeks? – No 
 Have you felt excessively tired?- not particularly 
 Have you been diagnosed with (haemorrhoids it is also called piles) or polyps or 
any other bowel disease?- No  
 Have you seen a GP regarding this issue?- No  
 Are you taking any medication for this problem? No 
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We now have these choices: 
18. medication suggested : buy the pdt (pharmacist might say things like this: Anal 
fissure or Haemorroid. This might be just to ease the bleeding) 
19. Recommendation to consult a GP- oh, is it serious?! Can I wait since I have to go 
away for a week regd work or Oh, how soon do you think I should see a doc, can 
it wait till after I come back from a work trip next week? 
20. Both - same reply as stated above 
21. If pharmacists says “I can get the appt for you now so that you can go before your 
trip”- just say that you would do it yourself 
22. No recommendations 
23. Other recommendations 
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Appendix 4.8: Bowel Symptom Scenarios Checklist 
 
 
CONSTIPATION CHECKLIST 
Name of Pharmacy-  
1. Did the Pharmacy assistant refer you to a pharmacist or any other person 
after hearing your symptoms    Yes  No 
2. how long did you have to wait to see the pharmacists? Approx 
_____________mins 
3. Did you feel that you would be overheard by other customers at any stage in 
the pharmacy       Yes   No 
4. Did the staff offer to take you to a private space to speak?   
       Yes    No 
5. Did the staff ask you the following questions 
 the duration of the symptom   Yes  No 
 about any medications that you were taking? Yes  No 
 other medical condition that you may have?  Yes   No 
 how frequently you went to the toilet? Yes  No 
 about any discomfort in back passage like soreness, lump, itchiness
       Yes  No 
 if you had seen the GP regarding this particular issue?Yes      No 
  if you had this problem often?  Yes  No 
 If you had any change in bowel habit  Yes  No 
 Did he ask if you thought it could be any food that you must have 
had       Yes  No 
6. What other questions did he/she ask? 
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7. Was there any medication sold?   Yes  No 
If yes, please specify 
 
 
 
8. Was there any recommendation to consult a doctor? Yes  No  
9. Who was it who finally dealt with your issue? 
Student              
 Pharmacy assistant   
Pharmacist 
Trainee 
Other ________________________________________ 
10. How confident was the staff in making recommendations?  (for e.g. I think 
you should see the doc….after a while or after u ask some questions like 
stated in the ‘choices’ box, he/she changing advice to just use this 
medication for 2-3 days and then see a doc if necessary…  
 Very confident 1 2 3 4 5 Not confident   
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DIARRHOEA CHECKLIST 
Name of Pharmacy-  
1. Did the Pharmacy assistant refer you to a pharmacist or any other person 
after hearing your symptoms     Yes  No 
2. how long did you have to wait to see the pharmacists?   approx 
____________ mins 
3. How many people did you speak to till you were finally offered an advice 
and/or product? ______________________________ 
4. Did you feel that you would be overheard by other customers at any stage in 
the pharmacy       Yes   No 
5. Did the staff ask you the following questions 
 the duration of the symptom     Yes  No 
 about any medications that you were taking?   Yes  No 
  other medical condition that you may have?  Yes   No 
  how frequently you went to the toilet?   Yes  No 
  about any discomfort in back passage like soreness, lump, itchiness 
         Yes  No 
  if you had seen the GP regarding this particular issue? Yes  No 
  if you had this problem often?     Yes  No 
 If you had any change in bowel habit    Yes  No 
 If there was any weight loss      Yes  No 
 If you were feeling tired      Yes  No 
 Did he ask if you thought it could be any food that you must have had? 
         Yes   No 
6. What other questions did he/she ask? 
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7. Was there any medication sold?    Yes  No
  
If yes, please specify 
 
8. Was there any recommendation to consult a doctor? Yes  No
  
9. Who was it who finally dealt with your issue? 
Student              
 Pharmacy assistant   
Pharmacist 
Trainee 
Other ________________________________________ 
10. How confident was the staff in making recommendations?  (for eg, I think 
you shud see the doc….after a while or after u ask some questions like stated in 
the ‘choices’ box, he/she changing advice to just use this medication for 2-3 
days and then see a doc if necessary…  
 Very confident 1 2 3 4 5 Not confident   
 
 
 
 
 
 
 
216 
 
 
 
 
ALTERNATING CONSTIPATION AND DIARRHOEA CHECKLIST 
 Name of Pharmacy-  
1. Did the Pharmacy assistant refer you to a pharmacist or any other person 
after hearing your symptoms     Yes  No 
2. how long did you have to wait to see the pharmacists?   approx 
_________________________ mins 
3. Did you feel that you would be overheard by other customers at any stage in 
the pharmacy        Yes   No 
4. Did the staff offer to take you to a private space to speak?   Yes    No 
5. Did the staff ask you the following questions 
 the duration of the symptom     Yes  No 
 about any medications that you were taking?  Yes  No 
  other medical condition that you may have?  Yes   No 
  how frequently you went to the toilet?   Yes  No 
  about any discomfort in back passage like soreness, lump, itchiness 
         Yes  No 
  if you had seen the GP regarding this particular issue? Yes  No 
  if you had this problem often?     Yes  No 
 If you had any change in bowel habit    Yes  No 
 If there was any weight loss      Yes  No 
 If you were feeling tired      Yes  No 
6. What other questions did he/she ask? 
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7. Was there any medication sold?    Yes  No
  
If yes, please specify 
 
8. Was there any recommendation to consult a doctor? Yes  No
  
9. Who was it who finally dealt with your issue? 
Student              
 Pharmacy assistant   
Pharmacist 
Trainee 
Other ________________________________________ 
10. How confident was the staff in making recommendations?  (for eg, I think 
you shud see the doc….after a while or after u ask some questions like stated in 
the ‘choices’ box, he/she changing advice to just use this medication for 2-3 
days and then see a doc if necessary…  
 Very confident 1 2 3 4 5 Not confident   
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RECTAL BLEEDING CHECKLIST 
Name of Pharmacy-  
1. Did the Pharmacy assistant refer you to a pharmacist or any other person after 
hearing your symptoms       Yes  No 
2. how long did you have to wait to see the pharmacists?   approx 
_________________________ mins 
3. Did you feel that you would be overheard by other customers at any stage in the 
pharmacy         Yes   No 
4. Did the staff offer to take you to a private space to speak?  Yes    No 
5. Did the staff ask you the following questions 
 the duration of the symptom     Yes  No 
 about any medications that you were taking?  Yes  No 
  other medical condition that you may have?  Yes   No 
  how frequently you went to the toilet?   Yes  No 
  about any discomfort in back passage like soreness, lump, itchiness 
         Yes  No 
  if you had seen the GP regarding this particular issue? Yes  No 
  if you had this problem often?     Yes  No 
 If you had any change in bowel habit    Yes  No 
 If there was any weight loss      Yes  No 
 If you were feeling tired      Yes  No 
6. What other questions did he/she ask? 
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7. Was there any medication sold?     Yes  No
  
If yes, please specify 
 
8. Was there any recommendation to consult a doctor?  Yes  No 
9. Who was it who finally dealt with your issue? 
Student              
 Pharmacy assistant   
Pharmacist 
Trainee 
Other ________________________________________ 
10. How confident was the staff in making recommendations?  (for eg, I think 
you shud see the doc….after a while or after u ask some questions like stated in 
the ‘choices’ box, he/she changing advice to just use this medication for 2-3 
days and then see a doc if necessary…  
 Very confident 1 2 3 4 5 Not confident   
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Appendix 5.1: Scoring sheet - TPB 
 
Questions measuring Perceived Behavioural Control of pharmacy staff for 
management of embarrassing bowel symptoms 
 
1. For me to take a customer to a private space to speak about his/her embarrassing 
symptoms is 
Extremely difficult   1 2 3 4 5  Extremely easy 
 
2. For me to obtain the reason for the patient’s visit to the pharmacy with 
embarrassing symptoms is generally 
Extremely difficult   1 2 3 4 5  Extremely easy 
 
3. I am confident in making recommendations to customers regarding their lower 
bowel symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree  
4. I am confident in recognising signs, symptoms and risk factors (or just- warning 
signs) of bowel disease that may require consultation with the general 
practitioner (GP) 
Strongly disagree  1 2 3 4 5 Strongly agree  
 
5. Providing cognitive services to customer with lower bowel symptoms would be 
a burden on pharmacy staff 
Strongly disagree  1 2 3 4 5 Strongly agree  
 
 
 
 
Questions measuring subjective norms of pharmacy staff when providing 
cognitive service to clients presenting with bowel symptoms. 
1. I would like to provide cognitive services to customers with lower bowel 
symptoms because customers expect it 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
2. I would like to provide cognitive services to customers with lower bowel 
symptoms because other pharmacies are doing it 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
3. I would like to provide cognitive services to customers with lower bowel 
symptoms because the pharmacy owner/manager expects me to do it 
Recode Question 5 which has negative endpoint. Mean of item score gives overall PBC 
score. 
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Strongly disagree  1 2 3 4 5 Strongly agree 
 
 
 
Questions measuring attitude of pharmacy staff when providing cognitive service 
to clients presenting with bowel symptoms. 
 
1. Pharmacists providing recommendation to customers regarding their lower 
bowel symptoms is consistent with good professional practice 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
2. Providing cognitive services to customers with lower bowel symptoms  will 
allow pharmacists to provide an even higher level of care to patients  
Strongly disagree  1 2 3 4 5 Strongly agree 
 
3. Providing cognitive services to customers with lower bowel symptoms will 
enhance customer satisfaction even more 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
4. Providing cognitive services to customer with lower bowel symptoms will make 
it even more likely that pharmacists will ensure that people with lower bowel 
symptoms get appropriate care 
      Strongly disagree  1 2 3 4 5 Strongly agree 
 
 
 
 
Questions measuring intention of pharmacy staff when providing cognitive service 
to clients presenting with bowel symptoms. 
 
1. In the future I will provide cognitive services to customers with lower bowel 
symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
2. In the future I will change my usual/current practice for customers with lower 
bowel symptoms 
 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
Mean of item score gives an overall subjective norm score. 
 
Mean of item score gives an overall Attitude score. 
 
Mean of item score gives an overall Attitude score. 
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Appendix 5.2: TPB-Questionnaire 
 
Please do not consult any member of the team when filling in this questionnaire 
1. For me to take a customer to a private space to speak about his/her embarrassing 
symptoms is 
Extremely difficult   1 2 3 4 5  Extremely easy 
 
2. For me to obtain the reason for the patient’s visit to the pharmacy with 
embarrassing symptoms is generally 
Extremely difficult   1 2 3 4 5  Extremely easy 
 
3. I am confident in making recommendations to customers regarding their lower 
bowel symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree  
4. I am confident in recognising signs, symptoms and risk factors (or just- warning 
signs) of bowel disease that may require consultation with the general 
practitioner (GP) 
Strongly disagree  1 2 3 4 5 Strongly agree  
 
Cognitive pharmaceutical services can be defined as professional services 
provided by pharmacists, who use their skills and knowledge to take an 
active role in patient health, through effective interaction with both 
patients and other health professionals. 
 
5. Providing cognitive services (Please refer to the definition given above) to 
customer with lower bowel symptoms would be a burden on pharmacy staff 
Strongly disagree  1 2 3 4 5 Strongly agree  
 
6. I would like to provide cognitive services to customers with lower bowel 
symptoms because customers expect it 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
7. I would like to provide cognitive services to customers with lower bowel 
symptoms because other pharmacies are doing it 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
8. If you are the owner/manager of this pharmacy please move to question 9 
 
I would like to provide cognitive services to customers with lower bowel 
symptoms because the pharmacy owner/manager expects me to do it 
Strongly disagree  1 2 3 4 5 Strongly agree 
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9. Pharmacists providing recommendation to customers regarding their lower 
bowel symptoms is consistent with good professional practice 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
10. Providing cognitive services to customers with lower bowel symptoms  will 
allow pharmacists to provide an even higher level of care to patients  
Strongly disagree  1 2 3 4 5 Strongly agree 
 
11. Providing cognitive services to customers with lower bowel symptoms will 
enhance customer satisfaction even more 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
12. Providing cognitive services to customer with lower bowel symptoms will make 
it even more likely that pharmacists will ensure that people with lower bowel 
symptoms get appropriate care 
      Strongly disagree  1 2 3 4 5 Strongly agree 
 
13. In the future I will provide cognitive services to customers with lower bowel 
symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree 
 
14. In the future I will change my usual/current practice for customers with lower 
bowel symptoms 
Strongly disagree  1 2 3 4 5 Strongly agree 
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As an Elsevier journal author, you retain the right to include the article in a thesis or 
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university’s digital repository of the thesis provided that if you include the published 
journal article (PJA) version, it is embedded in your thesis only and not separately 
downloadable 
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Appendix 6.2: Script for Usual Practice Video 
 
 
Scenario: Query asked of Pharmacy Assistant and Pharmacist only. 
 
 
 
 
 
 
 
 
 
 
PAUSE. Screen fades out then up again  
 
 
 
 
 
 
 
 
      PAUSE. Screen fades out then up again.  
 
 
 
 
 
 
 
About client: Frank James: 55 year-old male who has a cough that has been 
bothering you for about two months. You are frustrated and concerned.  
Client sounds like: A typically worried customer asking for help at a Pharmacy 
(Chemist). 
 
What the pharmacy assistant will say: 
 Hello, how can I help you today? 
 
 
 
 
 
 
What the pharmacy assistant will say: 
1. Let me get the Pharmacist for you. 
 
 
 
 
 
What the Pharmacist says: 
 Hello, my assistant tells me you have a problem   which has been 
bothering you for sometime. 
 What have you tried for it? 
What client says: 
1. I’ve tried most of the things over there (you point to the medication in 
the aisle)...but nothing seems to work. Have you got something 
stronger? 
 
What client says:  I’ve got this problem … 
 
What client says: 
 It’s been hanging around for a while and nothing I’ve tried seems to 
work.  
 Can you give me some advice 
 I’m looking for something stronger. 
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PAUSE. Screen fades out then up again. 
 
 
 
 
 
What client says to the pharmacist: 
 
1.  Thanks for that thorough advice. 
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Appendix 6.3: Screenshot of Usual Practice Video 
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Appendix 6.4: Script for Quality-Enhanced Video 
 
Scenario: Query asked of Pharmacy Assistant/Pharmacist and to GP 
Reception 
 
 
 
 
 
 
 
 
 
 
PAUSE. Screen fades out then up again  
 
 
 
 
 
 
 
 
 
 
 
 
PAUSE: Screen fades out then up again 
 
 
 
About client: Frank James: 55 year-old male who has a cough that has been 
bothering client for about two months. Client are frustrated and concerned.  
Client sound like: A typically worried customer asking for help at a Pharmacy 
(Chemist). 
What client say:  I’ve got this problem … 
 
What the pharmacy assistant will say: 
 Hello, how can I help you today? 
 
 
 
 
 
 
What the pharmacy assistant will says: 
 Let me get the Pharmacist for you. 
 
 
 
 
 
What the Pharmacist says: 
 
 Hi, Mr James, my assistant says you have a problem let’s move to a 
quieter place, so I can help you. 
 
 
What client says: 
 It’s been hanging around for a while and nothing I’ve tried seems to 
work.  
 Can you give me some advice 
 I’m looking for something stronger. 
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PAUSE. Screen fades out then as it returns, the pharmacist gives a paper to the customer. 
and the customer leaves the pharmacy with a paper in his hand. 
 
 
 
 
 
PAUSE: Screen fades out and starts again with customer giving the paper to the 
receptionist in the medical clinic 
What client says: 
 
 I’ve tried most of the things over there (you point to the medication in 
the aisle)...but nothing seems to work. Have you got something 
stronger? 
What you say: 
 
 I’ve got an appointment to see Dr Harvey, and I have this report from 
the Pharmacist for Dr Harvey to see. (Handing over the piece of paper 
to the Receptionist). 
 
What the Pharmacist says: 
 
 In order for me to help you, could you please answer a few questions in 
this questionnaire? It would take a couple of minutes. 
What client says: 
 
 Thank you for the thorough advice I will make an appointment to see 
the Doctor and take this report with me.  
What the Pharmacist says: 
 
 My assistant tells me this problem has been bothering you for some 
time. 
 What have you tried for it? 
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Appendix 6.5: Screenshot of Quality-Enhanced Service Video 
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Appendix 6.6: Willingness to Pay–Information Sheet and Consent form 
 
Participant Information Sheet 
  
This study seeks to evaluate the value of pharmacist’s advice and how much people 
are willing to pay for service where pharmacy staffs use a tool which would guide 
them to identify symptomatic patients who should be advised to consult a medical 
practitioner. 
 Who can participate? 
You are eligible to participate if you are over 18 years of age and able to provide 
informed consent. 
 What will I be asked to do? 
 
You will be asked to provide some information about yourself including your 
contact details.  This information will be used ONLY for the purpose of this study. 
You will be asked to watch a video clipping You will be asked to answer a brief 
questionnaire. This will take you approximately five (5) minutes to complete.  
 How will my privacy be protected?   
We believe it is extremely important to keep your personal information 
confidential. The information provided will be used for the purpose of this project 
ONLY and results will be reported in groups. 
 Can I decline to take part or withdraw if I change my mind? 
Participation in this study is purely voluntary. You may decline to take part or 
withdraw from this study at any time.   
 Are there any risk or benefits?  
There are no risks involved in this study. This study will help in evaluation the 
monetary value you would ascribe for a pharmacists’ advice.  
 Study Team Contact Details 
If you would like a copy of this questionnaire for your own information or would like 
further information on the study, please contact: 
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Deepa Sriram 
Curtin Health Innovation Research Institute (CHIRI) 
Curtin University  
GPO Box U1987, PERTH WA 6845 
Phone: 9266 9581, Fax: 9266 9801 
 
Email: d.sriram@curtin.edu.au 
 
 
This study has been approved by the Curtin University Human Research Ethics 
Committee - approval number - HR19/2013 
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Consent Form 
 You have been asked to volunteer for this study that seeks to evaluate the value of 
pharmacist’s advice and how much people are willing to pay for service where 
pharmacy staffs use a tool which would guide them to identify symptomatic patients 
who should be advised to consult a medical practitioner. 
  
Please note: It is important we are able to contact you by email. So please ensure 
these details are both complete and correct 
By completing the consent form below you certify that you: 
 
  
 You are over the age of 18. 
 Have read the “Participant Information Sheet” and have had any questions 
answered to your satisfaction by the researcher.  
 Have been informed of the benefits and risks associated with this research study.  
 Understand that you are free to withdraw from the study at any time, for any 
reason, and without prejudice.  
 Agree to take part in this research study and for the data obtained to be published, 
provided your name or other identifying information is not used.  
  
If you are unclear about anything you have read in the Participant Information 
Sheet or this Consent Form, please speak to the researcher before signing this 
Consent Form. 
  
 Yes, I agree with the above points and consent to participate in this study  
 
This study has been approved by the Curtin University Human Research Ethics Committee (Approval Number HR -
19/2013). The committee is comprised of members of the public, academics, lawyers, doctors and pastoral carers. 
Its main role is to protect participants. If needed, the verification of approval can be obtained either by writing to 
the  Curtin University  Human  Ethics Committee, c/- office of research and Development, Curtin University, GPO 
Box U1987, Perth, 6845 or by telephoning (08) 9266 2784 or by emailing hrec@curtin.edu.au 
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Appendix 6.7: Willingness to Pay Questionnaire 
 
About yourself 
 
1. What is your age in years on your last birthday? _______ 
 
2. What is your gender 
Female 
Male 
 
3. What is your present marital status? 
Never Married, single 
Widowed 
Married or domestic partnership 
Separated  
Divorced 
 
4. Highest level of Education… 
Completed primary school 
Less than Year 10 
Year 10 or equivalent 
Year 12 or equivalent 
Trade certificate/TAFE 
Diploma or equivalent 
Tertiary education 
 
5. What is your current employment status? 
Unemployed/homemaker  
Employed full time 
Employed part time 
Student 
Pensioner or on social security 
Other (Please specify)     ………………. 
 
6. What is your annual household income? 
       Less than $40,000 
      $41,000-$80,000 
       $81,000 - $120,000 
      $120,000 -$160,000 
       More than $1,60,000 
       I prefer not to answer this question 
7. What is the post code of your place of residence    .............. 
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8. In which state do you reside? 
 
About the videos/consultation 
1. Did you notice a difference in the way the man was dealt with in Video 1 compared to 
Video 2?  
Yes    
No    
Not sure  
 
2. Which consultation do you think was longer?  
Video 1  
Video 2  
Not sure   
 
3. In which video was the man offered more privacy? 
Video 1  
Video 2  
Not sure   
 
4. Assuming that the man had the same problem in both the videos, which consultation 
do you think was more helpful in providing advice? 
Video 1  
Video 2  
Neither  
Not sure  
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5. If you were the man in the video, which type of service/consultation would you prefer? 
Video 1  
Video 2 
Neither  
Both  
 
6. If you were the man in Video 1, would you be willing to pay for the service you received 
in the pharmacy? 
Yes  
No 
Not sure 
If yes, how much would you be willing to pay?  _$_____ 
 
7. If you were the man in Video 2, would you be willing to pay for the service you received 
in the pharmacy? 
Yes  
No 
Not sure 
If yes, how much would you be willing to pay? _$_____ 
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Appendix 7.1: JLT Letter-pad 
Jodi Lee Test for Bowel Symptoms 
Name of customer  ______________________   Date _____________ 
Have you had any bowel problems in the past 12 months?  
Haemorrhoids (piles)  ☐ 
Colitis    ☐ 
Polyps    ☐ 
Cancer    ☐ 
Other    ☐ (please specify) __________________________ 
List any medication that you are currently taking (including medicines bought without a 
prescription, and natural products):  
__________________________________________________________________________________________
____________________________________________________________ 
 
Recommendation 
See your GP  ☐ 
Other                           ☐ __________________________ 
 
 
 
Symptom Present Present for more than 1 week* 
Diarrhoea ☐ ☐ 
Constipation ☐ ☐ 
Alternating diarrhoea and constipation ☐ ☐ 
Bleeding from back passage ☐ ☐ 
Discomfort at your back passage 
(soreness, itch, lump) 
☐ ☐ 
 *Refer to pharmacist if any box above 
ticked  
About the presenting symptom  Yes  No 
Have you talked to a doctor about this symptom(s)? ☐ ☐ 
Have you lost weight unexpectedly in the past 4 
weeks? 
☐ ☐ 
Symptom associated with pain? ☐ ☐ 
How much pain do you have? (circle the most relevant number in this scale) 
0     1     2      3      4      5     6      7      8      9     10 
None          Mild                   Moderate                   Severe          worst  imaginable 
